Microarray for evaluation of stress-related genes in skin

ABSTRACT

The present invention provides a novel DNA microarray chip that can be used for simultaneous testing of transcriptional responses to cutaneous stressors in the context of neuro-endocrine-immune functions of the skin. The transcriptional responses to ultraviolet radiation in epidermal keratinocytes were tested using such microarray chip containing more than 700 neuro-endocrine-immune related genes. The gene expression pattern was non-random and time dependent; it included increased expression of genes involved in water and salt balance, prostaglandin synthesis, keratinocyte differentiation as well as genes coding for stress effectors, cytokines and metalloproteinases. In contrast, expression was decreased for genes coding for growth factors and their receptors, and for elements of extracellular matrix. This stochastic pattern suggests that transcriptional responses are coordinated and aimed at preservation of epidermal barrier function, prevention of early carcinogenic events and remodeling of extracellular matrix.

CROSS-REFERENCE TO RELATED APPLICATION

This non-provisional application claims benefit of provisional patent applications Ser. No. 60/592,875, filed Jul. 30, 2004, now abandoned.

FEDERAL FUNDING LEGEND

This invention was produced in part using funds obtained through a grant (AR047079-01A2) from the National Institutes of Health. Consequently, the federal government has certain rights in this invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates generally to the molecular biology and genomics technology. More specifically, the present invention relates to microarrays for the investigation of skin neuro-endocrine-immune functions.

2. Description of the Related Art

As a biological barrier, the skin is continuously subjected to the environmental stresses such as ultraviolet radiation, pathogens and thermal and chemical insults (Slominski and Wortsman, 2000). To provide systemic protection, skin cells have numerous defense mechanisms, presumably evolving from a network of intracellular communications coordinated by messages from the local neuro-endocrine-immune system (Slominski and Wortsman, 2000).

This concept, of skin as a peripheral neuroendocrine organ, would imply that local homeostasis (and by inference systemic homeostasis) is regulated by the expression of hormones, neurotransmitters, neuropeptides, cytokines and their receptors. Accordingly, expression of the respective genes should be hierarchical, coordinated and organized into patterns defining functional pathways after exposure to environmental stressors and/or pathological events. The predominant environmental stressor for the skin is solar radiation, especially its UV wavelengths (200-320 nm) (Slominski and Pawelek, 1998). Primary responses to UV radiation (UVR) involve induction of melanin pigmentation and immunomodulation and endocrine activity represented by production of vitamin D and neuropeptides (Slominski and Pawelek, 1998; Slominski and Wortsman, 2000).

Chronic UVR exposure has potent carcinogenic and aging effects. However, the prior art is deficient in the development of a microarray assay to obtain further insight into the cutaneous stress response under chronic UVR exposure. The present invention fulfills this long-standing need and desire in the art by developing microarrays that could be used for simultaneous testing of transcriptional responses to cutaneous stressors in context of neuroendocrine-immune functions of the skin.

SUMMARY OF THE INVENTION

The present invention is directed to a microarray comprising a human molecular chip composed of approximately 700 genes developed to study peripheral response to stress. The chip was designed to evaluate hierarchical and coordinated gene expression patterns organized into functional pathways in response to environmental stress, dyshomeostatic stimuli or pathology. These human microarrays included oligonucleotides corresponding to genes encoding enzymes involved in hormonal production or degradation or neuropeptide processing, precursors to neuropeptide, cytokines, corresponding receptors, other immune markers. For completeness of such molecular chips, several structural genes governing melanogenesis (specific for melanocytes) or epidermal barrier formation by keratinocytes (different cytokeratins) were also included to allow evaluation of the neuroendocrine and immune pathways in relation to differentiated state of prevalent cells of the epidermal component. The oligonucleotides for genes in the microarray chip not limited to include the ones shown in Table 1.

This technology was then applied to the testing of transcriptional activity in keratinocytes exposed to UVR. Significant expression changes of genes arranged in patterns defining functional pathways were found. Thus, this chip could be used as an efficient molecular technology to study neuroendocrine and immune functions of the skin and other organs on a comprehensive molecular level in relation to external and internal stress or any dyshomeostatic signal. It would further allow shaping the modern concept of skin as a neuroendocrine organ requiring that local homeostasis and by inference systemic homeostasis is dependent on the regulated local expression of hormones, neurotransmitters, neuropeptides, cytokines and their receptors.

In one aspect of the present invention, there is provided a DNA microarray chip for measuring transcriptional responses to stress in a cell. The chip comprises 761 oligonucleotides for genes related to production and metabolism of hormones, neurotransmitters, neuropeptides, cytokines, biological modulators, growth factors, corresponding receptors and normal skin metabolism genes.

In another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell that comprises following steps. The cell is challenged with stress and nucleic acid samples are isolated from the cell. This is followed by measuring gene expression levels of a group of genes. Subsequently, the gene expression levels are analyzed statistically and compared to those without stress, where a statistically significant upregulation of the gene expression indicates transcriptional responses to stress.

In yet another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell that comprises the same steps of challenging, isolating nucleic acid and measuring gene expression levels. However, in this case the gene expression levels are analyzed statistically and compared to those without stress, where a statistically significant downregulation of the gene expression indicates transcriptional responses to stress.

Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiment of the invention. This embodiment is given for the purpose of disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features, advantages and objects of the invention as well as others which will become clear are attained and can be understood in detail, more particular descriptions and certain embodiments of the invention briefly summarized above are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.

FIG. 1 shows detection of differentially expressed genes. Green dots represent genes with higher level of A546 labeled cDNA. Red dots represent genes with higher level of A647 labeled cDNA. Two green spots on the top are landing marks.

FIGS. 2A and 2B show relative expression of genes in UV-irradiated keratinocytes. FIG. 2A shows real-time RT-PCR results that were calculated by comparing UV-irradiated keratinocytes (incubated 12 hours after irradiation) against controls (no treatment). Data was normalized to GAPDH expression and represented mean ±SD (N=3). Ratios statistically significantly different from 1 (no difference) are denoted by asterisks (p<0.05). FIG. 2B shows RT-PCR of human gastrin. The samples were loaded as follows: immortalized keratinocytes (HaCaT; lane 1); epidermal keratinocytes (HeKa; lane 2); epidermal fibroblasts (lane 3); different melanomas (lanes 4-9); melanocytes (lane 10). M denotes molecular marker.

DETAILED DESCRIPTION OF THE INVENTION

The following abbreviations are used herein: AQP, aquaporin; CYP4F8, cytochrome P450, subfamily IVF, polypeptide 8; COX-2, prostaglandin-endoperoxide synthase 2; IL-6, interleukin 6; IL-1, interleukin 1; IL-2, interleukin 2; IL-8, interleukin 8; TNFSF9, tumor necrosis factor superfamily member 9; BMP3, bone morphogenetic protein 3; IGFBP6, insulin-like growth factor binding protein 6; VGEF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; KGF, keratinocyte growth factor; KGFR, keratinocyte growth factor receptor; TNFSF10 (TRAIL), tumor necrosis factor superfamily member 10; MMPs, metalloproteinases; CRF-R2, corticotropin releasing factor receptor type 2.

The present invention used microarray technology to detect several genes with changed expression levels (up- or down-regulated) in a time-dependent manner afetr exposure to UVR. Although the affected genes were mostly involved in water and salt balance and prostaglandin metabolism, they also included interleukins and growth factors, metalloproteinases, markers of keratinocyte differentiation and genes involved in stress response. Functional assessment revealed that majority of the detected genes represented defense mechanisms against malignant transformation. Thus, activation of interleukins, of keratinocyte differentiation markers and down-regulation of EGFR, KGF and KGFR may all represent anti-cancer defense mechanisms. In contrast, the stimulation of metalloproteinases, the enzymes responsible for the extracellular matrix rearrangement or the down-regulation of TRAIL might promote tumor progression in the human skin. Among all the genes that were analyzed, stimulation of COX-2, TNFSF9 and down-regulation of KGF and KGFR were the most interesting observation. Many of the gene expression changes induced by UVR have been already described. Thus, confirming the results obtained by using the microarray chip of the present invention with that already known made the data more reliable. The data was also verified independently using real-time PCR and sequencing. Thus, the microarray chip can be reliably used for the simultaneous assessment of the effect of different agents on the expression of a large set of endocrine-related genes.

In one aspect of the present invention, there is provided a DNA microarray chip for measuring transcriptional responses to stress in a cell. The chip comprises 761 oligonucleotides for genes related to production and metabolism of hormones, neurotransmitters, neuropeptides, cytokines, biological modulators, growth factors, corresponding receptors and normal skin metabolism genes. The oligonucleotides for genes in the DNA microarray chip have SEQ ID Nos. shown in SEQ ID No. 25-785.

In another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell, comprising the steps of: challenging the cell with stress; isolating nucleic acid samples from the cell; measuring gene expression levels of a group of genes; and analyzing the gene expression levels statistically as compared to those without stress, wherein a statistically significant upregulation of the gene expression indicates transcriptional responses to stress. The gene expression is measured by DNA microarray and further verified by RT-PCR. Representative examples of the stress are ultraviolet radiation, thermal stress, chemical stress, or immune stress. The preferred cell is epidermal keratinocyte, melanocyte, fibroblast, or immune cell. Representative examples of the statistical analysis that can be performed are one-way analysis of variance, post-hoc test or student t test. The statistically significant upregulation is atleast a 1.5-fold increase of expression of the genes. The group of genes not limited to include genes involved in water and salt balance, genes involved in prostaglandin metabolism, interleukin genes, growth factor genes, markers of keratinocyte differentiation genes, metalloproteinases genes, and stress response genes. The upregulated genes not limited to include the genes selected from the group of genes encoding for gastrin, vasopressin, aquaporin, prostaglandin-endoperoxide synthase 2, CYP4F8, IL-1, IL-2, IL-6, IL-8, tumor necrosis factor superfamily member 9, bone morphogenetic protein 3, insulin-like growth factor binding protein 6, vascular endothelial growth factor B, stromelysins 1 and 2, corticotropin releasing factor receptor type 1 and 2, and aldo-keto reductase.

In yet another aspect of the present invention, there is provided a method of detecting transcriptional responses to stress in a cell that comprises the same steps of challenging, isolating nucleic acid samples, measuring gene expression levels and statistical analysis of the gene expression levels as compared to those without stress as described supra. However in this case, a statistically significant downregulation of the gene expression indicates transcriptional responses to stress. All other aspects regarding the assay to measure gene expression and to verify its expression, the types of stress, type of cell and the genes whose expression is measured is the same as described supra. The down-regulated genes not limited to include genes selected from the group of genes encoding for epidermal growth factor receptor, keratinocyte growth factor, keratinocyte growth factor receptor, activin A receptor type I, and tumor necrosis factor superfamily member 10.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the cells and methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

EXAMPLE 1

Cell Lines and Cell Culture

Human adult epidermal keratinocytes and melanocytes were purchased from Cascade Biologics and cultured according to the company's protocol (Cascade Bio, Portland, Oreg.). Melanocytes were grown in Medium 154 and keratinocytes in EpiLife medium supplemented with appropriate growth factors and antibiotics. For co-cultivation experiments, keratinocytes and melanocytes were mixed in the ratio 20:1 and incubated in Medium 154 supplemented with HKGS (Cascade Bio, Portland, Oreg.).

EXAMPLE 2

Ultraviolet Light Treatment

Ultraviolet irradiation of cells was performed as previously described (Pisarchik and Slominski, 2001). Briefly, cells were cultured in 75 cm² flasks at 85% confluency. The flasks were placed on the UV transilluminator 2000 (BioRad) and irradiated with 50 mJ/cm² UVB (Pisarchik and Slominski, 2001). Time of exposure, corresponding doses and UV spectrum had been established previously; after UV exposure (50 mJ/cm²) the morphology of the cells did not change significantly (Pisarchik and Slominski, 2001). Irradiated cells were further incubated in culture media for 4, 12 and 24 hours, detached and processed for RNA isolation.

EXAMPLE 3

Microarray Slides

Oligonucleotides for genes related to production and metabolism of hormones, neurotransmiters, neuropeptides, cytokines, biological modulators, growth factors, corresponding receptors and normal skin metabolism genes were designed (http://www.utmem.edu/pathology/molecular-endocrinology.htm). The location of the oligos for each gene was chosen according to the structure of the corresponding gene obtained from the GeneBank. Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, Iowa) and printed on superamine slides (TeleChem, Sunnyvale, Calif.) at the University of Tennessee Molecular Resource Center.

EXAMPLE 4

RNA extraction, cDNA Preparation and Fluorescent Labeling

Total RNA was extracted using Trizol isolation kit (Gibco-BRL, Gaithersburg, Md.). The cDNA was synthesized, hybridized and labeled with Genisphere Array 50 kit according to the manufacturer protocol (Genisphere, Hatfield, Pa.).

EXAMPLE 5

Hybridization Protocol

Slides were washed by 0.2% SDS (2 min), water (two times, 2 min), dipped in absolute ethanol (1 min), dried by centrifugation (300×g, 2 min) followed by the injection of 100 μl of the hybridization mixture under the cover slip (LifterSlip cover glass, Erie Scientific Company, Portsmouth, N.H.). Slide hybridization and washing were done according to the protocol of the Genisphere Array 50 kit manufacture (Genisphere, Hatfield, Pa.). Slides were incubated overnight at 53° C. in the dark.

EXAMPLE 6

Data Acquisition and Analysis

At least four arrays were used in every experiment (every time-point). Fluorescence corresponding to A546 and A647 dyes was measured by Axon scanner at The University of Tennessee Molecular Resource Center. Program Fine PixPro 4.0 was used to identify spots and subtract background. Data was normalized by LOWES method (intensity-dependent) using the BRB-Array Tools 2.1 program written by Dr. Richard Simon (Biometrics Research Branch, National Cancer Institute) and Amy Peng (EMMES Corporation). The output Excel spreadsheet contained normalized logarithms (base 2) of ratios for each gene on the slide.

For easy interpretation, logarithms were recalculated into ratios. The factor of 1.5 was chosen as the cut-off for increase/decrease of gene expression, instead of the generally-used factor of 2. This was done because some genes that did show statistically significant stimulation of expression did not attain the 2-fold difference. To avoid false positives, only those genes that were consistently up- or down-regulated on several slides including dye-flip slides as presented on FIG. 1 were selected. Table 2 lists the average ratios for these genes. It is apparent from the table that the majority of selected genes were stimulated or inhibited at least 2 fold.

EXAMPLE 7

RT-PCR and Real-Time RT-PCR

Total RNA (10 μg) was treated with DNAse (Invitrogen), purified by Rneasy MinElute Cleanup kit (Quigen, Valencia, Calif.) and reverse transcribed by Superscript First-Strand Synthesis System (Invitrogen). The resulting cDNA was diluted 100 times in water and aliquots were subjected to quantitative real-time PCR in an iCycler (BioRad). The PCR mixture (25 μl) contained 5 μl of the diluted cDNA, 2.5 μl of each primer (0.04 μM) and 12.5 μl of SYBR Green (Applied Biosystems, Warrington, UK). Each sample was amplified in triplicate. Reactions were performed with initial hot start incubation at 95° C. for 10 min, followed by 40 cycles of denaturation at 95° C. for 10 sec and 60° C. for 1 min. The mixture was then incubated at 60° C. for 10 min, heated gradually in 0.4 increments and the melting curve was then analyzed. Relative gene expression was recalculated by ΔΔCt method. Briefly, the difference (ΔCt) between the Ct values of the target and the house-keeping gene (GAPDH or β-actin) were calculated: ΔCt=Ct(target)−Ct(GAPDH) ΔΔCt is the difference between UV-irradiated and control samples: ΔΔCt=ΔCt(UV)−ΔCt(control) The fold-time stimulation of gene expression is calculated as =2^(ΔΔCt)

Primers used for the PCR were as follows: prostaglandin-endoperoxide synthase 2 (COX-2) P898 (ATGAGTGTGGGATTTGACCAG, forward, SEQ ID No. 1) and P899 (TTCCGGTGTTGAGCAGTTTTC, reverse, SEQ ID No. 2); TNRSF9 P900 (AGCTACAAAGAGGACACGAAG, forward, SEQ ID No. 3) and P901 (CGCAGCTCTAGTTGAAAGAAG, reverse, SEQ ID No. 4); Keratinocyte growth factor receptor P904 (GATGGTGCGGAAGATTTTGTC, forward, SEQ ID No. 5) and P905 (GCCGCTTTTCCATCTTTTCTG, reverse, SEQ ID No. 6); stromelysin 2 P908 (ATTTTGGCCCTCTCTTCCATC, forward, SEQ ID No. 7) and P909 (TGATGGCCCAGAACTCATTTC, reverse, SEQ ID No. 8); stromelysin 1 P910 (GGAAATCAATTCTGGGCCATC, forward, SEQ ID No. 9) and P911 (CATCGATTTTCCTCACGGTTG, reverse, SEQ ID No. 10); aquaporin 3 P912 (TTTGGCTTTGCTGTCACTCTG, forward, SEQ ID No. 11) and P913 (AAGCACATGGCAAAGGTCAC, reverse, SEQ ID No. 12); aquaporin 9 P916 (TTTGCTGGTGGAAAACTGCTG, forward, SEQ ID No. 13) and P917 (AAATGCGTTCGCCAGAGATAG, reverse, SEQ ID No. 14); keratin 1 K1-L (TGACCAAGGTGGACCTTCAG, forward, SEQ ID No. 15) and K1-R (ATGATGCTGTCCAGGTCGAG, reverse, SEQ ID No. 16); involucrin IVL-L (TCAGCCTTACTGTGAGTCTGG, forward, SEQ ID No. 17) and IVL-R (AGTCTTGAGGAGCTCCTGAC, reverse, SEQ ID No. 18); GAPDH G-L (TGATGACATCAAGAAGGTGGTGAAG, forward, SEQ ID No. 19) and G-R (TCCTTGGAGGCCATGTAGGCCAT, reverse, SEQ ID No. 20); β-actin BA-L (GCCCTGGCACCCAGCACAAT, forward, SEQ ID No. 21) and BA-R (TCATAGTCCGCCTAGAAGCA, reverse, SEQ ID No. 22).

The 283 bp long band corresponding to human Gastrin was amplified by primers P432 (TGCAGACGAGATGCAGCGAC, SEQ ID No. 23) and P433 (GTCCATCCATCCATAGGCTTC, SEQ ID No. 24). The reaction mixture (25 μl) contained 2.0 mM MgCl₂, 0.25 of each dNTP, 0.4 μM of each primer, 75 mM Tris-HCl (pH 8.8), 20 mM (NH₄)2SO₄, 0.01% Tween 20 and 1.25 u of Taq polymerase (Promega). The mixture was heated to 94° C. for 2.5 minutes and then amplified for 25 cycles: 94° C. for 10 seconds (denaturation), 55° C. for 10 seconds (annealing) and 72° C. for 30 seconds (extension). Amplification products were separated by agarose electrophoresis and visualized by ethidium bromide staining. The identified PCR products were excised from the agarose gel and purified using a GFX PCR DNA and gel band purification kit (Amersham-Pharmacia-Biotech). Sequencing was performed at the Molecular Resource Center at the University of Tennessee HSC (Memphis) using Applied Biosystems 3100 Genetic Analyzer and BigDye™ Terminator Kit.

EXAMPLE 8

Statistical Analysis

Data was analyzed using one-way analysis of variance and appropriate post-hoc test or by Student t test using Prism 4.00 software (GraphPad Software, San Diego, Calif.).

EXAMPLE 9

Technological Considerations

Exposure to sunlight is the leading cause of skin cancer due to its UV component (Ichihashi et al., 2003). A number of genes have been reported to be involved in the response to UVR including those coding for the cytokines IL-1β, IL-6, IL-10 (Kimbauer et al., 1991; Grewe et al., 1995). These data, generated by conventional approach were, however, concentrated on a limited number of well-known genes and consequently limited in scope. To overcome such constraints, DNA microarrays searching for a range of genes that might be differentially expressed in human keratinocytes in response to UV irradiation were developed. The known limitation of this technology was the small number of experimental samples that could be tested simultaneously versus the large number of variables (probes); thus statistically significant effects could reflect experimental biasing while lack thereof might reflect low sensitivity, rather than absence of biological effect. To minimize possible bias, detected effects were verified by RT-PCR.

Another important aspect of microarray technology is data normalization; for which there are several approaches (Bilban et al., 2002). The most widely accepted method was used herein: LOWES normalization (intensity dependent). The strongest factors affecting data reliability were the technical quality of the slides and intrinsic precision and consistency of the individual techniques. Sometimes it might be impossible to eliminate false positives due to nonspecific dye binding, but this could be solved by dye-flip experiments, as presented in FIG. 1. Briefly, if the dot is green on the first slide it should be red on the second with the opposite dye combination. This was exemplified in FIG. 1 where both dye combinations showed identical changes of gene expression (up- or down-regulation).

DNA microarray with 761 probes was specifically designed herein to investigate neuroendocrine functions in the skin, including probes for the barrier function (Slominski and Wortsman, 2000). Genes were chosen to reflect functional pathways activated in response to environmental stressors or pathological events; e.g. carbohydrate metabolism-related hormones; pituitary and thyroid hormones; steroidogenic enzyme receptors. Genes coding for neurotransmitters, catecholamines, growth factors, cytokines, housekeeping genes and others involved in the protective function of the skin were also added. The full list of the genes as well as oligonucleotide sequences are listed on Table 1.

The oligonucleotide design approach used herein was a modification of the commonly used technique of searching for oligos with desired melting temperature, preferably at the 3′ end of the gene. Instead the oligos were placed on the borders between different exons to avoid unspecific labeling of DNA impurities. It is well known that human introns contain a wide range of simple repetitive sequences of which polyA sequences are most common. Hence, the use of total RNA and poly(dT) sequence to synthesize cDNA for microarray experiments may result in some unspecific labeling since poly(dT) sequence may hybridize to introns. This concept was tested by hybridizing cDNA synthesized from total and polyA RNA of HaCaT cell line (data not shown). The polyA RNA sample showed lower signal but, when normalized the conditions showed identical results. TABLE 1 DNA Microarray Chips for Neuroendocrine Functions in the Skin Short Full Primer gene gene Accession name name name number Primer sequence Comments M001 GCG Glucagon NM_002054 TTCAAGACACAGAGGAGAAATC

50 bp; e2-3 AGATCATTCTCAGCTTCCCAGG

GAC (SEQ ID NO: 25) M002 GCGR glucagon NM_000160 TGGTACCTGCCTTGGCACCACAA

50 bp; e4-5 receptor GTGCAACACCGCTTCGTGTTCAA

AG (SEQ ID NO: 26) M003 CRH-R1 GTGCCAGGAGATCCTCAATGAG

50 bp; e4-5 AGAAAAAAAGCAAGGTGCACTA

CATG (SEQ ID NO: 27) M004 AGGAGATCCTCAATGAGGAGAA

40 bp; e4-5 AAAAGCAAGGTGCACTA (SEQ ID NO: 28) M005 ATCCTCAATGAGGAGAAAAAAA

30 bp; e4-5 CAAGGTG (SEQ ID NO: 29) M006 GTGCCAGGAGATCCTCAATGAG

50 bp, 62% GC, AGGAGCCTGGGACTCAGGCACA

e4-cryptic; CCTG detects CRF-R1h (SEQ ID NO: 30) M007 AGGAGATCCTCAATGAGGAGGA

40 bp, 62% GC CCTGGGACTCAGGCACA e4-cryptic; (SEQ ID NO: 31) detects CRF-R1h M008 ATCCTCAATGAGGAGGAGCCTG

30 bp, 62% GC GACTCAG e4-cryptic; (SEQ ID NO: 32) detects CRF-R1h M009 GTTCTACTGTTTCCTCAATAGTG

50 bp; e13-14; GGTCCGTTCTGCCATCCGGAAGA

GT (SEQ ID NO: 33) M010 ACTGTTTCCTCAATAGTGAGGT

40 bp; e13-14; GTTCTGCCATCCGGAA (SEQ ID NO: 34) M011 CAACTCCTTCCTGGAATCCTTCC

50 bp; e13-15; GGTCCGTTCTGCCATCCGGAAGA

detects deletion GT of exon 13 (SEQ ID NO: 35) M012 CCTTCCTGGAATCCTTCCAGGT

40 bp; e13-15; GTTCTGCCATCCGGAA detects deletion (SEQ ID NO: 36) of exon 13 M013 5HTR2B Serotonin XM002541 ATTGCCCTCTTGACAATAATGTT

50 bp, e1-2; receptor 2B GAGGCTATGTGGCCCCTCCCACT

full-length GT (SEQ ID NO: 37) M014 CCTCTTGACAATAATGTTTGAG

40 bp, e1-2; TATGTGGCCCCTCCCA full-length (SEQ ID NO: 38) M015 TGACAATAATGTTTGAGGCTAT

30 bp, e1-2; GGCCCC full-length (SEQ ID NO: 39) M016 ATTGCCCTCTTGACAATAATGTT

50 bp, e1-3; GGCATTGCCATTCCAGTCCCTAT

5HTR2

 detects AA deletion of exon 2 (SEQ ID NO: 40) M017 CCTCTTGACAATAATGTTTGGCA

40 bp, e1-3; 5HTR2

TGCCATTCCAGTCCCT detects deletion of (SEQ ID NO: 41) exon 2 M018 TGACAATAATGTTTGGCATTGC

30 bp, e1-3; 5HTR2

TTCCAG detects deletion of (SEQ ID NO: 42) exon 2 M019 5HTR7 Serotonin XM015676 CCCTGTGCGTGATCAGCATTGA

50 bp, e1-2; 58% GC receptor 7 GGTACCTTGGGATCACAAGGCC

TC (SEQ ID NO: 43) M020 TGCGTGATCAGCATTGACAGGTA

40 bp, e1-2; 58% GC CTTGGGATCACAAGGC (SEQ ID NO: 44) M021 GATCAGCATTGACAGGTACCTT

30 bp, e1-2; 58% GC GATCAC (SEQ ID NO: 45) M022 CRF-R2 CACCCCTGGACCCCGAGGGTCC

40 bp; e4-5; 65% GC; alpha ACTCCTACTGCAACAC detects alpha isoform (SEQ ID NO: 46) M023 CRF-R2 CATGACCCTCACCAACCTCTCA

50 bp; e2-5; 65% GC; beta TCCCTACTCCTACTGCAACACGA

detects beta isoform CT (SEQ ID NO: 47) M024 CRF-R2 CCCTCACCAACCTCTCAGGTCC

40 bp; e2-5; 65% GC; beta ACTCCTACTGCAACAC detects beta isoform (SEQ ID NO: 48) M025 CRF-R2 CTTTCCTCAGCTCTTCTGCCAAG

50 bp; e3-5; 54% GC; gamma TCCCTACTCCTACTGCAACACGA

detects gamma isoform CT (SEQ ID NO: 49) M026 CRF Corticotropin CGAGCAGTTAGCACAGCAAGCT

50 bp releasing ACAGCAACAGGAAACTCATGGA

factor ATTA (SEQ ID NO: 50) M027 Uro Urocortin CTTCTCTGTCCATTGACCTCACC

50 bp TCACCTGCTGCGGACCCTGCTG

G (SEQ ID NO: 51) M028 CRFBP Corticotropin ATAAAGACAGACCCCAACCTCT

50 bp; est E1-2 releasing CCTTGCAATGTCATTTCTCAGA

factor CC binding (SEQ ID NO: 52) protein M029 FSH Follicle NM_000510 TGTGCTGGCTACTGCTACACCA

49 bp, e2-3, 55% GC beta stimulating GATCTGGTGTATAAGGACCCAG

hormone, A p-p b

(SEQ ID NO: 53) M030 FSHR Follicle NM_000145 GAACCTTCCCAACCTTCAATAT

50 bp, e3-4, 38% GC stimulating GTTAATATCCAACACAGGTATTA

hormone GC receptor (SEQ ID NO: 54) M031 CGB chorionic NM_000737 CACCAAGGATGGAGATGTTCCA

48 bp, e1-2, 58% GC; gona

GGGCTGCTGCTGTTGCTGCTGCT

It should also detect tropin, beta A CGB7, CGB8, proba

polypeptide (SEQ ID NO: 55) also CGB1, CGB5, CGB6 M032 GLYCA glycoprotein AH007338 CTCCATTCCGCTCCTGATGTGCA

50 bp, e2-3, 56% GC; alpha subunit GATTGCCCAGAATGCACGCTAC

GGA (SEQ ID NO: 56) M033 CTGTGTAGCTAAATCATATAACA

50 bp, e3-4, 42% GC; GGTCACAGTAATGGGGGGTTTC

AAG (SEQ ID NO: 57) M034 LHB Luteinizing NM_000894 TGTGCCGGCTACTGCCCCACCAT

47 bp, e1-2, 67% GC; hormone beta ATGCGCGTGCTGCAGGCGGTCC

high homology to C

p-p (SEQ ID NO: 58) M035 LHCGR Luteinizing NM_000233 TCAATGGGACGACACTGACTTCA

50 bp, e6-7, 46% GC; hormone TGGAGCTAAAGGAAAACGTACA

receptor CTG (SEQ ID NO: 59) M036 GNRH1 Gonadotropin- NM_000825 CCTCCGAGACCTGAAAGGAGCT

50 bp, e2-3, 50% GC; releasing GGAAAGTCTGATTGAAGAGGAA

hormone CTG (SEQ ID NO: 60) M037 GNRH2 Gonadotropin- NM_001501 CCCAGAATGCCCTTAGGCCCCCA

47 bp, e2-3, 67% GC; releasing GAAGGGCCCTGGACACTGCAGC

hormone (SEQ ID NO: 61) M038 GNRHR gonadotropin- NM_000406 CGGGTCCTTCATCAGGACCCCCA

50 bp, e2-3, 52% GC; releasing GAACTACAACTGAATCAGTCCA hormone GAA (SEQ ID NO: 62) M039 GNRH2 gonadotropin- NM_057163 TAGTTTCCTGCTTGCCTTCCCCC

50 bp, e2-3, 56% GC; releasing GCTGTTCCTGTTCCACACGGTCC

horomone CT type 2 (SEQ ID NO: 63) M040 GH2 growth TTCCAACAGGGTGAAAACGCAG

50 bp, e3-43, 50% GC

horomone AGAAATCTAACCTAGAGCTGCT

more specific for GH

GCA than GH1, but can (SEQ ID NO: 64) detect all GH, CSH M041 GH1 growth NM_000515 CAGGGAGGAAACACAACAGAAA

50 bp, e3-4, 54% GC, horomone CCAACCTAGAGCTGCTCCGCAT

will also detect CSH

CCC CSH2, GH2 (SEQ ID NO: 65) M042 AGCCTGGTGTACGGCGCCTCTGA

47 bp, e4, more speci

AGCAACGTCTATGACCTCCTAAA

for GH1 than to CSH (SEQ ID NO: 66) M043 GHR growth NM_000163 AAGTGTTTCTCTGTTGATGAAAT

50 bp, e4-5, 44% GC; horomone GTGCAACCAGATCCACCCATTG

receptor CT (SEQ ID NO: 67) M044 GHRH growth NM_021081 CCACCTCCCCCTTTGACCCTCAG

47 bp, e1-2, 62% GC; horomone ATGCGGCGGTATGCAGATGCCA

releasing (SEQ ID NO: 68) horomone M045 GHRHR growth NM_000823 TTCTCTCACTTCAGCTCAGAGTC

50 bp, e3-4, 48% GC; horomone GGGGCTGTGAAACGGGATTGTA

releasing TAT horomone (SEQ ID NO: 69) receptor M046 ghrelin ghrelin AB029434 GAGCCCTGAACACCAGAGAGTC

50 bp, e1-2, 56% GC; AGCAGAGAAAGGAGTCGAAGAA

homol to motilin CCAC (the same?) (SEQ ID NO: 70) M047 MC1R melanocortin XM_047456 AACCTCTTTCTCGCCCTCATCAT

50 bp, only 1 exon, 1 receptor GCAATGCCATCATCGACCCCCT

52% GC; specific for T MC1R (SEQ ID NO: 71) M048 MC2R melanocortin NM_000529 GATCGTCCTGCTGGCTGTGTTCA

50 bp, only 1 exon, 2 receptor GAATAAGAATCTCCAGGCACCC

50% GC; specific for TGT MC2R (SEQ ID NO: 72) M049 POMC proopiomelano

NM_000939 CTCACCACGGAAAGCAACCTGC

46 bp, e2-3, 63% GC; tin GGAGTGCATCCGGGCCTGCAAG

(SEQ ID NO: 73) M050 TCAGAGAGCAGCCTCCCGAGAC

46 bp, e1-2, 60% GC; GAGCCTCAGCCTGCCTGGAAGA

(SEQ ID NO: 74) M051 LOC5105 preproprolactin NM_015893 ACTCCATGGAGATCCGCACCCCT

48 bp, e1-2, 58% GC; releasing ACATCAATCCTGCCTGGTACGC

palindrom at 5′ end peptide (SEQ ID NO: 75) M052 PrRPR prolactin AB048946 TGCTGCTGGTCACCTACCTGCTC

49 bp, only 1 exon, releasing CTCTGCTGGTCATCCTCCTGTCT

57% GC; peptide (SEQ ID NO: 76) receptor M053 PRL prolactin XM_033558 GGGCATGGAGCTGATAGTCAGC

50 bp, e4-5, 48% GC; AGGTTCATCCTGAAACCAAAGA

may detect peptides AATG similar to prolactin (SEQ ID NO: 77) M054 PRLR prolactin NM_000949 GGATTTGATGCTCATCTGTTGGA

50 bp, e9-10, 46% GC

receptor AAGGGCAAGTCTGAAGAACTA

should be absent whe

GAG is alternatively (SEQ ID NO: 78) spliced in cancer (PRLR1b) M055 SST somatostatin NM_001048 TGGCTGCTGCCGCGGGGAAGCA

47 bp, e1-2, 62% GC; GAACTGGCCAAGTACTTCTTGG

have a palindron (SEQ ID NO: 79) M056 SSTR1 somatostatin NM_001049 CCTCTATGGCTTTCTCTCAGACA

50 bp, only 1 exon, receptor 1 CTTCAAGCGCTCTTTCCAACGCA

50% GC; specific for CC SSTR1 (SEQ ID NO: 80) M057 SSTR2 somatostatin XM_085745 GGCTATCCATTCCATTTGACCTC

50 bp, only 1 exon, receptor 2 ATGGCTCTGTGGTGTCAACCAA

50% GC; specific for CC SSTR2 (SEQ ID NO: 81) M058 TCAATCAGTTCACCAGCATCTT

50 bp, only 1 exon, GCCTGACAGTCATGAGCATCGA

50% GC; less specific GA may also detect SST

(SEQ ID NO: 82) 3, 5 genes M059 SSTR3 somatostatin NM_001051 CGCTCTTCGTGCTCTGCTGGATG

50 bp, only 1 exon, receptor 3 CCTTCTACGTGCTCAACATCGTC

56% GC; specific for AC SSTR3 (SEQ ID NO: 83) M060 SSTR4 somatostatin XM_009594 GTCTTCGTGGTCTACACTTTCCT

47 bp, only 1 exon, receptor 4 CTGGGCTTCCTGCTGCCCGTGCT

59% GC; may also (SEQ ID NO: 84) detect SSTR1 M061 SSTR5 somatostatin NM_001053 TCACCAACATCTACATTCTCAA

50 bp, only 1 exon, receptor 5 TGGCAGTGGCCGACGTCCTGTA

59% GC; may also TG detect SSTR2, 3, 4 (SEQ ID NO: 85) M062 TRH thyrotropin- XM_002795 AAGGGGACCAGGGTGAGCACT

48 bp, e2-3, 56% GC; releasing GCGTCCCAGATCTITTCAATCTGA

horomone T (SEQ ID NO: 86) M063 TRHR thyrotropin- XM_017795 CAGCACAGTATCTTCAAGGAAG

50 bp, e1-2, 52% GC; releasing AGGTCACCAAGATGCTGGCAGT

horomone GTTG receptor (SEQ ID NO: 87) M064 TSHb Thyroid stimu- NM_000549 CTGTGCTGGATATTGTATGACA

50 bp, e1-2, 42% GC; lating hormon, GGATATCAATGGCAAACTGTTT

beta subunit TC (SEQ ID NO: 88) M065 TSHR Thyroid stimu- NM_000369 GCTTACCGCCCAGTACGCAGACT

50 bp, e1-2, 52% GC; lating hormon TGAAGCTTATTGAGACTCACCT

receptor GA (SEQ ID NO: 89) M066 DIO1 type I 5′ S48220 TGCAACATTTGGGAGTTTATGCA

50 bp, e1-2, 42% GC; iodothyronine GGTAATAGGCCACTGGTGCTGA

deiodinase TT (SEQ ID NO: 90) M067 DIO2 type 2 5′ NM_000793 CTGGAAGAGCTTCCTCCTCGAT

50 bp, e2-3, 52% GC; iodothyronine CTACAAACAGGTGAAATTGGGT

deiodinase v2 AGG (SEQ ID NO: 91) M068 DIO3 type 3 5′ NM_001362 GCTACCAGGTCTCTGAGCTGCG

50 bp, only 1 exon iodothyronine CTTGGTTGGAACGCTATGATGA

54% GC; deiodinase AA (SEQ ID NO: 92) M069 SLC26A4 Iodine NM_000441 AGAGCACTGGAGGAAAGACACA

50 bp, e9-10, 52% GC

transport GTTGCTGGCATCATCTCTGCTG

ATT (SEQ ID NO: 93) M070 THRA thyroid XM_008585 ACTTGTGAGGGCTGCAAGGGCT

50 bp, e4-5, 54% GC; horomone TTTCGCCGCACAATCCAGAAGAA

receptor, CT alpha (SEQ ID NO: 94) M071 THRB thyroid NM_000461 ATCTATGTTGGCATGGCAACAGA

50 bp, e6-7, 48% GC; hormone TTGGTGCTGGATGACAGCAAGA

receptor, bet GCT (SEQ ID NO: 95) M072 TG thyroglobulin NM_003235 TAGGGAAGCCCAAGAAATGCCC

50 bp, e9-10 (the ACGCCCTGTCAAUACAGGCTGA

biggest), 54% GC; CAA (SEQ ID NO: 96) M073 CAAGGGCGGGAACTGGCTGAGA

50 bp, e7-8 (Assuming AGGTTTGGAGTTGTTACTGGAT

that it can also be AAT shorter protein), (SEQ ID NO: 97) 50% GC M074 AG Androgen L29496 TATGAAGCAGGGATGACTCTGG

50 bp, e3-4, 50% GC; receptor AGCCCGGAAGCTGAAGAAACTT

GTAA (SEQ ID NO: 98) M075 SBP plasma sex X05792 AGGGACTCAGGCAGAATTCAAT

50 bp, 50% GC; will steroid- TCCGAGACATTCCCCAGCCTCAT

also detect SHGB, binding CAG SHGB-2 protein (SEQ ID NO: 99) M076 ESR1 estrogen XM_045967 TGCTACGAAGTGGGAATGATGA

50 bp, e3-4, 48% GC; receptor 1 AGGTGGGATACGAAAAGACCGA

GAGG (SEQ ID NO: 100) M077 ESRRB o

estrogen AB006590 TTACGAAGTGGGAATGGTGAAG

50 bp, e3-4, 53% GC; ESR2 receptor GTGGCTCCCGGAGAGAGAGATG

beta GGGT (SEQ ID NO: 101) M078 ESRRA estrogen- NM_004451 ATCAGCTGGGCCAAGAGCATCC

50 bp, e3-4, 58% GC; related AGGCTTCTCATCGCTGTCGCTGT

receptor TGA alpha (SEQ ID NO: 102) M079 estrogen L25275 GACTCTGTTGGATCAGAAGGTCA

50 bp, e4-5, 50% GC; sulfotrans- GGTGGTCTATGTTGCCCGAAAC

may also detect phen

ferase AA and aryl (SEQ ID NO: 103) sulphotransferase M080 REA repressor of NM_007273 GAGCAGCCCAGAATATCTCCAA

50 bp, e6-7, 50% GC estrogen ACGATCGCCACATCACAGAATC

receptor ATC activity (SEQ ID NO: 104) M081 glucocorticoid X03225 TGAAATGGGCAAAGGCAATAC

50 bp, e5-6, 46% GC; receptor M10901 GGTTTCAGGAACTTACACCTGGA

detects both alpha and X03348 M11 GAG beta receptors (SEQ ID NO: 105) M082 alpha- X03225 GACGATGAGTATTGAATTCCCC

50 bp, e10, 42% GC; glucocorticoid M10901 GATGTTAGCTGAAATCATCACCA

detects only alpha receptor TC receptor = NR3C1 (SEQ ID NO: 106) M083 LOC1432 similar to XM_089709 ACAAAGCAGGGAAGAGAAACTT

50 bp, e2-3, 42% GC glucocorticoid AGGTGGGAGCATGTGTCAGTCTT

receptor CCC (SEQ ID NO: 107) M084 MR mineralocorticoid M16801 CTTCAAGCTGGAATGAATTTAG

50 bp, e4-5, 40% GC; receptor GCACGAAAGTCAAAGAAGTTG

detects full-length = AAA NR3C2 (SEQ ID NO: 108) M085 mineralocorticoid AJ315514 CTTCAAGCTGGAATGAATTTAG

50 bp, e4-?, 44% GC; receptor delta GAGAGAAGATGCATCAGTCTGC

should detect delta ATG isoform (SEQ ID NO: 109) M086 BZRP benzodiazapine NM_000714 TTCTTTGGTGCCCGACAAATGG

50 bp, e2-3, 58% GC; receptor TGGGCCTTGGTGGATCTCCTGCT

GT (SEQ ID NO: 110) M087 NR1H2 nuclear NM_007121 CCTCCTGAAGGCATCCACTATC

50 bp, e7-8, 56% GC; receptor GATCATGCTGCTAGAGACAGCC

subfamily 1, GGC group H (SEQ ID NO: 111) member 2 M088 NR1I3 nuclear NM_005122 GTGAGGGCTGCAAGGGTTTCTT

50 bp, e3-4, 56% GC; receptor GGAGAACAGTCAGCAAAAGCAT

subfamily 1, GGT group I, (SEQ ID NO: 112) member M089 NR2C1 nuclear NM_003297 TGATCTGTCTGCACAACACCTG

50 bp, e2-3, 48% GC; receptor GCTCCTAACAGATAATTCTCCA

subfamily 2, CC group C (SEQ ID NO: 113) member 1 M090 NR2C2 nuclear NM_003298 TTCAGACACACACGTCACATTTA

50 bp, e10-11 46% G

receptor GCTAACAATGCCCAGTCCAATG

may detect some subfamily 2, AG orphan receptors group C, (SEQ ID NO: 114) member 2 M091 NR2F2 nuclear NM_021005 AAGGCCATAGTCCTGTTCACCT

50 bp, e2-3, 52% GC; receptor GATGCCTGTGGTCTCTCTGATGT

subfamily 2, GC group F, (SEQ ID NO: 115) member 2 M092 NR4A1 nuclear NM_002135 TGGCGGTGGGCATGGTGAAGGA

47 bp, e3-4, 57% GC; receptor GTTGTCCGAACAGACAGCCTGA

subfamily 4, G group A, (SEQ ID NO: 116) member 1 M093 NR0B1 nuclear NM_000475 CGCTTCTGTACCGCTGCTGCTTT

44 bp, e1, 60% GC; receptor GCGGTGAAGACCACCCGCAGCA

subfamily 0, (SEQ ID NO: 117) group B, member 1 M094 NR2F1 nuclear NM_005654 TCAAAGTGGGCATGAGGCGGGA

47 bp, e1-2, 57% GC; receptor GCGGTTCAGCGAGGAAGAATG

has homology to orphan subfamily 2, T receptor (COUP-TFI) group F, (SEQ ID NO: 118) member 1 M095 NR1H4 nuclear NM_005123 GCACTGACCTGTGAGGGGTGTA

50 bp, e4-5, 48% GC receptor AGGTTTCTTCAGGAGAAGCATTA

farnesol receptor subfamily 1, CAA group H, (SEQ ID NO: 119) member 4 M096 NR2E1 nuclear AF411525 TGAGCAAGCCAGCCGGATCAAC

50 bp, e1-2, 50% GC receptor AGCCGCATTTTAGATATCCCCTG

subfamily 2 AAA group E (SEQ ID NO: 120) member 1 M097 NR4A2 nuclear NM_006186 TGTITTGTCCTTCGATTAGCATAC

50 bp, e6-7, 48% GC; receptor GGTCCAACCCAGTGGAGGGTAA

almost the same as subfamily 4, CTC NGFI-B/nur77 (acc group A, (SEQ ID NO: 121) S77154)-has several member 2 exons deleted M098 NR4A3 nuclear NM_006981 CTCAGTGTTGGAATGGTAAAAG

50 bp, e6-7, 42% GC receptor AGTTGTCCGTACAGATAGTCTGA

neuron derived orphan subfamily 4, AGG receptor (NOR-1, group A, (SEQ ID NO: 122) #D78579) member 3 M099 NR5A1 nuclear NM_004959 TGCTCACGTGTGAGAGCTGCAA

56 bp, e1-2, 58% GC = receptor GGCTTCTTCAAGCGCACGGTGCA

steroidogenic factor subfamily 5, (SEQ ID NO: 123) 1(#U76388) group A, member 1 M100 AAGTTCATCATCCTCTTCAGCCT

50 bp, e5-6, 40% GC GATTTGAAGTTCCTGAATAACCA

AT (SEQ ID NO: 124) M101 NR6A1 nuclear NM_033334 CGCCCTCCGATGAAGAACTACA

50 bp, e5-6, 50% GC = receptor AGATTTAGTGATGAAGGGATGG

gem cell nuclear subfamily 6, GGTG receptor, GCNF group A, (SEQ ID NO: 125) (S83309) member 1 M102 PGR progesterone NM_000926 CTTCTTTAAGAGGGCAATGGAA

50 bp, e2-3, 44% GC receptor GGCAGCACAACTACTTATGTGCT

GAA (SEQ ID NO: 126) M103 Delta GCTGTCAGGCTGGCATGGTCCTT

50 bp, e2-3, 46% GC isoform GAGGTTTTCGAAACTTACATATT

AT (SEQ ID NO: 127) M104 PGRMC1 progesterone NM_006667 AGTGACTGGGAGTCTCAGTTCA

receptor TTCAAGTATCATCACGTGGGCAA

membrane CT component 1 (SEQ ID NO: 128) M105 PGRMC2 progesterone NM_006320 CGAGAATGGGAAATGCAGTTTA

50 bp, e2-3, 36% GC receptor AGAAAAATATGATTATGTAGGC

membrane GACT component 2 (SEQ ID NO: 129) M106 RARA retinoic acid NM_000964 TTTGAAGTGGGCATGTCCAAGGA

50 bp, e4-5, 46% GC receptor, GTCTGTGAGAAACGACCGAAAC

alpha AGAA (SEQ ID NO: 130) M107 RARB v1 retinoic acid NM_000965 GGTCAGCGCCTGTGAGGGATGT

50 bp, e2-3, 52% GC; (NR1B2) receptor, AGGGCTTTTTCCGCAGAAGTATT

detects both v1 and beta, v

AGA v

 isoforms (SEQ ID NO: 131) M108 RARG retinoic acid NM_00096 ACCTCCGGGGCATCAGCACTAA

49 bp, e6-7, 55% GC receptor, GGAGCTGAAAGGGCCATTACTC

gamma GAA (SEQ ID NO: 132) M109 RXRA retinoid X NM_002957 ATCTGCGGGGACCGCTCCTCAG

46 bp, e3-4, 58% GC receptor, AAGCACTATGGAGTGTACAGCT

alpha (SEQ ID NO: 133) M110 RXRB retinoid X NM_021976 CAATCTGCGGGGACAGAAGCTC

48 bp, e1-2, 50% GC receptor, GGCAAACACTACGGGGTTTACA

beta CT (SEQ ID NO: 134) M111 AKR1D1 aldo-keto NM_005989 TGGTACCTACTCAGAACCTAAAT

50 bp, e1-2, 52% GC reductase GACCCCTAAGGGAGCCTGTGCA

family 1 CAT member D1 (SEQ ID NO: 135) M112 CYP11A cytochrome P45

NM_000781 TCCAGAAGTATGGCCCGATTTA

48 bp, e1-2, 54% GC subfamily X1A GGGAGAAGCTCGGCAACGTGGA

P450 scc T (SEQ ID NO: 136) M113 CYP11B1 cytochrome P4

NM_000497 AAATGTGGCGTGTTCTTGCTGAA

50 bp, e2-3, 50% GC subfamily X1B GGGCCTGAATGGCGCTTCAACC

(steroid 11-beta- polypeptide 1 ATT hydroxylase) will also (SEQ ID NO: 137) detect CYP11B2 M114 CYP17 cytochrome P4

NM_000102 ACTTCTCTGGGCGGCCTCAAAT

48 bp, e2-3, 54% GC subfamily XVI

CAACTCTAGACATCGCGTCCAA

Steroid 17-alpha- (SEQ ID NO: 138) hydroxylase M115 CYP19 cytochrome P4

NM_000103 GCTCTTCTTGAGGATCCCTTTGG

50 bp, e5-6, 46% GC subfamily XIX CGAAAGTGCTATCGTGGTTAAA

aromatization of CC androgens (SEQ ID NO: 139) M116 CYP21A2 cytochrome P4

NM_000500 TGTGGACGTGATTCCCTTTCTCA

50 bp, e5-6, 54% GC subfamily XXI

GTTCTTCCCCAATCCAGGTCTCC

Steroid 21-hydroxylase GA (SEQ ID NO: 140) M117 CYP24 cytochrome P4

XM_030593 CTCAAGAAACAGCACGACACCC

50 bp, e1-2, 50% GC subfamily XXI

GGTGGAGTACCACAAGAAGTAT

vitamin D 24- GCAA hydroxylase (SEQ ID NO: 141) M118 CYP27A1

cytochrome P4

NM_000784 GGTTGGAATGCCATCTTTTCCTT

50 bp, e4-5, 44% GC subfamily GGGAAGAAGCTGATTGATGAGA

Steroid 27-hydroxylase XXVIIA GCT (SEQ ID NO: 142) M119 CYP2C9 cytochrome P4

NM_000771 CTGCTGAAGCACCCAGAGGTCA

48 bp, e6-7, 50% GC subfamily IIC AGCTAAAGTCCAGGAAGAGATT

Mephenytoin 4- AA hydroxylase; will also (SEQ ID NO: 143) detect CYP2C8, 17,

 19 M120 CYP3A4 cytochrome P4

NM_017460 AGTCGCCTCGAAGATACACAAA

50 bp, e6-7, 48% GC subfamily IIIA GCACCGAGTGGATTTCCTTCAG

niphedipine oxidase GAT will detect other CYP

(SEQ ID NO: 144) genes M121 HSD17B1 17beta- AF037438 AGTGTGGCTGCCTTCGAGGGTCA

= ERAB (U96132) hydroxysteroid GTTGGACAAGCTGCATACTCTG

dehydrogenase T type 10 (SEQ ID NO: 145) M122 HSD17B3 hydroxysteroid NM_000197 CCTGAACGCACCGGATGAAATC

50 bp, e5-6, 50% GC (17-beta) AGAGCCTCATCCATTGTAACAT

dehydrogenase CCT (SEQ ID NO: 146) M123 HSD17B8 hydroxysteroid NM_014234 AACATCAGTAGCATCGTAGGAA

50 bp, e4-5, 51% GC (17-beta) GGTGGGGAACGTGGGGCAGACA

dehydrogenase ACT (SEQ ID NO: 147) M124 adrenaline E07358 TTCGTGCTCTGCTGGTITCCCCTT

50 bp, 50% GC alpha2CII TCTTCAGCTACAGCCTGTACGG

receptor T (SEQ ID NO: 148) M125 adrenaline E14946 AGGCTTTGCCAACGGCTCGACG

50 bp, e1-2, 57% GC beta receptor GGCTTCTTGGGGAGTTTCTTAG

(SEQ ID NO: 149) M126 PNMT phenylethanola

NM_002686 AACATGCCTGCCTCATTGAGGG

46 bp, e2-3, 54% GC ne N-methyl AGGGGGAATGCTGGCAGGATAA

transferase (SEQ ID NO: 150) M127 SLC6A2 solute carrier NM_001043 TTCTACCGCTTGAAAGAGGCCA

50 bp, e5-6, 50% GC family 6 GTATGGATTGATGCCGCAACTCA

neurotransmitter AT transporter, (SEQ ID NO: 151) noradrenalin M128 ADM adrenomedullin NM_001124 TGTCGCGTCGGAGTTTCGAAAGA

50 bp, e2-3, 52% GC GTGGAATAAGTGGGCTCTGAGT

GTG (SEQ ID NO: 152) M129 ADMR adrenomedullin NM_007264 TCCCAAGGGAAACTCAGGCGTG

46 bp, e1-2, 55% GC receptor GCTGGTCCCAATGTCAGTGAAA

(SEQ ID NO: 153) M130 ANGPT1 angiopoietin 1 NM_001146 CAACCTTGTCAATCTTTGCACTA

50 bp, e4-5, 38% GC AGAAGGTGTTTTACTAAAGGGA

GAA (SEQ IDNO: 154) M131 ANGPT2 angiopoietin 2 XM_034835 ATCCCAGTCCACCTGAGGA 50 bp, e9, 46% GC ACTGTCTCGAACTATTTTCAAA

CTTAAGC (SEQ ID NO: 155) M132 ANGPT4 angiopoietin 4 NM_015985 AAGAAAGGGCTAACGCCTCGG

47 bp, e4-5, 59% GC; CCGGCCTTCATAATGGCAGGTGA

angiopoetin-3 (SEQ ID NO: 156) M133 CDT6 angiopoietin- NM_021146 AGACGGTCACTCAGACCTCCGC

47 bp, e1-2, 57% GC like fact GATGCCATCTACGACTGCTCTT

(SEQ ID NO: 157) M134 LOC1643 similar to XM_092738 AACTGGATCTGAGCGCAAAAAG

50 bp, only 1 exon Angiopoietin 1 AAGACACAGACGGTCAAAAAC

50% GC receptor CCCC precursor (SEQ ID NO: 158) M135 TEK TEK tyrosine XM_005480 TGTGGAGTCAGCTTGCTCCTTTC

50 bp, e1-2, 50% GC kinase GGAACTGTGGAAGGTGCCATGG

CTT (SEQ ID NO: 159) M136 BDKRB1 bradykinin NM_000710 CTGCTGCACAGAGTGCTGCCAA

50 bp, e2, 52% GC receptor B1 TTTATCATCTCCATCTGTTTCTT

G (SEQ ID NO: 160) M137 BDKRB2 bradykinin XM_040854 TCCGTGCCCACCACGGCCTCTTT

46 bp, e1-2, 60% GC receptor B2 AGCGCCGACATGCTCAATGTCA

(SEQ ID NO: 161) M138 PTGIS prostaglandin NM_000961 TGATGAAAAGGCCAGGATGAAA

50 bp, e3-4, 50% GC I2 (prosta- TGACTCTTCTCCACAGAGAGCT

cyclin) AGG synthase (SEQ ID NO: 162) M139 CT Calcitonin X00356 J001 TCATGTTAGCATGCCCCAGAAT

50 bp, e3, 48% GC CAACTAAACTCCTCCCTTTTCCTT

CT (SEQ ID NO: 163) M140 CALCA Calcitonin M64486 ATCATTGCCCAGAAGAGAGCCT

49 bp, e3, 54% G with different GACACTGCCACCTGTGTGACTCA

Detected in medullar C-term C thyroid carcinoma (SEQ ID NO: 164) M141 CALCB calcitonin- XM_113645 TCAAGCCTGAGCAGATGAATGA

50 bp, e8-9, 50% G related TCCAGGAAGAAGGTTATCATGA

polypeptide, ACTG beta (SEQ ID NO: 165) M142 CALCR calcitonin NM_001742 AGGGCCGTGTACTTCAATGACA

receptor TGCTGGCTGAGTGTGGAAACCCA

TT (SEQ ID NO: 166) M143 ECE2 endothelin NM_014693 AGCCACTGAGAGACCTCATTGA

49 bp, e5-6, 49% GC converting AAGATTGGTGGTTGGAACATTA

enzyme 2 GG (SEQ ID NO: 167) M144 ECE2 Variants A AF428263 GGCTGCCTTGTGGCCCTAGGGGT

47 bp, e3-9, 55% GC AF428264 TATGGGATGGATTATTFGCAGCA

(SEQ ID NO: 168) M145 ECE1 endothelin NM_001397 CTCTCATCAACACCACCGACAG

50 bp, e9-10, 50% G converting GCCTGCTCAACAACTACATGAT

enzyme 1 GG (SEQ ID NO: 169) M146 EDN1 endotbelin 1 XM_165812 ACATCATTTGGGTCAACACTCCT

50 bp, e2-3, 50% GC AGCACGTTGTTCCGTATGGACTT

GA (SEQ ID NO: 170) M147 EDN2 endothelin 2 NM_001956 ACATCATCTGGGTGAACACTCCT

50 bp, e2-3, 54% GC AACAGACAGCTCCTTACGGCCT

GA (SEQ ID NO: 171) M148 EDN3 endothelin 3 XM_030725 ACATCATTTGGATCAACACTCC

49 bp, e2-3, 53% GC AACAGACGGTGCCCTATGGACT

C (SEQ ID NO: 172) M149 EDNRA endothelin NM_001957 TGATCTCCCTATCAATGTATTTA

50 bp, e2-3, 50% GC receptor GCTGCTGGCTGGGCGCTGGCCTT

type A TG (SEQ ID NO: 173) M150 EDNRB endothelin XM_007108 TGACATCCCTATCAATGTCTACA

50 bp, e1-2, 50% GC receptor GCTGCTGGCAGAGGACTGGCCA

very similar to M149 type B TG (SEQ ID NO: 174) M151 GTCTATGTGCTCTGAGTATTGA

50 bp, e2-3, 50% GC GATATCGAGCTGTTGCTTCTTGG

sure only EDNRB GT (SEQ ID NO: 175) M152 CCK cholecystokinin NM_000729 AGATACATCCAGCAGGCCCGGA

50 bp, e2-3, 54% GC AGCTCCTTCTGGACGAATGTCCA

CGT (SEQ ID NO: 176) M153 CCKBR cholecystokinin NM_000731 TGCAAGGCGGTTTCCTACCTCAT

47 bp, e2-3, 57% GC; receptor GGGGTGTCTGTGAGTGTGTCCA

will also detect gastric (SEQ ID NO: 177) receptor M154 GAS gastrin NM_000805 CCCACACCTCGTGGCAGACCCGT

41 bp, e1-2, 63% GC CAAGAAGCAGGGACCAT (SEQ ID NO: 178) M155 CGACTATGTGTGTATGTGCTGAT

49 bp, e1, 53% GC TTTGCACTGGCTCTGGCCGCCTT

T (SEQ ID NO: 179) M156 GRP gastrin- NM_002091 AAAGATGTAGGTTCAAAAGGCA

50 bp, e2-3, 44% GC releasing AGTTGGTAGACTCTCTGCTCCA

peptide TTC (SEQ ID NO: 180) M157 GRPR gastrin- NM_005314 AGGGAATATACATGTCAAGAAG

50 bp, e1-2, 46% GC releasing AGATTGAATCCCGGAAGCGACT

peptide GCCA receptor (SEQ ID NO: 181) M158 LEP leptin NM_000230 CAGGATCAATGACATTTCACACA

50 bp, e1-2, 46% GC GCAGTCAGTCTCCTCCAAACAGA

AG (SEQ ID NO: 182) M159 LEPR Leptin NM_002303 ACCTTTTCATGGCCTATGAGCAA

50 bp, e15-16, 46% G

GTAAATATCGTGCAGTCACTCA

GC (SEQ ID NO: 183) M160 MCH-R2 melanin- AF399937 TCATGACTGTAATGAGTGTGGA

50 bp, e2-3, 46% GC concentrating GGTACTTTGCCCTCGTCCAACCA

hormone TT receptor (SEQ ID NO: 184) M161 PMCH pro-melanin- XM_006590 CGAAGAGGAAAATAAAGTTTCA

50 bp, e1-2, 34% GC concentrating AGAACACAGGCTCCAAACATAA

hormone TTCT (SEQ ID NO: 185) M162 CATGCTCAGATGTATGCTGGGAA

50 bp, e3, 50% GC AGTCTACCGACCTTGTTGGCAA

CT (SEQ ID NO: 186) M163 Something GTAGCGTTAAGATAGATCAGTA

50 bp, 36% GC sim

 from CCAAAATCATAGGCTTTTTCTGT

chromosome 5 CAT (SEQ ID NO: 187) M164 CABP1 calcium NM_031205 GGAACTGCGAGATGCTTTCCGA

50 bp, e5-6, 50% GC binding AGTTTGACACCAATGGTGATGG

protein 1 v1 GAAA (SEQ ID NO: 188) M165 Variant 2 TCCACTGAGAAATCTCTCAAGGA

50 bp, e1-3, 46% GC GGATAGATCACTGCGACCAGAG

AAA (SEQ ID NO: 189) M166 CABP2 calcium NM_016366 GCAGCATAAAGGACTCAAGGA

47 bp, e7, 55% GC protein 2 v1 ACAGCCTCTGCCCACCAGCATGT

(SEQ ID NO: 190) M167 CABP3 calcium NM_016367 CTCAAGAAATGCTTCCCGCAGCT

50 bp, e1-2, 50% GC binding TTCAATCTCATCTTGTCCCAGTG

protein 3 TC (SEQ ID NO: 191) M168 CABP5 calcium NM_019855 CACTGGGACAAGATGAGATTGA

50 bp, e1-2, 48% GC binding GAGCTGCGGGAAGCATTTCTTGA

protein 5 TTC (SEQ ID NO: 192) M169 CALM1 calmodulin 1 NM_006888 AACTGTCATGAGGTCACTGGGT

50 bp, e2, 50% GC GAACCCAACAGAAGCTGAATTG

will also detect AGG calmodulin 2 (SEQ ID NO: 193) M170 CALM2 calmodulin 2? D45887 AGAAGCATTCCGTGTGTTTGATA

50 bp, e3-4, 48% GC GGATGGCAATGGCTATATTAGT

TG (SEQ ID NO: 194) M171 CALM3 calmodulin 3 NM_005184 ATATGATCAATGAGGTGGATGC

50 bp, e3-4, 48% GC GATGACCTTCCAGGGAACGGGA

CATTGA (SEQ ID NO: 195) M172 CALN1 calneuron 1 NM_031468 CACGATAGACAGCATATTCTGG

50 bp, e3-4, 44% GC GTTTGACATGCAAAGGATAACT

GG (SEQ ID NO: 196) M173 CAMKK2 calcium/calmo

XM006592 CACGTCTCCATCACGGGTATGCA

49 bp, e2-3, 51% GC n-dependent GACTGTGTGCAGCTGAATCAGTA

protein kinase A kinase 2 (SEQ ID NO: 197) M174 PDE1A phosphodiester

NM_005019 GAAACAGTTTGCAGCAGCCTGA

50 bp, e10-11, 50% G

1A, calmodulin GGGATTGACAGAGCCAAAACCA

dependent GTCC (SEQ ID NO: 198) M175 MLN motilin NM_002418 CTATGGCGAACTCCAGAGGATG

50 bp, e2-3, 50% GC AGGAAAAGGAACGGAATAAAG

CAAA (SEQ ID NO: 199) M176 NPPB natriuretic NM_002521 ACTTGGAAACGTCCGGGTTACA

46 bp, e2, 56% GC; peptide GAGCAGCGCAACCATTTGCAGG

precursor B (SEQ ID NO: 200) M177 NPPC natriuretic NM_024409 CAAATACAAAGGAGCCAACAA

48 bp, e1-2, 52% GC peptide AGGGCTTGTCCAAGGGCTGCTT

precursor C (SEQ ID NO: 201) M178 NPR1 natriuretic NM_000906 CGGATGTGGAACCGAAGCTTTC

50 bp, e3-4, 52% GC peptide AGGTGTGACAGGATACCTGAAA

receptor A TTGA (SEQ ID NO: 202) M179 GGATCCCGAGAATGGTGCCTTC

50 bp, e5-6, 50% GC GGTTGTACTGAACTACAATGGG

TT (SEQ ID NO: 203) M180 NPR2 natriuretic NM_003995 AAAGATGCAGGGACGAAGATAT

50 bp, e4-5, 50% GC peptide ACGGTGTAACTGGGCTGGTTGT

receptor B TGG (SEQ ID NO: 204) M181 TTGGACGACCCATCCTGTGATAA

50 bp, e6-7, 46% GC ACTCCACTTTCAACCCTGGCAAT

GT (SEQ ID NO: 205) M182 NPR3 natriuretic NM_000 CAATATCCAGGCCAGTGAGAGA

48 bp, e1-2, 52% GC peptide TGGTGATCATGTGTGCGAGCAG

receptor C A (SEQ ID NO: 206) M183 KIAA097 netrin G1f NM_014917 CCCTCCTGAGACGTTCTGTGCAA

50 bp, e2-3, 50% GC GGGCAATCCCTACATGTGCAATA

TG (SEQ ID NO: 207) M184 KIAA185 netrin G2 NM_032536 CCCTGAGAGGTTCTGCTCCCAT

48 bp, e1-2, 54% GC GAATCCCTACCTATGCAGCAAC

(SEQ ID NO: 208) M185 NTN1 Netrin 1 NM_004822 CAGCAGCGTGGAGGAGCCTGAA

45 bp, e3-4, 59% GC ACTGCGATTCCTACTGCAAGG (SEQ ID NO: 209) M186 NTN4 Netrin 4 NM_02122 TTCTCAGCTCCAGATGCTTGCAA

49 bp, e1-2, 51% GC CCGTGTTCCTGCCATCCAGTAG

T (SEQ ID NO: 210) M187 iNOS nitric oxide AF051164 CAGGATGACCCTAAGAGTCACA

50 bp, 48% GC synthase GCATCAAAATGGTTTCCCCCAGT

will also detect NOS

CCT (SEQ ID NO: 211) M188 NOS1 nitric oxide NM_000620 CAACTCTGTGCAGGAAGAAAGG

50 bp, e15-16, 50% G

synthase 1 AGAGCTACAAGGTCCGATTCAA

AGCG (SEQ ID NO: 212) M189 NOS2 nitric oxide TGACACAGGATGACCTTCAGTA

50 bp, 48% GC in one synthase 2 ACAACCTCAGCAAGCAGCAGAA

exon will also detect GAG iNOS (SEQ ID NO: 213) M190 NOS3 nitric oxide CACAGGAAATGTTCACCTACAT

50 bp, 46% GC synthase 3 GCAACCACATCAAGTATGCCAC

AAC (SEQ ID NO: 214) M191 PEDF pigment M76979 GCCTCCCGGATCGTCTTTGAGA

A 50 bp, e4-5, 50% GC epithelium- AAGCTGCGCATAAAATCCAGCT

differenti- GT ation factor (SEQ ID NO: 215) M192 NPY5R neuropeptide NM_006174 GCTACTGTCTGGACACTAGGTTT

50 bp, single exon, Y

 receptor Y5 GCCATCTGTTCTCCCCTTCCAGT

50% GC TT (SEQ ID NO: 216) M193 neuropeptide U42389 AATGGGTCCAATAGGTGCAGAG

50 bp, single exon, y/peptide YY CTGATGAGAACCAGACAGTGGA

50% GC receptor type 2 GAAA (SEQ ID NO: 217) M194 PPY2 pancreatic NM_021092 TTGGAGCCATTGTACCGAGGGG

44 bp, 54% GC polypeptide 2 AATACCACACCGGAGCAGAT (SEQ ID NO: 218) M195 PPYR1 pancreatic NM_005972 TACACCATCATGGACTACTGGAT

50 bp, single exon, polypeptide TTTGGAGAGACCCTCTGCAAGAT

48% GC receptor 1 TC (SEQ ID NO: 219) M196 PYY peptide YY NM_004160 ACTACCTCAACCTGGTCACCCG

41 bp, e2-3, 54% GC AGCGGTATGGGAAAAGA (SEQ ID NO: 220) M197 PYY2 peptide YY, 2 NM_021093 TACGCCTATCCTCGCCAGTACCT

46 bp, single exon, ATCCTGGTCACTCAGCCGTCGT 54% GC (SEQ ID NO: 221) M198 VIP vasoactive NM_003381 TTACAGGGCACCTTCTGCTCT

50 bp, e1-2, 50% GC intestinal GGTTGGGTGACAGAATACCCTTT

peptide AG (SEQ ID NO: 222) M199 AGTCTCTTATGGGAAAACGTGTT

50 bp, e3-4, 42% GC GCAGTAACATCTCAGAAGACCC

GTA (SEQ ID NO: 223) M200 PTH parathyroid NM_000315 AAATCGGATGGGAAATCTGTTA

50 bp, e2-3, 38% GC hormon GAAGAGATCTGTGAGTGAAATA

AGCT (SEQ ID NO: 224) M201 PTHR1 parathyroid NM_000316 GGTGCCCATCCTGGCCTCCATT

50 bp, e10-11, 50% G

hormone GCTCAACTTTCATGCTCTTCATCA

receptor 1 TA (SEQ ID NO: 225) M202 CATATACTGTTTCTGCAATGGC

50 bp, e14-15, 40% G

GGTACAAGCTGAGATCAAGAA

CTT (SEQ ID NO: 226) M203 PTHR2 parathyroid NM_005048 GGCATGACACAAGGAAGCAATA

50 bp, e10-11, 50% G

hormone AGGAAACTGGCCAAATCGACA

receptor 2 GGTC (SEQ ID NO: 227) M204 GGCAACTTCTGTGGACAAATCA

50 bp, e6-7, 44% GC ATATATCGGGTGCAAGATTGCT

TG (SEQ ID NO: 228) M205 CYP4F8 cytochrome P4

NM_007253 GTCCGATCTGTCATCAATACCT

50 bp, e2-3, 44% GC subfamily IVF, GATGCCATTACAGACAAGGACA

polypeptide 8 AGT (SEQ ID NO: 229) M206 PTGDR prostaglandin XM_051711 CACTATGTGTTCTCTGCCCGTAA

50 bp, e1-2, 42% GC D

 receptor TTATCGCGCTTACTATGGAGCAT

TA (SEQ ID NO: 230) M207 CYP4F11 cytochrome P4

NM_021187 GCCTATCACCAGTGCCTCAGCT

47 bp, e1-2, 53% GC subfamily IVF, TGTCGCACCCAAGGATATGATTT

polypeptide 11 (SEQ ID NO: 231) M208 CYP4F12 cytochrome P4

NM_023944 AACAAGAGTGCAAACATCATGC

50 bp, e4-5, 50% GC isoform 4F12 TGACAAGTGGCAGCACCTGGCC

AGA (SEQ ID NO: 232) M209 CYP4F2 cytochrome P4 NM_001082 ATCCGGTCTGTCATCAACGCCT

50 bp, e3-4, 52% GC subfamily IVF, GCTGCCATTGCACCAAAGGACA

polypeptide 2 GTT (SEQ ID NO: 233) M210 CYP4F3 cytochrome P4 XM_029072 CATTGATGTACTCCTGCTGAGCA

50 bp, e6-7, 48% GC subfamily IVF, GGATGAAGATGGGAAGAAGTT

polypeptide 3 CCG (SEQ ID NO: 234) M211 PTGER1 prostaglandin E NM_000955 CGTGCATCTGCTGGAGCCCAAT

40 bp, e2-3, 62% GC receptor 1 TGGTGTTGGTGGCGCT (SEQ ID NO: 235) M212 PTGER2 prostaglandin E NM_000956 CGCCGTCTGCTCCTTGCCTTTCA

50 bp, e1-2, 44% GC receptor 2 GATTTTTGCATATATGAATGAAA

CT (SEQ ID NO: 236) M213 PTGER3 prostaglandin E NM_000957 AGGACTTGGTGCAGTTCTCATGA

50 bp, e1-2, 48% GC receptor 3 AGAGAACCCTGCAGTGTCCAGC

AAG (SEQ ID NO: 237) M214 PTGER4 prostaglandin E NM_000958 TCATCTGCTCCATCCCGCTCGTG

48 bp, e2-3, 52% GC receptor 4 TGCGAGTATTCGTCAACCAGTTA

(SEQ ID NO: 238) M215 PTGFR prostaglandin F NM_000959 TCCTGTATTTGTTGGAGCCCATT

50 bp, e2-3, 42% GC receptor CTGGTTACAATGGCCAACATTG

AT (SEQ ID NO: 239) M216 PTGIR prostaglandin NM_000960 TGTGCTCCCTGCCTCTCACGATC

37 bp, e2-3, 62% GC I2 (prosta- GCTGCTTCACCCA cyclin) (SEQ ID NO: 240) receptor M217 PTGS2 prostaglandin- NM_000963 TTCTATGGAGAAAACTGCTCAA

50 bp, e2-3, 32% GC endoperoxide CCGGAATTTTTGACAAGAATAA

synthase 2 ATT (SEQ ID NO: 241) M218 CAGACAAGCAGGCTAATACTGA

50 bp, e7-8, 38% GC AGGAGAGACTATTAAGATTGTG

TTGA (SEQ ID NO: 242) M219 TBXA2R thromboxane A NM_001060 TCTCTGTCGCTTCATGGGCGTCG

44 bp, 54% GC receptor CATGATCTTCTTCGGCCTGT (SEQ ID NO: 243) M220 TBXAS1 thromboxane A NM_001061 TTTCAGTCCTGAAAAGCTGAAC

50 bp, e4-6, 33% GC synthase 1 GATGGTTCCCCTCATCAGCCAA

CT (SEQ ID NO: 244) M221 GGTAGACGTTTTTAAGGAGAAA

49 bp, e9-10, 51% GC ACATGGCCCCTGAGTTCTGCAG

TC (SEQ ID NO: 245) M222 AGTR1 angiotensin XM_051470 TGTACGCTAGTGTGTTTCTACTC

50 bp, 46% GC receptor 1 CGTGTCTCAGCATTGATCGATA

TG (SEQ ID NO: 246) M223 AGTR2 angiotensin XM_030897 ATTTACTCCTTTTGGCTACTCTT

50 bp, 36% GC receptor 2 TCTATGGGCAACCTATTATTCTT

T (SEQ ID NO: 247) M224 ACE angiotensin I XM_044372 CTTCTACAACAGGAAAGACTTCA

50 bp, e6-7, 50% GC converting GATCAAGCAGTGCACACGGGTC

enzyme CGA (SEQ ID NO: 248) M225 AGT angiotensinoge NM_000029 TTCAACACCTACGTCCACTTCCA

50 bp, e2-3, 52% GC GGGAAGATGAAGGGCTTCTCCC

GCT (SEQ ID NO: 249) M226 REN renin NM_000537 CGACAGACACCACCACCTTTAAA

50 bp, e1-2, 50% GC GGATCTTCCTCAAGAGAATGCC

CA (SEQ ID NO: 250) M227 GGAGCCAAGAAGAGGCTGTTTG

49 bp, e7-8, 51% GC TTATGTCGTGAAGTGTAACGAG

CC (SEQ ID NO: 251) M228 RENBP renin binding NM_002910 AAGTATGTGTGGCTGCAGGGGA

49 bp, e3-4, 53% GC protein GCAGGTATGGATGTATTGTCGC

GT (SEQ ID NO: 252) M229 ACE2 ACE-related AF291820 AGAACTGAAGTTGAAAAGGCCA

50 bp, e16-17, 48% G

carboxypeptidase CAGGATGTCCCGGAGCCGTATC

ATGA (SEQ ID NO: 253) M230 SCT secretin NM_021920 CTGGTGGGGAAGCGCAGCGAG

47 bp, e2-3, 65% GC GGACGCAGAGAACA

(SEQ ID NO: 254) M231 SCTR Secretin NM_002980 GGATGCTCACCAGCAGAAATGG

49 bp, e3-4, 51% GC receptor TCCTTGTTCCGAAACTGCACACA

GA (SEQ ID NO: 255) M232 UTS2 Urotensin 2 NM_021995 ATGCTGGGTGCAGAAAGAGGG

50 bp, 48% GC TATTCTCAGGAAAGCAGACTCA

GTAC (SEQ ID NO: 256) M233 AQP4 aquaporin 4 NM_001650 CAGTTATCATGGGAAATTGGGA

50 bp, e3-4, 44% GC AACCATTGGATATATTGGGTTG

CCC (SEQ ID NO: 257) M234 AVPR1A arginine XM_006934 ACAGAACATTGTCTTACTTGAT

50 bp, e1-2, 42% GC vasopressin TCCCGATGACCTCAACAACAGG

receptor 1A AAG (SEQ ID NO: 258) M235 AGATTTCAAGTCCAGCATCTCAA

50 bp, e2-3, 44% GC GCGACAACCTTGGTAACTCTGCA

GA (SEQ ID NO: 259) M236 AVPR1B arginine NM_000707 CGGTGACCATGCTCACGGCCTG

41 bp, e2-3, 61% GC vasopressin ACAGCCTCATCTGCCAT receptor 1B (SEQ ID NO: 260) M237 CCACCAATGTGGCTTTCACCAT

50 bp, e3, 50% GC CTAGCTTTTGGGCAACCTCAA

GC (SEQ ID NO: 261) M238 AVPR2 arginine NM_000054 ATGCTCATGGCGTCCACCACTT

40 bp, e1-2, 62% GC vasopressin GCTGTGCCTGGGCATC receptor 2 (SEQ ID NO: 262) M239 OXTR oxytocin NM_000916 ATGCCAACGCGCCCAAGGAAG

43 bp, e1-2, 58% GC receptor TCGGCCTTCATCATCGTCAT (SEQ ID NO: 263) M240 OXT oxytocin NM_000915 AAAGGCCGCTGCTTCGGGCCCA

39 bp, e2, 61% GC ATCTGCTGCGCGGAA (SEQ ID NO: 264) M241 oxytocinase U62769 CACCGCTTTATCAAATATGCCTA

50 bp, e3-4, 40% GC GAAGTCATCAGTCGTTCTAGAT

TG (SEQ ID NO: 265) M242 RLN1 relaxin 1 NM_006911 CCTCAGACACCTAGACCAGTGG

50 bp, e1-2, 46% GC AGAAATTGTACCATCCTTCATCA

will also detect CAA relaxin 2 (SEQ ID NO: 266) M243 CTATCTGAGAGGCAACCATCATT

50 bp, e2, 48% GC CCAGAGCTACAGCAGTATGTAC

specific for GC relaxin 1 (SEQ ID NO: 267) M244 RLN2 relaxin 2 NM_006911 GAGAGTTCCTTGGTGCCCTTTC

50 bp, e2-3, 46% GC AATTGTGCCATCCTTCATCAACA

AG (SEQ ID NO: 268) M245 RLN3 relaxin 3 NM_080864 ATCCTGGCCCACGAGGCTATGG

45 bp, e1-2, 57% GC AGATACCTTCCCGGATGCAGAT

(SEQ ID NO: 269) M246 vasopressin AF031476 ATGTCCGACCTGGAGCTGAGAC

36 bp, e1-2, 63% GC precursor GTGCCTCCCCTGC (SEQ ID NO: 270) M247 TTTGCTGCAACGACGAGAGCTG

34 bp, e2-3, 61% GC TGACCGAGCC (SEQ ID NO: 271) M248 CHRNA1 cholinergic NM_000079 GACAACCAATGTGCGTCTGAAA

50 bp, e3-4, 42% GC receptor, AGCAATGGGTGGATTACAACCT

nicotinic, AAAT alpha poly- (SEQ ID NO: 272) peptide 1 (muscle) M249 TATTCTACCTGCCCACAGACTCA

50 bp, e6-7, 42% GC GGGAGAAGATGACTCTGAGCAT

TCT (SEQ ID NO: 273) M250 CHRNA2 cholinergic NM_000742 ACCACCAACGTCTGGCTAAAAC

49 bp, e4-5, 53% GC receptor, GGAGTGGAGCGACTACAAACTG

nicotinic, GCT alpha poly- (SEQ ID NO: 274) peptide 2 (neuronal) M251 CHRNA4 cholinergic NM_000743 TCATGGAGACCAACCTGTGGCT

50 bp, e3-4, 48% GC receptor, AGCAAATCTGGAATGACTACAA

nicotinic, CTG alpha poly- (SEQ ID NO: 275) peptide 3 M252 CHRNA4 cholinergic NM_000744 GTCCATCGCTCAGCTCATTGAC

50 bp, e2-3, 50% GC receptor, GGATGAGAAGAACCAGATGAT

nicotinic, CCA alpha poly- (SEQ ID NO: 276) peptide 4 M253 CHRNA5 cholinergic XM_007577 CACCAGACATCGTTTTGTTTGAT

50 bp, e4-5, 44% GC receptor, ATGCAGATGGACGTTTTGAAGG

nicotinic, ACC alpha poly- (SEQ ID NO: 277) peptide 5 M254 CHRNA6 cholinergic CHRNA6 GGAAACCAATTTGTGGCTGCGT

50 bp, e2-3, 42% GC receptor, CATCTGGAATGATTATAAATTG

nicotinic, CT alpha poly- (SEQ ID NO: 278) peptide 6 M255 CHRNA7 cholinergic NM_000746 GAGCCTCCTGCAGATCATGGAC

50 bp, e1-2, 48% GC receptor, GGATGAGAAGAACCAAGTTTTA

nicotinic, CCA alpha poly- (SEQ ID NO: 279) peptide 7 M256 CHRNB1 cholinergic NM_000747 ATCCTGGCGCAACTCATCAGCCT

49 bp, e2-3, 51% GC receptor, AACGAGAAGGATGAAGAGATGA

nicotinic, CA beta poly- (SEQ ID NO: 280) peptide 1 (muscle) M257 CHRNB2 cholinergic NM_000748 AGCAGATCATGACCACCAATGT

50 bp, e3-4, 50% GC receptor, GGCTGACCCAGGAGTGGGAAGA

nicotinic, TAT beta poly- (SEQ ID NO: 281) peptide 2 (neuronal) M258 CHRNB3 cholinergic NM_000749 TTCCTGACATAGTTCTCTTTGAA

50 bp, e1-2, 48% GC receptor, ATGCTGACGGCCGCTTCGAAGG

nicotinic, CC beta poly- (SEQ ID NO: 282) peptide 3 M259 CHRNB4 Cholinergic XM_039151 AGAATGACGATGAAGACCAGA

50 bp, e1-2, 50% GC receptor, GTCGTTGAGGACTGGAAGTACG

nicotinic, GGCT beta poly- (SEQ ID NO: 283) peptide 4 M260 DRD1 dopamine XM_003966 AGACTTTGCCCTGCGACGAATAA

50 bp, 44% GC receptor GCCATAGAGACGGTGAGTATCA

D1 TAA (SEQ ID NO: 284) M261 DRD2 dopamine NM_000795 CTCCTCTTCGGACTCAATAACG

50 bp, e5-6, 50% GC receptor GACCAGAACGAGTGCATCATTG

D2 CAA (SEQ ID NO: 285) M262 DRD3 dopamine XM_113416 TTCTGTTTGGCTTTAATACCACA

49 bp, e4-5, 51% GC receptor GGGACCCCACTGTCTGCTCCAT

D3 C (SEQ ID NO: 286) M263 DRD4 dopamine XM_006145 TGGTGCTGCCGCTCTTCGTCTA

36 bp, e1-2, 63% GC receptor CCGAGGTCCAGG D4 (SEQ ID NO: 287) M264 AANAT arylalkylamine NM_001088 CTTTGAGATCGAGCGTGAAGCC

44 bp, e2-3, 54% GC acetyl- CATCTCCGTCTTGGGCGTCT transferase (SEQ ID NO: 288) M265 ACAAGGAGAGACTCATGCAGGA

39 bp, e2-3, 53% GC TCACTGACGCTGCACA

(SEQ ID NO: 289) M266 TPH Tryptophan X52836 GATCTGAACTAGATGCAGACCA

50 bp, e4-5, 46% GC hydroxylase CTGGCTTCAAAGACAATGTCTA

GT (SEQ ID NO: 290) M267 ATAAAAGCCCTGAAAATCTTTCA

49 bp, e1-3, 46% GC GTATGGAAACTGTTCCTTGGTTT

might detect deletion C exon 2 (regulatory (SEQ ID NO: 291) domain) M268 CAGATCCCTTCTATACCCCAGA

50 bp, e6-7, 50% GC CAGATACCTGCCATGAACTCTTA

GT (SEQ ID NO: 292) M269 HIOMT acetylserotonin NM_004043 AAGAACAGATTGACTTCCAGGA

50 bp, e7-8, 46% GC methyl- GGGGATTTCTTCAAAGACCCTCT

transferase CCG (SEQ ID NO: 293) M270 ABAT 4-aminobutyrat

NM_000663 GGAAGTCCCAGGGCCTAGATCT

50 bp, e2-3, 44% GC amino- AGGAGTTAATGAAACAGCTGAA

transferase ATAA (SEQ ID NO: 294) M271 AOX1 aldehyde NM_001159 GCCAGAATTTGAGGAAGGAAGT

50 bp, e6-7, 44% GC oxidase 1 AGACAAGTCCAAAACTCTTCGC

GAAG (SEQ ID NO: 295) M272 DBH dopamine NM_000787 TACCACAACCCACTGGTGATAGA

48 bp, e5-6, 52% GC beta- AGGACGAAACGACTCCTCAGG

hydroxylase TC (SEQ ID NO: 296) M273 CHAT vN choline NM_020549 CGTCATCGTAGCCTGCTGCAAT

50 bp, e6-7, 44% GC acetyl- GTTCTTTGTCTTGGATGTTGTCA

detects all variants transferase A (SEQ ID NO: 297) M274 Variant N1 TGAGGCTTTGAGAAAGGAGTAG

50 bp, e1, 50% GC AGCCTAGCATTCCGGCAGAGGA

GAAA (SEQ ID NO: 298) M275 COMT catechol-O- NM_000754 AGAGGGCTGGAGCCTGCTCAGA

42 bp, e1-2, 59% GC methyl- GTGCTTTGAAGATGCCGGA will detect only MB transferase (SEQ ID NO: 299) isoform M276 CATGAACGTGGGCGACAAGAAA

46 bp, e3-4, 54% GC GCAAGATCGTGGACGCCGTGAT

will detect all (SEQ ID NO: 300) isoform M277 DDC dopa XM_033775 AAAGGACTGCAGGCTTATATCC

49 bp, e9-10, 51% GC

decarboxylase AAGCATGTCCAGCTGTCCCATGA

T (SEQ ID NO: 301) M278 GAD2 glutamate NM_000818 CTCTGCTCTCCTGGTTAGAGAA

50 bp, e12-13, 48% G

decarboxylase GGGATTGATGCAGAATTGCAAC

2 AAA (SEQ ID NO: 302) M279 GAD2 glutamate NM_013445 GACTTCTCTAATCTGTTTGCTAG

50 bp, e3-4, 46% GC decarboxylase GATCTGCTTCCGGCTAAGAACG

Detects both 25 and GA isoforms (SEQ ID NO: 303) M280 glutamine Y00387 GACAGTGAGCCCAAGTGTGTGG

50 bp, e3-4, 52% GC; synthetase AGAGTTGCCTGAGTGGAATTTC

should detect also so

TGG gene on chr 11 (SEQ ID NO: 304) M281 CATGCGGGAGGAGAATGGTCTG

50 bp, e7-8, 52% GC; AGTACATCGAGGAGGCCATTGA

should detect also so

AAAC genes on chr 2, 9 (SEQ ID NO: 305) M282 HNMT histamine NM_006895 AAGATGCTCATTATTGTTGTGT

50 bp, e5-6, 48% GC N-methyl GGAAGCAGTGGCTGGGACAAG

transferase GTG (SEQ ID NO: 306) M283 MAOA monoamine NM_000240 CTGGGTACAAGAACCTGAATCA

50 bp, e13-14, 50% G

oxidase A AGGACGTTCCAGCGGTAGAAAT

ACCC (SEQ ID NO: 307) M284 MAOB monoamine NM_000898 GGGAGGCAGGACTTACACTCTT

50 bp, e2-3, 46% GC oxidase B GGAACCAAAAGGTTAAATATGT

GACC (SEQ ID NO: 308) M285 HRH1 histamine XM_052382 CCGAGAGGACAAGTGTGAGACA

50 bp, 50% GC receptor H1 ACTTCTATGATGTCACCTGGTTC

AGG (SEQ ID NO: 309) M286 HRH2 histamine NM_022304 AAGGGCAATCATACCACCTCTA

50 bp, 44% GC receptor H2 GTGCAAAGTCCAGGTCAATGAA

TGTA (SEQ ID NO: 310) M287 HRH3 histamine AF321910 TCAACCTCGCCATCTCCGACTT

43 bp, e1-2, 60% GC receptor H3 TCGTCGGCGCCTTCTGCAT (SEQ ID NO: 311) M288 HRH4 histamine NM_021624 GGCCATCTCTGACTTCTTTGTGG

50 bp, e1-2, 48% GC receptor H4 TGTGATCTCCATTCCTTTGTACA

C (SEQ ID NO: 312) M289 MTNR1A melatonin NM_005958 GTATCGGAACAAGAAGCTCAGG

50 bp, e1-2, 48% GC receptor 1A ACGCAGGAAACATCTTTGTGGT

GCT (SEQ ID NO: 313) M290 MTNR1B melatonin NM_005959 AGGAACCGCAAGCTCCGGAACG

48 bp, e1-2, 52% GC receptor 1B AGGTAATTTGTTCTTGGTGAGT

G (SEQ ID NO: 314) M291 NTS neurotensin NM_006183 TTCAGCTCCTGGAGTCTGTGCT

50 bp, e1-2, 44% GC GATTCAGAAGAGGAAATGAAA

ATT (SEQ ID NO: 315) M292 NTSR1 neurotensin NM_002531 CATCTCGGATGAGCAGTGGACT

50 bp, e2-3, 50% GC receptor 1 GTTCCTCTATGACTTCTACCACT

(high CT affinity) (SEQ ID NO: 316) M293 NTSR2 neurotensin NM_012344 ACCGCGCTCCAAGTCTTTATCCA

47 bp, e1-2, 53% GC receptor 2 GTGAATGTGCTGGTGTCCTTCGT

(SEQ ID NO: 317) M294 ADRA1A adrenergic, NM_033303 TTTTCTTAGTCATGCCCATTGGG

50 bp, e1-2, 44% GC alpha CTTTCTTCCCTGATTTCAAGCCC

1A-, receptor T (SEQ ID NO: 318) M295 ADRA1B adrenergic, NM_000679 TACCCTTCTTCATCGCTCTACCG

48 bp, e1-2, alpha TGGCTCCTTGTTCTCCACCCTGA

54% GC = adral c? 1B-, receptor (SEQ ID NO: 319) M296 ADRA1D adrenergic, NM_000678 TGCTGGTTCCCTTTCTTCTTTGT

45 bp, e1-2, 55% GC alpha TGCCGCTCGGCTCCTTGTTC 1D-, receptor (SEQ ID NO: 320) M297 ADRA2A adrenergic, NM_000681 TCTCCCTACTCTCTCCCGCCGCT

50 bp, 5′UTR, 44% G

alpha GAAATAAAACTTGGCTGTATTA

2A-, receptor A (SEQ ID NO: 321) M298 ADRA2B adrenergic, NM_000682 TTCCTCATTCTCTTTACCATCTT

50 bp, 50% GC alpha GCAACGCTCTGGTCATCCTGGCT

2B-, receptor T (SEQ ID NO: 322) M299 ADRA2C adrenergic, NM_000683 CAACAGCTCGCTCAACCCGGTCA

50 bp, 50% GC; may alpha CTACACGGTCTTCAACCAGGATT

also detect ADRA 2A 2C-, receptor (SEQ ID NO: 323) and 2B c M300 ADRB1 adrenergic, NM_000684 TAAGACCGATAGCAGGTGAACT

50 bp, 3′UTR, 48% G

beta GAAGCCCACAATCCTCGTCTGA

1-, receptor CAT (SEQ ID NO: 324) M301 ADRB2 adrenergic, NM_000024 GAGACCTGCTGTGACTTCTTCA

49 bp, 51% GC beta AACCAAGCCTATGCCATTGCCT

2-, receptor T (SEQ ID NO: 325) M302 ADRB3 adrenergic, NM_000025 CCTGAAGGACAAGAAGCAACAA

50 bp, 3′UTR, 46% G

beta TCTGTTGATCAGAACCTGTGGAA

3-, receptor ACC (SEQ ID NO: 326) M303 HTR1A serotonin XM_003692 AATTGGCTGGGCTACTCCAACT

50 bp, 48% GC receptor CTGCTTAACCCCGTCATTTACG

1A TA (SEQ ID NO: 327) M304 HTR1B serotonin XM_004117 TGGAAAAGAAGAAACTCATGG

49 bp, 51% GC receptor GCTAGGGAGCGCAAAGCCACCA

similarity to 1 D? 1B (SEQ ID NO: 328) M305 HTR1D serotonin XM_001542 CCAAATCTTGTGTGACATCTGG

49 bp, 51% GC receptor GTCCTCTGACATCACGTGCTGCA

1D A (SEQ ID NO: 329) M306 HTR1E serotonin XM_004134 GGAAACATGAACATCACAAACT

50 bp, 46% GC receptor TACCACAGAGGCCAGCATGGCT

1E TAAG (SEQ ID NO: 330) M307 HTR1F serotonin XM_003092 ATTGTGTATATTGTGAGAGAGA

50 bp, 44% GC receptor TGGATTATGGGGCAAGTGGTCT

1F GA (SEQ ID NO: 331) M308 HTR2A serotonin XM_007123 CATGTTAACCATCCTGTATGGGT

45 bp, e1-255% GC receptor CCGGTGGCCTCTGCCGAGCAA

2A (SEQ ID NO: 332) M309 HTR2C serotonin XM_013121 CTGTCTCTCCTGGCAATCCTTTA

50 bp, e2-3, 44% GC receptor GATTATGTCTGGCCACTACCTA

2C TA (SEQ ID NO: 333) M310 HTR3A serotonin XM_006444 TCCCGGACATTCTCATCAATGA

50 bp, e4-5, 48% GC receptor TCGTGGATGTGGGGAAGTCTCCA

3A AT (SEQ ID NO: 334) M311 HTR3B serotonin XM_006445 ACCTTCAAGAGCATTCTGCATA

50 bp, e5-6, 48% GC receptor GTGGAAGACGTAGACCTGGCCT

3B CT (SEQ ID NO: 335) M312 HTR4 serotonin NM_000870 TTCCTGTAATGGACAAACTTGAT

50 bp, e5-6, 42% GC receptor CTAATGTGAGTTCTGAGGAGGG

4 TC (SEQ ID NO: 336) M313 HTR5A serotonin XM_017055 ACCCATATCCGAAGCTGTGGAG

44 bp, e5-6, 53% GC receptor GAAGGACTCTGCCAAACAG 5A (SEQ ID NO: 337) M314 HTR6 serotonin XM_001435 TTTGTGGCCAACATAGTCCAGG

40 bp, e2-3, 55% GC receptor GTGTGCGACTGCATCT 6 (SEQ ID NO: 338) M315 EGF epidermal NM_001963 AGAGAGATGGGAAAACATGTA

50 bp, e7-8, 48% GC growth GGTTGTTCCTCACCCGATAATG

factor GGA (SEQ ID NO: 339) M316 EGFR epidermal NM_005228 AAGTGCGAAGGGCCTTGCCGCA

50 bp, e7-8, 48% GC growth AGTGTGTAACGGAATAGGTATT

factor GTGA receptor (SEQ ID NO: 340) M317 ATACGCGGCAGGACCAAGCAA

49 bp, e10-11, 51% G

TGGTCAGTTTTCTCTTGCAGTC

CA (SEQ ID NO: 341) M318 ERBB2 v-erb-b2 NM_004448 TGAACTGGTGTATGCAGATTGC

49 bp, e20-21, 51% G

erytbroblastic AGGGGATGAGCTACCTGGAGGA

leukemia viral GT oncogene (SEQ ID NO: 342) homolog 2 M319 FGF1 fibroblast NM_000800 CACCGACGGGCTTTTATACGGCT

50 bp, e3-4, 48% GC growth ACAGACACCAAATGAGGAATGT

factor 1 TGT (SEQ ID NO: 343) M320 FGF2 fibroblast NM_002006 GTCCGGGAGAAGAGCGACCCT

50 bp, e1-2, 52% GC growth CATCAAGCTACAACTTCAAGCA

factor 2 AAGA (SEQ ID NO: 344) M321 FGF3 fibroblast NM_005247 TGGCCATGAACAAGAGGGGAC

46 bp, e1-2, 54% GC growth CTCTATGCTTCGGAGCACTACA

factor 3 (SEQ ID NO: 345) M322 FGF4 fibroblast NM_002007 GGCAAGCTCTATGGCTCGCCCTT

45 bp, e2-3, 57% GC growth TTCACCGATGAGTGCACGTTC factor 4 (SEQ ID NO: 346) M323 FGFS fibroblast NM_004464 GATCCCACGAAGCCAATATGTTA

50 bp, e1-2, 38% GC growth GTGTTTTGGAAATATTTGCTGTG

factor 5 CT (SEQ ID NO: 347) M324 FGF6 fibroblast NM_020996 CAGTAAAGGAAGATTGTACGCA

50 bp, e2-3, 46% GC growth CGCCCAGCTTCCAAGAAGAATG

factor 6 AAGT (SEQ ID NO: 348) M325 FGF7 fibroblast NM_002009 ACCCAAGAGATGAAGAATAATT

50 bp, e1-2, 38% GC growth CAATATCATGGAAATCAGGACA

factor 7 TGGC (SEQ ID NO: 349) M326 FGF8 fibroblast NM_033163 AGAAGGGGAAGCTGATCGCCAA

45 bp, e1-2, 55% GC growth AGCAACGGCAAAGGCAAGGACT

will detect longer and factor 8 (SEQ ID NO: 350) shorter isoforms M327 FGF10 fibroblast NM_004465 AGAAGGGGAAACTCTATGGCTC

50 bp, e2-3, 38% GC growth AAAGAATTTAACAATGACTGTA

factor 10 GCTG (SEQ ID NO: 351) M328 FGF11 fibroblast NM_004112 ATGCTGAGGGACTGCTCTACAG

48 bp, e,3-4, 54% GC growth CGCCGCATTTCACAGCTGAGTGT

homol to fgf-3? factor 11 (SEQ ID NO: 352) M329 FGF12 fibroblast NM_021032 ACCAAGGACGAAAACAGCGACT

50 bp, e2-3, 48% GC growth CACTCTCTTCAATCTAATTCCCG

factor 12 GGG (SEQ ID NO: 353) M330 FGF13 fibroblast NM_004114 AAGAAGAGGCGCAGAAGAAGA

50 bp, e1-2, 48% GC growth AGAGCCTCAGCTTAAGGGTATA

factor 13 TAC (SEQ ID NO: 354) M331 FGF14 fibroblast NM_004115 ACCAAGGATGACAGCACTAATT

50 bp, e2-3, 48% GC growth ACACTCTTCAACCTCATACCAGT

factor 14 GG (SEQ ID NO: 355) M332 FGF16 fibroblast NM_003868 ACCTAGGAATGAATGAGCGAG

50 bp, 48% GC growth GAACTCTATGGGTCGAAGAAAC

factor 16 CACA (SEQ ID NO: 356) M333 FGF17 fibroblast NM_003867 TTCTCTGCTGTCAAACTCAGGG

50 bp, e2-3, 48% GC growth AGAATCACCCGTCTCCTAATTTT

factor 17 AC (SEQ ID NO: 357) M334 FGF18 fibroblast NM_033649 CCTCCGCCTGCACTTGCCTGTGT

46 bp, e1-2, 56% GC growth TACACTTCCTGCTGCTGTGCTT factor 18 (SEQ ID NO: 358) M335 FGF19 fibroblast NM_005117 GACGGCAAGATGCAGGGGCTG

45 bp, e2-3, 57% GC growth TCAGTACTCGGAGGAAGACTGT

factor 19 (SEQ ID NO: 359) M336 FGF20 fibroblast NM_019851 GAATGACAAAGGAGAAGTCTAT

50 bp, e2-3, 40% GC growth GATCAGAGAAACTTACTTCCGAA

factor 20 GCA (SEQ ID NO: 360) M337 FGF21 fibroblast NM_019113 TGCTGACCAGAGCCCCGAAAGT

45 bp, e1-2, 55% GC growth CCTGCAGCTGAAAGGCTTGAA factor 21 (SEQ ID NO: 361) M338 FGF22 fibroblast NM_020637 CCACGGCCAGGACAGCATCCTG

40 bp, e1-2, 62% GC growth AGATCCGCTCTGTACAC factor 22 (SEQ ID NO: 362) M339 FGF23 fibroblast NM_020638 TTTCAGAGGCAACATTTTTGGAT

50 bp, e2-3, 44% GC growth ACACTATTTCGACCCGGAGAAC

factor 23 CA (SEQ ID NO: 363) M340 FGFR1 fibroblast NM_000604 CGACTACTATAAAAAGACAACC

50 bp, e13-14, 50% G

growth ACGGCCGACTGCCTGTGAAGTG

factor ATGG receptor

(SEQ ID NO: 364) M341 FGFR2 fibroblast NM_000141 TTCTTGGAGCCTGCACACAGGAT

50 bp, e13-14, 48% G

growth GGCCTCTCTATGTCATAGTTGA

detects almost all factor AT variants (tyrosine receptor

(SEQ ID NO: 365) kinase domains) M342 FGFR3 fibroblast XM_044120 ACCGTAGCCGTGAAGATGCTGA

49 bp, e10-11, 53% G

growth AGACGATGCCACTGACAAGGA

factor TGT receptor

(SEQ ID NO: 366) M343 FGFR4 fibroblast NM_002011 ACTGTGGCCGTCAAGATGCTCAA

48 bp, e11-12, 54% G

growth GACAACGCCTCTGACAAGGACC

factor G receptor

(SEQ ID NO: 367) M344 FIBP fibroblast NM_004214 CACTACTCATCGAGAGGTACTAT

50 bp, 50% GC growth CCTTTGATGAGGCCTITTGTTCGG

factor (acidic) AG intracellular (SEQ ID NO: 368) binding protein M345 SPRY1 sprouty homolog XM_036349 CTGTTCACAATCACACTGCTGCT

50 bp, 48% GC 1, antagonist TAGATACCTGTGTATGGGAGCCA

of FGF GT signaling (SEQ ID NO: 369) M346 SPRY2 sprouty homolog NM_005842 CCCAGAACGTGATTGACTATGG

50 bp, 48% GC 2, antagonist ACTTGTGTATGCTGTGTGAAAG

of FGF CTC signaling (SEQ ID NO: 370) M347 IGF1R insulin-like NM_000875 TACCGGCACAATTACTGCTCCAA

50 bp, e9-10, 46% GC

growth factor GACAAAATCCCCATCAGGAAGT

1 receptor TGC (SEQ ID NO: 371) M348 IGF2 insulin-like NM_000612 TCGACCCCTCCGACCGTGCTTC

41 bp, e3-4, 61% GC growth factor GACAACTTCCCCAGATA 2 (SEQ ID NO: 372) M349 IGF1 insulin-like X00173 GACATGCCCAAGACCCAGAAGG

50 bp, e3-4, 48% GC growth factor AGTACATTTGAAGAACGCAAGT

1 GAGG (SEQ ID NO: 373) M350 IGFBP1 insulin-like NM_000596 GAATGGATTTTATCACAGCAGA

50 bp, e2-3, 47% GC growth factor GTGTGAGACATCCATGGATGGA

binding protein AGGC (SEQ ID NO: 374) M351 IGFBP2 insulin-like NM_000597 AAGCATGGCCTGTACAACCTCA

50 bp, e3-4, 50% GC growth factor ACAGTGCAAGATGTCTCTGAAC

binding protein GGCA (SEQ ID NO: 375) M352 IGFBP3 insulin-like NM_000598 AAGCGGGAGACAGAATATGG 50 bp, e2-3, 50% GC growth factor TCCCTGCCGTAGAGAAATGGAA

binding protein ACACACT (SEQ ID NO: 376) M353 IGFBP4 insulin-like NM_001552 AACGGCAACTTCCACCCCAAGC

42 bp, e2-3, 57% GC growth factor GTGTCACCCAGCTCTGGAT binding protein (SEQ ID NO: 377) M354 IGFBP5 insulin-like U20271 CAAAGGATTCTACAAGAGAAAG

49 bp, e3-4, 51% GC growth factor AGTGCAAACCTTCCCGTGGCG

binding protein AG (SEQ ID NO: 378) M355 IGFBP6 insulin-like NM_002178 GCGCGCCTGCTGTTGCAGAGGA

42 bp, e1-2, 54% GC growth factor AATCCTAAGGAGAGTAAAC binding protein (SEQ ID NO: 379) M356 IMP-1 IGF-II mRNA- AF117106 ATGGTACAGTAGAGAACTGTGA

50 bp, e2-3, 50% GC binding protein CAAGTGAACACCGAGAGTGAGA

GGCA (SEQ ID NO: 380) M357 IMP-2 IGF-II mRNA- NM_006548 GGACAGTGGAGAATGTGGAACA

50 bp, e4-5, 50% GC binding protein GTCAACACAGACACAGAAACCG

CGTT (SEQ ID NO: 381) M358 IMP-3 IGF-II mRNA- AF117108 TATCCCGCCTCATTTACAGTGG

50 bp, e2-3, 48% GC binding protein GGTGCTGGATAGTTTACTAGTC

GT (SEQ ID NO: 382) M359 NGFB nerve growth NM_002506 GTTCTACACTCTGATCACAGCTT

50 bp, 50% GC factor, beta TCTGATCGGCATACAGGCGGAA

polypeptide CAC (SEQ ID NO: 383) M360 NGF-2 X53655 CAAGCTCTCCAAGCAGATGGTG

50 bp, 50% GC ACGTTAAGGAAAATTACCAGAG

ACCC (SEQ ID NO: 384) M361 NGFR nerve growth NM_002507 TTGTGGCCTACATAGCCTTCAA

50 bp, e4-5, 50% GC factor GGTGGAACAGCTGCAAGCAGAA

receptor AAG (SEQ ID NO: 385) M362 TDGF1 teratocarcinoma NM_003212 TCTTTGAACTGGGATTAGTTGC

44 bp, e2-3, 50% GC derived growth GGCTGGGCCATCAGGAATTT factor 1 (SEQ ID NO: 386) M363 PDGFA platelet- NM_002607 AGATAGACTCCGTAGGGAGTGA

48 bp, e3, 52% GC derived growth GATTCTTTGGACACCAGCCTGA

factor alpha G polypeptide (SEQ ID NO: 387) M364 PDGFB platelet- NM_002608 GACCTGTCCAGGTGAGAAAGAT

47 bp, e4-5, 51% GC derived growth GAGATTGTGCGGAAGAAGCCAA

b polypeptide C (SEQ ID NO: 388) M365 PDGFC platelet- NM_016205 TTTCCAGCAACAAGGAACAGAA

50 bp, e1-2, 46% GC derived growth GGAGTACAAGATCCTCAGCATG

factor C GAGA (SEQ ID NO: 389) M366 PDGFD platelet- AF336376 TCATACCATGACCGGAAGTCAA

50 bp, e5-6, 44% GC derived growth AGTTGACCTGGATAGGCTCAAT

factor D TGA (SEQ ID NO: 390) M367 PDGFRA platelet- NM_006206 TCAATGGACTTACCCTGGAGAA

50 bp, e5-6, 48% GC derived growth GAAAGGCAAAGGCATCACAAT

factor receptor, TGG alpha poly- (SEQ ID NO: 391) peptide M368 PDGFRB platelet- NM_002609 TGCCTACTATGTCTACAGACTC

50 bp, e4-5, 48% GC derived growth GGTGTCATCCATCAACGTCTCT

factor receptor, GA beta polypeptide (SEQ ID NO: 392) M369 VEGF vascular NM_003376 TGAGGAGTCCAACATCACCATG

50 bp, e3-4, 48% GC endothelial AGATTATGCGGATCAAACCTCA

growth factor AAG (SEQ ID NO: 393) M370 VEGFB vascular NM_003377 ACCAGAGGAAAGTGGTGTCATG

50 bp, 50% GC endothelial ATAGATGTGTATACTCGCGCTA

growth factor TGC B (SEQ ID NO: 394) M371 VEGFC vascular NM_005429 CAGCACGAGCTACCTCAGCAAG

50 bp, e1-2, 46% GC endothelial CGTTATTTGAAATTACAGTGCCT

growth factor TCT C (SEQ ID NO: 395) M372 VEGFD vascular NM_004469 CAGTAATGAACATGGACCAGTG

50 bp, e1-2, 46% GC endothelial AGCGATCATCTCAGTCCACATT

growth factor AAC D (SEQ ID NO: 396) M373 similar to XM_067723 TTTGCAGAACTTGTGGAAAAAC

50 bp, e4-5, 34% GC Vascular GAAAATAGTGGGTTTACATACT

endothelial AC growth factor (SEQ ID NO: 397) receptor M374 ADAR adenosine NM_001111 AAAGAAGGCCCTGCCCATGAA

48 bp, e4-5, 50% GC deaminase, RN CAAGTTCCAATACTGTGTTGCA

should detect all 3 specific G variants (SEQ ID NO: 398) M375 SPS selenium donor NM_012247 ATCGTAGACGACCCTTACATGAT

48 bp, e2-3, 52% GC protein GGCAGGATAGCGTGTGCCAATG

may also detect C LOC158861 (SEQ ID NO: 399) M376 SPS2 selenium donor NM_012248 ATGTTACTCAGCGTCAGCCAGA

50 bp, 50% GC protein 2 ATGAGTGAGGAGGAACGCGAAA

GGT (SEQ ID NO: 400) M377 LOC1235 similar to XM_063731 GAACTGAAGGGCACAGGCTGCA

50 bp, e1-2, 50% GC Selenide, water AGAGAACCACTTCCAAGAAGAT

dikinase 1 AGCA (SEQ ID NO: 401) M378 LOC1295 similar to XM_065297 TTAAAGATGCAGCCGAGGAAG

50 bp, e1-2, 42% GC selenophosphat

GGAATATGTAGAGTTGACATAC

synthetase AAGA (SEQ ID NO: 402) M379 LOC1505 -//- XM_086946 AAAATATGAATCCCACACCTGG

50 bp, e1-2, 42% GC CCACCTCTTAATCTAGACAGAAA

AGC (SEQ ID NO: 403) M380 LOC1588 -//- XM_005845 CAGAATGTGACAATATGCTGAT

50 bp, 40% GC TCCTTGGAGTCAGTAATAAAAT

CC (SEQ ID NO: 404) M381 LOC1670 -//- XM_094245 TTACAGTGCTTTTGCTGAAAAT

50 bp, e2-3, 38% GC GAATGCAGGAACTGAGACCAT

TTA (SEQ ID NO: 405) M382 LOC1684 -//- XM_095122 CAGAATGTGACAATATGCTGAT

50 bp, 40% GC TCCTTGGAGTCAGTAATAAAAT

CC (SEQ ID NO: 406) M383 LOC2020 -//- XM_116312 ATATCACAGGCTTTGGCATTCTA

50 bp, 46% GC GACACTCTCAGAACCTCGTGAA

AA (SEQ ID NO: 407) M384 SCYA21 small NM_002989 AAAGGAAAGGGCTCCAAAGGCT

44 bp, e3-4, 54% GC inducible CAAGAGGACTGAGCGGTCACA cytokine (SEQ DI NO: 408) subfamily A M385 ACVR1 activin A NM_001105 CCAATGTTGGAGACAGCACTTTA

50 bp, e4-5, 40% GC receptor type I CAGATTTATTGGATCATTCGTGT

CA (SEQ ID NO: 409) M386 ACVR1B activin A NM_004302 AGATTGCTCGAAGATGCAATTCT

50 bp, e7-8, 44% GC receptor type IB GAGGAGTCCATGAAGAATATCA

should detect only CTG isoform a (SEQ ID NO: 410) M387 ACVR2 activin A NM_001616 GCTGATCACAGCATTTCATGAAA

50 bp, e4-5, 40% GC receptor type 2 GGGTTCACTATCAGACTTTCTTA

GG (SEQ ID NO: 411) M388 ACVR2B activin A NM_001106 TGCTGGCTAGATGACTTCAACT

45 bp, e2-3, 51% GC receptor type 2B TACGATAGGCAGGAGTGTGTG (SEQ ID NO: 412) M389 INHBA inhibin, beta XM_042996 ATCATCACGTTTGCCGAGTCAG

47 bp, e1-2, 53% GC; A ACAGCCAGGAAGACGCTGCACT

same as erythroid (SEQ ID NO: 413) differentiation protein M390 INHBB inhibin, beta NM_002193 AATCATCAGCTTCGCCGAGACA

40 bp, e1-2, 60% GC B ATGGCCTCGCCTCCTCC (SEQ ID NO: 414) M391 INHBC inhibin, beta NM_005538 GAAATCATCAGCTTTGCTGAGA

49 bp, e1-2, 51% GC C GGCCTCTCCACCATCAACCAGA

C (SEQ ID NO: 415) M392 BLC B lymphocyte AF044197 ATGGTTGTCCAAGAAAAGAAAT

50 bp, e3-4, 34% GC chemo- ATAGTCTGGAAGAAGAACAAGT

attractant AATT (SEQ ID NO: 416) M393 TNFSF13 tumor necrosis NM_006573 GCCGTTCAGGGTCCAGAAGAAA

50 bp, e2-3, 50% GC factor (ligand) AGTCACTCAAGACTGCTTGCAA

AF132600, AF11645

superfamily, GAT AF186114, AF13471

member 13b (SEQ ID NO: 417) M394 TNFRSF5 tumor necrosis NM_001250 AAACAGTCAGTGCTGTTCTTTGT

50 bp, e2-3, 50% GC (CD40L) factor receptor CCAGCCAGGACAGAAACTGGTG

superfamily, GTG member 5 (SEQ ID NO: 418) M395 CNTF ciliary NM_000614 CTGACTGCTCTTACGGAATCCTA

50 bp, e1-2, 48% GC neurotrophic GTGAAGCATCAGGGCCTGAACA

factor GAA (SEQ ID NO: 419) M396 CNTFR ciliary NM_001842 ATCACCTTTGACGAGTTCACCAT

50 bp, e5-6, 44% GC neurotrophic GTGAAGCCTGATCCTCCAGAAA

factor receptor GT (SEQ ID NO: 420) M397 CSF1 colony NM_000757 ACATTTGAGTTTGTAGACCAGGA

50 bp, 44% GC = stimulating CAGTTGAAAGATCCAGTGTGCTA

CSF4? factor I CT (SEQ ID NO: 421) M398 CSF1R colony NM_005211 CTTCCTCCAACACAACAACACTA

50 bp, e4-5, 50% GC stimulating GCTCGCAATCCCTCAACAATCT

factor 1 CT receptor (SEQ ID NO: 422) M399 CSF2 colony NM_000758 TGAACCTGAGTAGAGACACTGC

50 bp, e1-2, 44% GC stimulating GCTGAGATGAATGAAACAGTAG

factor 2 AGTC (SEQ ID NO: 423) M400 CSF2RA colony NM_006140 CTAGTCTCAATGTGAGGTTTGA

50 bp, 46% GC stimulating CCAGGACGATGAATTTAAGCTG

factor 2 GAC receptor, (SEQ ID NO: 424) alpha low- affinity M401 CSF2RB colony NM_000395 GGCAGAGAAACACATAAAGAG

49 bp, e7-8, 51% GC stimulating CAGTGAACATCCAGATGGCCCC

factor 2 CA receptor, (SEQ ID NO: 425) beta low- affinity M402 CSF3 colony NM_000759 AGGAGAAGCTGGTGAGTGAGT

43 bp, e2-3, 55% GC stimulating GCCACCTACAAGCTGTGCCA factor 3 (SEQ ID NO: 426) M403 CTF1 cardiotrophin 1 XM_096076 CATGTGTACATCTCAGCCTTAT

50 bp, 48% GC CAAGGAGGTGACACCTTCTCTC

TG (SEQ ID NO: 427) M404 CLC cardiotrophin- AY049779 AAGCCTCAATGACAAACTGCGG

42 bp, 54% GC li

 cytokine TGACCCAGAACTACGAGGC (SEQ ID NO: 428) M405 EMAPII small inducible NM_004757 CAGGCAGAAATTCAAAATGGAG

50 bp, e2-3, 40% GC (SCYE1) cytokine GAAGCAAATAGCATTTCCATCT

subfamily E, TAC member 1 (SEQ ID NO: 429) M406 Epo erytropoetin X02157 CCGAGAATATCACGACGGGCTG

49 bp, e2-3, 51% GC GCTGAACACTGCAGCTTGAATGA

GAA (SEQ ID NO: 430) M407 CCR3 CC chemokine AF247361 CATGGCATGTGTAAGCTCCTCT

50 bp, 48% GC receptor 3 GGGTTTTATCACACAGGCTTGTA

AG (SEQ ID NO: 431) M408 eotaxin eosinophil- D49372 TGGCAAATGTCCCCAGAAAGCT

50 bp, e2-3, 50% GC selective CC GATCTTCAAGACCAAACTGGCC

chemokine AGG (SEQ ID NO: 432) M409 osteopont

osteopontin AF052124 CTAGGCATCACCTGTGCCATAC

50 bp, e2-3, 48% GC GTTAAACAGGCTGATTCTGGAA

TC (SEQ ID NO: 433) M410 GSN gelsolin NM_000177 AAGATGGGAAAATCTTTGTCTG

50 bp, e7-8, 48% GC AAGGCAAGCAGGCAAACACGGA

GAG (SEQ ID NO: 434) M411 GZMB granzyme B NM_004131 AGAGATTAAAAAGACTTCCTTTA

50 bp, e3-4, 46% GC GGGGGACTCTGGAGGCCCTCTT

GT (SEQ ID NO: 435) M412 CD44 CD44 hyaluronic X55150 GACAGGACCTCTTTCAATGACAA

50 bp, e5-6, 46% GC receptor GCAGCAGAGTAATTCTCAGAGC

(epithelial CT form) (SEQ ID NO: 436) M413 AGCACAGACAGAATCCCTCGTA

50 bp, e4-5, 46% GC CAATATGGACTCCAGTCATAGTA

AAC (SEQ ID NO: 437) M414 IFN-alpha interferon J00210 ATTCTGCACCGAACTCTACCAG

50 bp, 50% GC will a

alpha GCTGAATGACTTGGAAGCCTGT

detect IFN-alpha 13,

GA may detect 2, F, 6, 5,

(SEQ ID NO: 438) M415 IFN-alpha interferon X02959 TGCCTGAAGGACAGACATGACT

50 bp, 46% GC; may 14 alpha GAATTTCCCCAGGAGGAATTTGA

also detect IFN-alpha GG 1B, 21, 17, 5, F, 1B, (SEQ ID NO: 439) D, 2, 21 M416 IFN-alpha interferon X02957 ACAAAGGATTCATCTGCTGCTT

50 bp, 46% GC; may 16 alpha GATGAGACCCTCCTAGACAAAT

also detect IFN-alpha TA 14, F, 5, 6, 7, 8, (SEQ ID NO: 440) M417 IFN-alpha interferon X02955 AATACAGCCCTTGTGCCTGGGA

50 bp, 46% GC; will 4b alpha TTGTCAGAGCAGAAATCATGAG

also detect IFN-alpha TCC 21, 7, 13, 14, 1, 16, 1

(SEQ ID NO: 441) d, N, F, H, N, M1, A M418 IFN-alpha interferon X02956 GTAACAGGAGGACTTTGATGAT

50 bp, 40% GC; may alpha ATGGCACAAATGGGAAGAATCT

also detect IFN-alpha TCCT 14, H (SEQ ID NO: 442) M419 IFN-alpha interferon X02958 ATGACTTCAGATTTCCCCAGGA

50 bp, 48% GC; may alpha AGTTTGATGGCAACCAGTTCCA

also detect IFN-alpha AG 16, F (SEQ ID NO: 443) M420 IFN-alpha interferon X02960 AGCCTGCGTAATAGGAGGGCCT

50 bp, 50% GC; may alpha GATACTCCTGGCACAAATGGGA

also detect IFN-alpha GAAT 21, 17, 4, A, N, F, C, (SEQ ID NO: 444) 10, 8 M421 IFN-alpha interferon X03125 GAGATGATCCAGCAGACCTTCA

50 bp, 50% GC; will alpha CCTCTTCAGCACAAAGGACTCAT

also detect IFN-alpha TGC 1B, 201, may detect

(SEQ ID NO: 445) 21, 5, 7, 17, 4, 16, 10 M422 IFNAR1 interferon NM_000629 GACTCATTTACACCATTTCGCAA

50 bp, e3-4, 44% GC (alph GCTCAGATTGGTCCTCCAGAAGT

beta and CA omega (SEQ ID NO: 446) receptor 1 M423 IFNAR2 interferon NM_000874 CACTTAATTTGGTTCTCATGGTG

50 bp, e3-4, 38% GC; (alph ATATCAGCCTCGTGTTTGGTATT

will detect both soluble beta and CA and membrane-bound omega (SEQ ID NO: 447) receptors receptor 2 M424 IFN-beta fibroblast M35591 GATCAAGCAACTCCAGCAATTC

50 bp, 46% GC interferon GAAAGAAGACGCAGCTCTGACT

TCT (SEQ ID NO: 448) M425 IFN-beta interferon- X04430 ATGCTTCCAATCTGGATTCAAT

50 bp, e3-4, 42% GC = (IL6) beta- GGAGACTTGCCTGGTGAAAATC

IL6 (interleukin 6) CA (SEQ ID NO: 449) M426 IFMBR interferon A26595 GACTCATTTACACCATTTCGCAA

50 bp, e3-4, 44% GC beta GCTCAGATTGGTCCTCCAGAAGT

receptor CA (SEQ ID NO: 450) M427 IFN-gamma A25270 ACCTTCTAAGTCACGTCACCAT

antagonist NM_006083 GATGCCAAGGGAGTACAATGAG

cytokine ATG (SEQ ID NO: 451) M428 IFNG interferon, NM_000619 CTTAGGCATTTTGAAGAATTGGA

50 bp, e2-3, 36% GC gamma AGAGGAGAGTGACAGAAAAATA

TGC (SEQ ID NO: 452) M429 IFNGR1 interferon NM_000416 GTATGTGAGAATGAACGGAAGT

50 bp, e4-5, 40% GC gamma AGATCCAGTATAAAATACTCAC

receptor 1 AGA (SEQ ID NO: 453) M430 IFNGR2 interferon NM_005534 TTGTCTACCGAGTGCAGTTTTAAA

50 bp, e2-3, 46% GC gamma ACACCGACAGTAAATGGTTCAC

receptor 2 GCC (SEQ ID NO: 454) M431 ILI8 interleukin NM_001562 GATATGACTGATTCTGACTGTA

50 bp, e2-3, 40% GC 18 GATAATGCACCCCGGACCATATT

AT (SEQ ID NO: 455) M432 IL1A interleukin NM_000575 GCATTACATAATCTGGATGAAG

50 bp, e4-5, 36% GC 1, alpha GTGAAATTTGACATGGGTGCTTA

AA (SEQ ID NO: 456) M433 IL1B interleukin NM_000576 CCAGTGAAATGATGGCTTATTA

50 bp, e2-3, 40% GC 1, b

GTGGCAATGAGGATGACTTGTT

TT (SEQ ID NO: 457) M434 IL1E interleukin-1 AF206696 GATGGTGGAGGAAGGGCCGTCT

50 bp, e2-3, 46% GC epsilon TCAATCAATGTGTAAACCTATTA

TGG (SEQ ID NO: 458) M435 IL1R1 interleukin 1 NM_000877 GTAATAGAATTTATTACTCTAGA

50 bp, e4-5, 36% GC receptor, GAAAACAAACCCACAAGGCCTG

type I

GAT (SEQ ID NO: 459) M436 IL1R2 interleukin 1 NM_004633 CTGGCACCTACGTCTGCACTACT

50 bp, e2-3, 44% GC receptor, GAAATGCTTCTTACTGTGACAAA

type I

TG (SEQ ID NO: 460) M437 IL10 interleukin 10 NM_000572 CTTCAGCAGAGTGAAGACTTTCT

50 bp, e1-2, 42% GC TCAAATGAAGGATCAGCTGGAC

ACT (SEQ ID NO: 461) M438 IL10RA interleukin 10 NM_001558 TACCTGCTATGAAGTGGCGCTC

50 bp, e2-3, 50% GC receptor, alpha GAGGTATGGAATAGAGTCCTGG

ACT (SEQ ID NO: 462) M439 IL10RB interleukin 10 NM_000628 TTCTCTTCCACAGCACCTGAAA

50 bp, e6-7, 44% GC receptor, beta GTTTTTGGGCCATCCTCATCATA

CA (SEQ ID NO: 463) M440 IL11 interleukin 11 NM_000641 GACATGAACTGTGTTTGCCGCCT

40 bp, e1-2, 57% GC GTCCTGGTCGTGCTGA (SEQ ID NO: 464) M441 IL10RA interleukin 10 NM_004512 TATGAGAACTTCTCTTGCACTTG

49 bp, e5, 49% GC receptor, alpha AGTCCCAGCCAGATCAGCGGTT

C (SEQ ID NO: 465) M442 IL12 interleukin 12 AF180562 GGCCGTCAGCAACATGCTCCAG

50 bp, e2-3, 50% GC AGGCCAGACAAACTCTAGAATT

ACC (SEQ ID NO: 466) M443 IL12RB1 interleukin 12 NM_005535 TGACCCTGCAGCTCTACAACTCA

50 bp, e4-5, 50% GC receptor, beta TTAAATATGAGCCTCCTCTGGGA

1 A (SEQ ID NO: 467) M444 IL12RB2 interleukin 12 NM_00155 AGTAACAGCAGGCTCTGGAATA

50 bp, e6-7, 42% GC receptor, beta GGTTAATGTTACAAAGGCCAAA

2 GAAG (SEQ ID NO: 468) M445 IL13 interleukin 13 NM_002188 ATCACCCAGAACCAGAAGGCTC

46 bp, e1-2, 54% GC GCTCTGCAATGGCAGCATGGTAT

(SEQ ID NO: 469) M446 IL13RA1 interleukin 13 NM_001560 CCAGAATTTGAGAGAAATGTGG

50 bp, e6-7, 42% GC receptor, alpha GAATACATCTTGTTTCATGGTC

TGG (SEQ ID NO: 470) M447 IL13RA2 interleukin 13 NM_000640 TGGAGTGATAAACAATGCTGGG

50 bp, e8-9, 40% GC receptor, alpha AGGTGAAGACCTATCGAAGAAA

CTTT (SEQ ID NO: 471) M448 IL15 interleukin 15 NM_000585 CATTCATGTCTTCATTTTGGGCT

50 bp, e4-5, 44% GC TTCAGTGCAGGGCTUCCTAAAA

G (SEQ ID NO: 472) M449 IL15RA interleukin 15 NM_002189 TTCTGGAAAAGAGCCCGCAGCT

47 bp, e3-4, 51% GC receptor, alpha ATCTCCCAGCTCAAACAACACA

(SEQ ID NO: 473) M450 IL2 interleukin 2 NM_000586 ATTTAAGTTTTACATGCCCAAGA

50 bp, e2-3, 40% GC GGCCACAGAACTGAAACAGCTT

AGT (SEQ ID NO: 474) M451 IL2RA interleukin 2 NM_000417 AACCAATGTCAATGCACAAGCT

50 bp, e2-3, 44% GC receptor, alpha GCCACTCGGAACACAACGAAA

AGT (SEQ ID NO: 475) M452 IL2RB interleukin 2 NM_000878 AACCTGATCCTCGGAGCCCCAGA

50 bp, e4-5, 50% GC receptor, beta TCTCAGAAACTGACCACAGTTGA

AT (SEQ ID NO: 476) M453 IL2RG interleukin 2 NM_000206 TGGGAATGAAGACACCACAGCT

50 bp, e1-2, 50% GC receptor, gamma ATTTCTTCCTGACCACTATGCCC

CTG (SEQ ID NO: 477) M454 IL3 interleukin 3 NM_000588 ATCAGCAATTGAGAGCATTCTTA

50 bp, e3-4, 46% GC AAATCTCCTGCCATGTCTGCCC

GG (SEQ ID NO: 478) M455 IL3RA interleukin 3 NM_002183 TTGCCAACAGGCGTCAACAGTA

50 bp, 48% GC receptor, alpha GAGTGTCTTCACTACAAAACGG

GCT (SEQ ID NO: 479) M456 IL4 interleukin 4 NM_000589 TAACAGACATCTTTGCTGCCTC

50 bp, e2-3, 44% GC AGAACACAACTGAGAAGGAAA

TTC (SEQ ID NO: 480) M457 IL4R interleukin 4 NM_000418 TTGGAGTGAAAACGACCCGGCA

50 bp, e5-6, 46% GC receptor ATTTCAGAATCTATAACGTGAC

ACC (SEQ ID NO: 481) M458 IL5 interleukin 5 NM_000879 TCGAACTCTGCTGATAGCCAAT

50 bp, e1-2, 48% GC GACTCTGAGGATTCCTGTTCCTG

AC (SEQ ID NO: 482) M459 IL5RA interleukin 5 NM_000564 ACACGCAGTATTTTCTCTACTAT

50 bp, e7-8, 42% GC receptor, alpha GGTATGGCTCTTGGACTGAAGAA

GC (SEQ ID NO: 483) M460 IFNB1 interferon, NM_002176 AGTGTCTCCTCCAAATTGCTCTC

50 bp, 48% GC beta fibroblast TGTTGTGCTTCTCCACTACAGCT

TT (SEQ ID NO: 484) M461 IL6R interleukin 6 NM_000565 TCAAAGACATTCACAACATGGA

50 bp, e5-6, 46% GC receptor GGTCAAGGACCTCCAGCATCAC

TGT (SEQ ID NO: 485) M462 IL7 interleukin 7 NM_000880 TAATGGTCAGCATCGATCAATTA

50 bp, e2-3, 38% GC TGGACAGCATGAAAGAAATTGG

AGC (SEQ ID NO: 486) M463 IL7R interleukin 7 NM_002185 GGAGAAAGTGGCTATGCTCAAA

50 bp, e1-2, 46% GC receptor TGGAGACTTGGAAGATGCAGAA

TGGA (SEQ ID NO: 487) M464 IL8 interleukin 8 NM_000584 CTGATTTCTGCAGCTCTGTGTGA

50 bp, e1-2, 48% GC GGTGCAGTTTTGCCAAGGAGTG

AA (SEQ ID NO: 488) M465 IL8RA interleukin 8 NM_000634 CTTGGTCAAGTTTGTTTGTCTTG

50 bp, 46% GC receptor, alpha CTGCTGGGGACTGTCTATGAAT

GT (SEQ ID NO: 489) M466 IL8RB interleukin 8 NM_001557 GGAAGATTTTAACATGGAGAGT

50 bp, 40% GC receptor, beta ACAGCTTTGAAGATTTCTGGAAA

GTG (SEQ ID NO: 490) M467 IL9 interleukin 9 NM_000590 ACTAAAGAACAACAAGTGTCCA

50 bp, e4-5, 40% GC ATTTTTCCTGTGAACAGCCATG

ACC (SEQ ID NO: 491) M468 IL9R interleukin 9 NM_002186 TGTTCAAGCTGTCGCCCAGGGT

46 bp, e8-9, 50% GC receptor AGAGAATCTTCTAGCAGAACGT

(SEQ ID NO: 492) M469 LIF leukemia NM_002309 TGCCAATGCCCTCTTTATTCTCT

48 bp, e2-3, 53% GC inhibitory TACACAGCCCAGGGGGAGCCGT

factor (SEQ ID NO: 493) receptor M470 LIFR leukemia NM_002310 GGAGCCCTGTGAAGAACATTTCT

50 bp, e6-7, 44% GC inhibitory GGATACCTGATTCTCAGACTAA

factor TT receptor (SEQ ID NO: 494) M471 BLT1 leukotriene B4 AB008193 TCACTAGGTGTAGAGTTCATCT

50 bp, 48% GC receptor CTGCTGGCTATCATCCTGCTGTC

GT (SEQ ID NO: 495) M472 BLT2 leukotriene B4 AB008193 TTGGCCTTCTTCAGTTCTAGCGT

44 bp, 52% GC receptor AACCCGGTGCTCTACGTCTT (SEQ ID NO: 496) M473 CYSLT1 cysteinyl NM_006639 CAGGAAATCTGACAGTATCTTCT

50 bp, 44% GC leukotriene CCACATGCCATGACACTATTGAT

receptor 1 AC (SEQ ID NO: 497) M474 LTA4H leukotriene A4 NM_000895 TGTGAAATTAACCTATACTGCA

50 bp, e4-5, 44% GC hydrolase GGTGTCTGTCCCTAAAGAACTG

GG (SEQ ID NO: 498) M475 LTC4S leukotriene C4 NM_000897 GTCTACCGAGCCCAGGTGAACT

36 bp, e2-3, 58% GC synthase AGCGAGTACTTC (SEQ ID NO: 499) M476 LTB4DH NADP depende

XM_088569 ATGATGGGGCAGGAAGTGGCCA

50 bp, e4-5, 46% GC leukotriene b4

AGTTGTGGAAAGTAAAAATGTA

hydroxydehydro- CCCT genase (SEQ ID NO: 500) M477 SELL selectin L NM_000655 TCATCTCCAGAACCAACCTGTCA

50 bp, e5-6, 46% GC GTGATTCAGTGTGAGCCTCTAT

GC (SEQ ID NO: 501) M478 SCYC1 lymphotactin NM_002995 TCTCTCACTGCATACATTGTGGA

50 bp, e1-2, 44% GC GGTGTAGGGAGTGAAGTCTCAG

also detect SCYC2 = TAA SCYC1? (SEQ ID NO: 502) M479 CCXCR1 chemokine (C NM_005283 CAAACTCCTCAATATGATCTTCT

50 bp, 44% GC motif) XC CATCAGCCTCTACAGCAGCATCT

receptor 1 CT (SEQ ID NO: 503) M480 SCYA22 = small inducible NM_002990 TTCAAGCAACTGAGGCAGGCCC

42 bp, e1-2, 58% GC MDC? cytokine ACGGCGCCAACATGGAA subfamily A (SEQ ID NO: 504) (C

Cys), member 2 M481 CCR2 chemokine (C-

NM_000648 AGTGCTTGACTGACATTTACCT

50 bp, 48% GC shoul

motif) receptor TCAACCTGGCCATCTCTGATCT

detect both isoforms TT may also detect CCR (SEQ ID NO: 505) M482 SCYA3 small inducible NM_002983 AAGCCCGGTGTCATCTTCCTAA

41 bp, e2-3, 58% GC cytokine A3 AAGCGAAGCCGGCAGGT

(SEQ ID NO: 506) M483 SCYA4 small inducible NM_002984 GCTCCCAGCCAGCTGTGGTATT

50 bp, e2-3, 50% GC cytokine A4 AAACCAAAAGAAGCAAGCAAGT

TGT (SEQ ID NO: 507) M484 AMH anti-Mullerian NM_000479 AGCCCCGCGGAGAGGACTCCCG

30 bp, e3-4, 70% GC hormone CTGAGTA (SEQ ID NO: 508) M485 AMHR2 anti-Mullerian NM_020547 ATGAGGAGCGCTGGCAGAATG

48 bp, e7-8, 52% GC hormone receptor CAATATAAACCAGGTATTGCCCA

typeII C (SEQ ID NO: 509) M486 SCYD1 neurotactin NM_002996 TGCGGCAAACGCGCAATCATCT

47 bp, e2-3, 55% GC GAGACGAGACAGCACAGGCTGT

(SEQ ID NO: 510) M487 NRTN neurturin NM_004558 TCAGTGCTCTGCAGCTCCGTGCT

40 bp, e1, 57% GC TCCATCTGGATGTGTC (SEQ ID NO: 511) M488 BMP-8 bone morpho- NM_001720 AGGTGGTCCAGGAGCAGTCCAA

50 bp, e2-3, 50% GC genetic AGGGAGTCTGACTTGTTCTTTTT

protein 8 GAT (SEQ ID NO: 512) M489 FAAH fatty acid NM_001441 TGCTCTTCACCTATGTGGGAAA

49 bp, e2-3, 51% GC amide hydrolase CCTGGGAAGTGAACAAAGGGA

AA (SEQ ID NO: 513) M490 OSM oncostatin M NM_020530 ATCTCATGCAGGACACCAGCAG

50 bp, e2-3, 50% GC CTCCTGGACCCCTATATACGTAT

CAA (SEQ ID NO: 514) M491 OSMR oncostatin M NM_003999 TCCTTGAGGACTTACCAGAGTGA

50 bp, e2-3, 46% GC receptor GTCTTGGCTGAACGTTTACCATT

AC (SEQ ID NO: 515) M492 SCYA5 RANTES NM_002985 AAGTGCTCCAACCCAGCAGTCG

44 bp, e2-3, 54% GC TTTGTCACCCGAAAGAACCG (SEQ ID NO: 516) M493 RANTES L10918 TGTACTCCTTGGTATTTGTCATT

50 bp, 46% GC Receptor GCCTGGTTGGAAACATCCTGGT

TC (SEQ ID NO: 517) M494 relaxin H1 X00949 CCTCAGACACCTAGACCAGTGG

50 bp, e1-2, 46% GC AGAAATTGTACCATCCTTCATCA

should detect also CAA relaxin H2 (1 bp (SEQ ID NO: 518) different) M495 SDF1 stromal cell- XM_165565 CTCCAAACTGTGCCCTTCAGATT

50 bp, e2-3, 50% GC derived factor TAGCCCGGCTGAAGAACAACAA

1 AGA (SEQ ID NO: 519) M496 SDF2 stromal cell- NM_006923 CTTCACCTCTTTCTGGAAACCA

50 bp, e2-3, 48% GC derived factor AAGTGAGTGCTTTTGGTGAGGA

GGT (SEQ ID NO: 520) M497 SDFR1 stromal cell XM_015963 AGAATGCCAGCAACATGGAGTA

50 bp, e3-4, 48% GC derived factor AGGATCAATAAGCCGAGAGCTG

receptor 1 GGAT (SEQ ID NO: 521) M498 TGF-alpha transforming M31172 TTTTTGGTGCACGAGGACAAGC

48 bp, e2-3, 52% GC growth factor- GCATGTGTCTGCCATTC TGGGTA

alpha (SEQ ID NO: 522) M499 TGFB1 transforming NM_000660 GTGCTAATGGTGGAAACCCACA

50 bp, e1-2, 44% GC growth factor, CGAAATCTATGACAAGTTCAAG

beta 1 AGAG (SEQ ID NO: 523) M500 TGFB2 transforming M19154 GAAGAACTAGAAGCAAGATTTG

50 bp, e3-4, 42% GC growth factor, M22045 AGGTATTGATGGCACCTCCACAT

beta 2 M22046 TAG (SEQ ID NO: 524) M501 TGFB3 transforming J03241 GAGGTGATGGAAATCAAATTCA

50 bp, e4-5, 46% GC growth factor, AGGCGTGGACAATGAGGATGA

beta 3 ATGG (SEQ ID NO: 525) M502 TGFBR1 transforming NM_004612 ATGACAACGTCAGGTTCTGGCT

50 bp, e3-4, 46% GC growth factor, GGTTTACCATTGCTTGTTCAGAG

beta receptor AC 1 (SEQ ID NO: 526) M503 TGFBR2 transforming NM_003242 CACAGGAAGTCTGTGTGGCTGTA

50 bp, e2-3, 44% GC growth factor, GGAGAAAGAATGACGAGAACAT

beta receptor ACA 2 (SEQ ID NO: 527) M504 TGFBR3 transforming NM_003243 TGGGGTCTCCAGACTGTTTTTGG

50 bp, e3-4, 50% GC growth factor, GTCTGAGGGTTCTGTGGTCCAGT

beta receptor TT 3 (SEQ ID NO: 528) M505 THPO thrombopoietin NM_000460 TTTAGCTTGGGAGAATGGAAAA

50 bp, e3-4, 50% GC CCAGATGGAGGAGACCAAGGCA

AGGA (SEQ ID NO: 529) M506 TNF tumor necrosis NM_000594 CGAGTGACAAGGCTGTAGCCCA

46 bp, e2-3, 52% GC TNFSF2 factor GTTGTAGCAAACCCTCAAGCTGA

(SEQ ID NO: 530) M507 TNFSF1 lymphotoxin NM_000595 AAACCTGCTGCTCACCTCATTG

45 bp, e3-4, 53% GC (LTA) alpha GACCCCAGCAAGCAGAACTCA (SEQ ID NO: 531) M508 TNFSF3 lymphotoxin NM_002341 CTTAGTGCCCCAGGATCAGGGA

39 bp, e1-2, 59% GC (LTB) be

GACTGGTAACGGAGAC (SEQ ID NO: 532) M509 TNFSF4 tumor necrosis NM_003326 TGCCTGCACTTCTCTGCTCTTCA

50 bp, e1-2, 48% GC factor (ligand) GTATCACATCGGTATCCTCGAAT

superfamily, CA member 4 (SEQ ID NO: 533) M510 TNFSF5 tumor necrosis NM_000074 GAGGCCAGCAGTAAAACAACAT

50 bp, e2-3, 50% GC factor (ligand) TGTGTTACAGTGGGCTGAAAAA

superfamily, GATA member 5 (SEQ ID NO: 534) M511 TNFSF6 tumor necrosis NM_000639 GAGCTGAGGAAAGTGGCCCATT

50 bp, e3-4, 50% GC factor (ligand) AACAGGCAAGTCCAACTCAAGG

superfamily, CCAT member 6 (SEQ ID NO: 535) M512 TNFSF7 tumor necrosis NM_001252 TGCAGCTGAATCACACAGGACC

43 bp, e2-3, 55% GC = factor (ligand) AGCAGGACCCCAGGCTATA CD27? superfamily, (SEQ ID NO: 536) member 7 M513 TNFSF8 tumor necrosis NM_001244 ATTATGGTGTTGGTCGTTCAGA

50 bp, e1-2, 50% GC factor (ligand) ACGGACTCCATTCCCAACTCAC

superfamily, GA member 8 (SEQ ID NO: 537) M514 TNFSF9 tumor necrosis NM_003811 AGGGCATGTTTGCGCAGCTGGT

50 bp, e2-3, 50% GC factor (ligand) CCCAAAATGTTCTGCTGAT superfamily, (SEQ ID NO: 538) member 9 M515 TNFSF10 tumor necrosis NM_003810 GTACTTTACCAACGAGCTGAAG

50 bp, e1-2, 46% GC factor (ligand) GATGCAGGACAAGTACTCCAAA

superfamily, GTG member 10 (SEQ ID NO: 539) M516 TNFSF11 tumor necrosis NM_003701 GCCTTTCAAGGAGCTGTGCAAA

50 bp, e2-3, 42% GC factor (ligand) GGAATTACAACATATCGTTGGAT

superfamily, ACA member 11 (SEQ ID NO: 540) M517 TNFSF12 tumor necrosis NM_003809 CTCTACTACCTGTACTGTCAGGT

47 bp, e6-7, 51% GC factor (ligand) CACTTTGATGAGGGGAAGGCTG

superfamily, (SEQ ID NO: 541) member 12 M518 TNFSF13 tumor necrosis NM_003808 TGGAGTTTATCTGCTGTATAGC

50 bp, e4-5, 44% GC factor (ligand) GGTCCTGTTTCAAGACGTGACTT

superfamily, CA member 13 (SEQ ID NO: 542) M519 TNFSF14 tumor necrosis NM_003807 AGCTGATACAAGAGCGAAGGT

42 bp, e2-3, 54% GC factor (ligand) CACGAGGTCAACCCAGCAG superfamily, (SEQ ID NO: 543) member 14 M520 TNFSF15 tumor necrosis NM_005118 TCACCAAGAACCGAATGAACTA

50 bp, 44% GC factor (ligand) ACCAACAAATTCCTGCTGATCC

may also detect superfamily, GAG transmembrane LIGH

member 15 (SEQ ID NO: 544) mRNA (AY028261) M521 TNFSF18 tumor necrosis NM_005092 AAGGAGCCCTGTATGGCTAAGT

50 bp, e2-3, 44% GC factor (ligand) GGACCATTACCCTCAAAATGGCA

superfamily, AAT member 18 (SEQ ID NO: 545) M522 TNFRSF10B tumor necrosis NM_003842 TTTTCTGCTTGCGCTGCACCAGG

50 bp, e2-3, 50% GC factor receptor GTGATTCAGGTGAAGTGGAGCT

superfamily, AGT member 10B (SEQ ID NO: 546) M523 TNFRSF11A tumor necrosis XM_036978 ACAAATGCAGACCCTGGACCAA

50 bp, e4-5, 50% GC factor receptor TGTACCTTCCTTGGAAAGAGAGT

superfamily, GAA member 11A (SEQ ID NO: 547) M524 TNFRSF11B tumor necrosis NM_002546 TGGATTTGGAGTGGTGCAAGCT

50 bp, e2-3, 50% GC factor receptor AACCCCAGAGCGAAATACAGTT

superfamily, GCA member 11B (SEQ ID NO: 548) M525 TNFRSF12 tumor necrosis NM_003790 CACACACGGCTACTCTGTTCCC

45 bp, e4-5, 53% GC factor receptor AGAGATACTGACTGTGGGA superfamily, (SEQ ID NO: 549) member 12 M526 TNFRSF14 tumor necrosis NM_003820 GTGAAAAGAAGAAAGCCAAGG

50 bp, e6-7, 48% GC factor receptor TGATGTAGTCAAGGTGATCGTCT

superfamily, CGT member 14 (SEQ ID NO: 550) M527 TNFRSF17 tumor necrosis NM_001192 CATGTCAGCGTTATTGTAATGCA

50 bp, e1-2, 42% GC factor receptor GTGTGACCAATTCAGTGAAAGG

superfamily, ACG member 17 (SEQ ID NO: 551) M528 TNFRSF18 tumor necrosis NM_004195 ACTGCAAACCTTGGACAGACTG

49 bp, e3-4, 51% GC factor receptor ACCCAGTTCGGGTTTCTCACTGT

superfamily, TT member 18 (SEQ ID NO: 552) M529 TNFRSF19 tumor necrosis NM_018647 GTATTACTAGGCTATTTGTCATG 50 bp, e2-3, 38% GC factor receptor TAAAGTGACTTGTGAATCAGGAG superfamily, ACTG member 19 (SEQ ID NO: 553) M530 TNFRSF21 tumor necrosis NM_014452 ACTTATGTTCCCAAAGGCATGAA 50 bp, e2-3, 44% GC factor receptor CTCAACAGAATCCAACTCTTCTG superfamily, CCTC member 21 (SEQ ID NO: 554) M531 TNFRSF3 tumor necrosis NM_002342 ACTGAAGCCGAGCTCAAAGATG 50 bp, e4-5, 50% GC factor receptor AAGTTGGGAAGGGTAACAACCA superfamily, CTGCGT member 3 (SEQ ID NO: 555) M532 TNFRSF4 tumor necrosis NM_003327 TGCACGTGGTGTAACCTCAGAAG 41 bp, e2-3, 56% GC factor receptor TGGGAGTGAGCGGAAGCA superfamily, (SEQ ID NO: 556) member 4 M533 TNFRSF6 tumor necrosis NM_000043 AGATTGTGTGATGAAGGACATGG 50 bp, e3-4, 44% GC = factor receptor CTTAGAAGTGGAAATAAACTGCA Apo1 antigen? superfamily, CCCG member 6 (SEQ ID NO: 557) M534 TNFRSF6B tumor necrosis NM_003823 TCAGCACCAGGGTACCAGGAGC 38 bp, e2-3, 60% GC factor receptor TGAGGAGTGTGAGCGT superfamily, (SEQ ID NO: 558) member 6B M535 TNFRSF7 tumor necrosis NM_001242 CATCAACGAAGGAAATATAGAT 50 bp, e5-6, 42% GC factor receptor CAAACAAAGGAGAAAGTCCTGT superfamily, GGAGCC member 7 (SEQ ID NO: 559) M536 TNFRSF8 tumor necrosis NM_001243 CACGGAGCACACCAATAACAAG 50 bp, e9-10, factor receptor ATTGAGAAAATCTACATCATGAA 42% GC superfamily, GGCTG member 8 (SEQ ID NO: 560) M537 TNFRSF9 tumor necrosis NM_001561 TGTGACATATGCAGGCAGTGTAA 50 bp, e3-4, 48% GC factor receptor AGGTGTTTTCAGGACCAGGAAGG superfamily, AGTG member 9 (SEQ ID NO: 561) M538 GAPD glyceraldehyde- NM_002046 CCCTTCATTGACCTCAACTACAT 50 bp, e2-3, 40% GC 3-phosphate GGTTTACATGTTCCAATATGATT dehydrogenase CCAC (SEQ ID NO: 562) M539 CATTGACCTCAACTACATGGTTT 40 bp, e2-3, 35% GC ACATGTTCCAATATGAT (SEQ ID NO: 563) M540 ACCTCAACTACATGGTTTACATGTTCC 30 bp, e2-3, 32% GC AAT (SEQ ID NO: 564) M541 AGTATGACAACAGCCTCAAGATCATC 50 bp, e5-6, 50% GC AGCATGCCTCCTGCACCACCAAC (SEQ ID NO: 565) M542 GACAACAGCCTCAAGATCATCAGCAA 40 bp, e5-6, 52% GC TGCCTCCTGCACCA (SEQ ID NO: 566) M543 CAGCCTCAAGATCATCAGCAAT 30 bp, e5-6, 53% GC GCCTCCTG (SEQ ID NO: 567) M544 AACTTTGGTATCGTGGAAGGACT 50 bp, e6-7, 50% GC CATGACGACAGTCCATGCCATC ACTGC (SEQ ID NO: 568) M545 ACTB actin, beta NM_001101 AGATCACTGCCCTGGCACCCAG 50 bp, e4-5, 50% GC CAATGAAGATCAAGATCATTGC CT (SEQ ID NO: 569) M546 GCCCTGGCACCCAGCACAATGA 40 bp, e4-5, 52% GC GATCAAGATCATTGCTC (SEQ ID NO: 570) M547 TGGCACCCAGCACAATGAAGAT

30 bp, e2-3, 46% GC AAGATCA (SEQ ID NO: 571) M548 Negative Negative NM_002046 ATGACAACAGCCTCAAGATCAT

50 bp, 44% GC control control NM_001101 AGGAAGATCAAGATCATTGCTC

e5 of GAPD + e5 CCT ofACTB (SEQ ID NO: 572) M549 Negative Negative NM_002046 AACAGCCTCAAGATCATCAGGA

40 bp, 42% GC control control NM_001101 GATCAAGATCATTGCTC e5 of GAPD + e5 (SEQ ID NO: 573) ofACTB M550 Negative Negative NM_002046 CCTCAAGATCATCAGGAAGATC

30 bp, 40% GC control control NM_001101 AGATCAT e5 of GAPD + e5 (SEQ ID NO: 574) ofACTB M551 PTGDS prostaglandin NM_000954 AACCTGACCTCCACCTTCCTCAG

50 bp, e2-3, 52% GC D synthase AAAAACCAGTGTGAGACCCGAA

CAT (SEQ ID NO: 575) M552 PTGES prostaglandin NM_004878 ACGTGGAACGCTGCCTCAGGGC

42 bp, e2-3, 64% GC E synthase CACCGGAACGACATGGAGA (SEQ ID NO. 576) M553 LYST Chediak-Higas

U84744 CCTGTCCAAGAAGAAAAGGCAA

50 bp, e4-5, 46% GC syndrome protein AGATTTTAACCTACCGCTCTCAG

short iso AGA (SEQ ID NO: 577) M554 MITF microphthalmia

NM_000248 AATGCTAGAATATAATCACTAT

50 bp, e1-2, 44% GC associated GGTGCAGACCCACCTCGAAAAC

transcription CCA factor (SEQ ID NO: 578) M555 OCA2 oculocutaneous NM_000275 GTTTGCCTTTGTGGTGCTGTGTT

50 bp, e3-4, 44% GC albinism II ATTTTGTTCAGCCTATATCCGGA

C (SEQ ID NO: 579) M556 OMP olfactory marke

NM_006189 TGGCCAAGATCCGCAAGGTCAT

46 bp, 54% GC protein ACTTCCTCGTCACCTTTGGCGA (SEQ ID NO: 580) M557 TRP-2 tyrosinase- AJ000503 TCTTCCACCGGACCTGCAAGTG

50 bp, e1-2, 50% GC related NM_001922 CAGGAAACTTTGCCGGCTATAA

protein 2 GT (dopachrome (SEQ ID NO: 581) tautomerase) M558 TATTCTGTTAGAGATACATTATT

50 bp, e2-3, 46% GC GGACCAGGACGCCCCTACAGGG

CAT (SEQ ID NO: 582) M559 TYR tyrosinase NM_000372 AGCATCATTCTTCTCCTCTTGGC

50 bp, e1-2, 48% GC GATTGTCTGTAGCCGATTGGAG

GT (SEQ ID NO: 583) M560 TYRP1 tyrosinase- NM_000550 GCCTGTGACCAGAGGGTTCTCAT

50 bp, e2-3, 46% GC related GTCAGGAGAAATCTTCTGGACTT

protein 1 AG (SEQ ID NO: 584) M561 PNMT phenylethanola

NM_002686 TGCCTCATTTGAGGGCAAGGGGG

41 bp, e2-3, 56% GC ne N-methyl- ATGCTGGCAGGATAAGGA transferase (SEQ ID NO: 585) M562 HGF hepatocyte D14012 GCAGTGCACACAGGAAGTGGTG

50 bp, e4-5, 46% GC growth GCCACAACTCACAACTACGAC factor (SEQ ID NO: 586) M563 MET hepatocyte NM_000245 GATCTGTCTGCCTGCAATCTACA

50 bp, e5-6, 46% GC growth GGTTTTCCCAAATAGTGCACCC

factor TG receptor (SEQ ID NO: 587) M564 NPY neuropeptide NM_000905 ACATCAACCTCATCACCAGGCA

50 bp, e1-2, 50% GC Y AGATATGGAAAACGATCCAGCC

AGAG (SEQ ID NO: 588) M565 NPY2R neuropeptide NM_000910 GCAAAAACGCGAGGTCCAGGT

49 bp, e1-2, 53% GC Y receptor Y2 GTTGTAGACTCTTGTGCTGGTTG

AG (SEQ ID NO: 589) M566 neuropeptide M84755 ATTTATTTGCTACTTCAAGATAT

50 bp, e1-2, 28% GC y receptor TATACGCCTAAAAAGGAGAAA

ACA (SEQ ID NO: 590) M567 BDNF brain-derived NM_001709 TGATAGAAGAGCTGTTGGATGA

50 bp, 44% GC neurotrophic GACCATAAAGTTCGGCCCAATG

factor AGAA (SEQ ID NO: 591) M568 NTF3 neurotrophin 3 NM_002527 TTGCCAGAAGACTCGCTCAATT

50 bp, 46% GC CTCATTATTAAGCTGATCCAGG

GA (SEQ ID NO: 592) M569 NTF5 neurotrophin 5 NM_006179 TCCGCCAGTACTTCTTTGAAAC

50 bp, e4-5, 46% GC GCTGCAAGGCTGATAACGGTGA

GAA (SEQ ID NO: 593) M570 OGFR opioid growth NM_007346 TTGAGGAGAATCACTCCTACAT

50 bp, e4-5, 50% GC factor receptor AGTGGCTGTTTCCTCTGCGAGAA

CA (SEQ ID NO: 594) M571 OPRD1 opioid receptor NM_000911 CTTGTCATGTTCGGCATCGTCCG

50 bp, e1-2, 52% GC delta 1 TACACTAAGATGAAGACGGCCA

CAA (SEQ ID NO: 595) M572 OPRK1 opioid receptor NM_000912 CGCTGGTCATGTTCGTGATCAT

50 bp, e1-2, 46% GC kappa 1 GATACAGAAAGATGAAGACAG

ACC (SEQ ID NO: 596) M573 OPRM1 opioid receptor NM_000914 TCCTGGTCATGTATGTGATTGTC

50 bp, e1-2, 46% GC mu 1 GATACACCAAGATGAAGACTGC

ACC (SEQ ID NO: 597) M574 VIPR1 vasoactive NM_004624 ATGACAAGGCAGCGAGTTTGGA

50 bp, e3-4, 50% GC intestinal GAGCAGCAGACCATGTITCTACG

peptide TCT receptor 1 (SEQ ID NO: 598) M575 VIPR2 vasoactive XM_036413 CAGCGACCCGGAGGATGAGAG

50 bp, e4-5, 50% GC intestinal AGATCACGTTTTATATTCTGGTG

peptide AGG receptor 2 (SEQ ID NO: 599) M576 AKR1C2 aldo-keto XM_048859 ATTTGGCACCTATGCGCCTGCA

50 bp, e1-2, 48% GC reductase GGTTCCTAAAAGTAAAGCTCTA

may also detect family 1, GG AKR1C1, DD1 member C2 (SEQ ID NO: 600) M577 AKR1C3 aldo-keto NM_003739 TCATTCTCCAATGTCTCTAAAG

50 bp, e3-4, 44% GC reductase AGGTGAGGAACTTTCACCAACA

family 1, ATG member C3 (SEQ ID NO: 601) M578 CYP8B1 cytochrome P4

XM_046266 ATGTTTGAATTTCTGAAGCGCAT

50 bp, 46% GC subfamily VIIII

AGGACCAAGGATGGGGATGTGT

GAG (SEQ ID NO: 602) M579 EBRP emopamil NM_032565 CCATAGTCAAAGAAAAATATTA

50 bp, e3-4, 44% GC binding CGGCATTTCCTGCAGATCACCCT

related TGC protein (SEQ ID NO: 603) M580 HSD3A oxidative 3 U89281 GGAAGCCTTTTCAGATATTCTGA

50 bp, e1-2, 44% GC alpha hydroxy- GCGTGAGATTCAACATTTTGGG

steroid GA dehydrogenase (SEQ ID NO: 604) M581 HSD3B 3 Beta- X53321 TCTATCATGAATGTCAATGTGAA

50 bp, e2-3, 46% GC hydroxysteroid GGTACCCAGCTCCTGTTAGAGG

dehydrogenase TG (SEQ ID NO: 605) M582 RDHL retinol NM_005771 GTGAAGAACCAAGTTGGGGAGA

50 bp, e1-2, 48% GC dehydrogenase AGGTCTCTGGGGTCTGATCAATA

will also detect homolog TGC hydroxysteroid (SEQ ID NO: 606) epimerase (NM_003725) M583 sterol/retinol AF057034 TGAAGGAGTGCGTGAGAGACAA

50 bp, e1-2; 52% GC dehydrogenase GGACTCTGGGGGCTGGTGAATA

GCT (SEQ ID NO: 607) M584 TAC1 tachykinin, NM_003182 GGATTAATGGGCAAACGGGATG

50 bp, e3-4, 44% GC precursor 1 TGATTCCTCAATTGAAAAACAA

GGC (SEQ ID NO: 608) M585 TACR1 tachykinin NM_001058 GAGCAAGTCTCTGCCAAGCGCA

50 bp, e3-4, 50% GC receptor 1 GGTGGTCAAAATGATGATTGTC

will detect both GGT isoforms (SEQ ID NO: 609) M586 TACR2 tachykinin NM_001057 ATCTACTGCTGTCTCAACCACA

50 bp, e4-5, 54% GC receptor 2 TTTCGCTCTGGGTTCCGGCTTGC

TT (SEQ ID NO: 610) M587 TACR3 Tachykinin NM_001059 TCATCTACTGCTGTCTGAATAAA

50 bp, e4-5, 42% GC receptor 3 GATTTCGAGCTGGCTTCAAGAGA

CA (SEQ ID NO: 611) M588 TBG thyroxine- M14091 GAGGACAATGGTCTGAAACTTT

50 bp, e4-5, 50% GC = binding AATGCTGCCCATAAGGCTGTGCT

serine (or cysteine) globulin CA proteinase inhibitor (SEQ ID NO: 612) M589 TPO thyroid NM_000547 CCGCCATGTACGCCACGATGCA

50 bp, e2-3, 50% GC peroxidase AGAAACCTCAAGAAAAGAGGAA

CCTT (SEQ ID NO: 613) M590 CALB2b calbindin 2 NM_007087 GCTCCAGGAATACACCCAAACC

50 bp, e5-6, 46% GC TACTACGGATGTTTGACTTGAA

GGG (SEQ ID NO: 614) M591 CALB3 calbindin 3 NM_004057 GCTGAATTCCCCAGTTTACTCAA

50 bp, e2-3, 44% GC GGTCCAAACACCCTAGATGATCT

TT (SEQ ID NO: 615) M592 NCOA2 nuclear NM_006540 AAAAACCTGCTGCCAAAGTCTAGG

50 bp, e6-7, 46% GC receptor GTAAATGGGGGATCTTGGTCTGGAA

coactivator 2 GA (SEQ ID NO: 616) M593 VDR vitamin D NM_000376 GTGGACATCGGCATGATGAAGG

50 bp, e3-4, 48% GC receptor GTTCATTCTGACAGATGAGGAA

GCA (SEQ ID NO: 617) M594 VDBP vitamin D NM_000583 CTCTGAAGATTGCATGGCCAAA

50 bp, e7-8, 46% GC binding AGCTGCCTGAACACACAGTAAA

protein CTCT (SEQ ID NO: 618) M595 BMP1 bone NM_006128 TCGTAAGTCCTCCATCAAAGCT

50 bp, e2-3, 50% GC morphogenetic AGTTCCAGGAAACACTTCTACC

protein 1 CA (SEQ ID NO: 619) M596 BMP10 bone NM_014482 CATCATTAGGAGTTTCAAGAAT

50 bp, e1-2, 42% GC morphogenetic AGATCTGTTTTCCCAGCCGGTCA

detects almost all protein 10 TT splicing variants (SEQ ID NO: 620) M597 BMP11 bone AF100907 GTCATTAGCATGGCCCAGGAGA

45 bp, e1-2, 55% GC morphogenetic GGACCCAGCAGTACAGACAGAT

protein 11 (SEQ ID NO: 621) M598 BMP15 bone NM_005448 ACCAGTGTGGCAAGGCCTCACA

47 bp, e1-2, 53% GC morphogenetic AGGTACCTGGCATATACAGATC

protein 15 (SEQ ID NO: 622) M599 BMP2 bone NM_00120 ACTGTGCGCAGCTTCCACCATGA

50 bp, e2-3, 46% GC morphogenetic GAATCTTTGGAAGAACTACCAG

protein 2 AAC (SEQ ID NO: 623) M600 BMP3 bone NM_001201 CAGCTTTCGGGCGGCAGCAGCA

50 bp, e1-2, 48% GC morphogenetic AAACTCTTGAAAGAAAAGGACT

protein 3 TATA (SEQ ID NO: 624) M601 BMP4 bone NM_001202 AGCTTCCACCACGAAGAACATC

50 bp, e3-4, 50% GC morphogenetic GAGAACATCCCAGGGACCAGTG

protein 4 AAA (SEQ ID NO: 625) M602 BMP5 Bone NM_021073 CAGCTCTGTGCAGAAACAGGGG

50 bp, e1-2, 48% GC morphogenetic TGGACGCAGTATCAACGTAAAA

protein 5 GTGC (SEQ ID NO: 626) M603 BMP6 bone NM_001718 ACATGGTCATGAGCTTTGTGAA

50 bp, e1-2, 50% GC morphogenetic TGGTGGAGTACGACAAGGAGTT

protein 6 TCC (SEQ ID NO: 627) M604 BMP7 bone NM_001719 ATGGTCATGAGCTTGGTCAACCT

50 bp, e1-2, 46% GC = morphogenetic GTGGAACATGACAAGGAATTCT

TGF beta? protein 7 CA (SEQ ID NO: 628) M605 BMP8 bone NM_001720 AGGTGGTCCAGGAGCAGTCCAA

50 bp, e3-4, 50% GC morphogenetic AGGGAGTCTGACTTGTTCTTTTT

protein 8 GAT (SEQ ID NO: 629) M606 BMP9 bone AF188285 ATTGTGCGGAGCTFCAGCATGGA

50 bp, e1-2, 50% GC morphogenetic GATGCCATCTCCATAACTGCCA

protein 9 GA (SEQ ID NO: 630) M607 BMPR1A bone NM_004329 AGTGGGTCTGGACTACCTTTATT

50 bp, e8-9, 44% GC morphogenetic GTTCAGCGAACTATTGCCAAACA

protein AT receptor (SEQ ID NO: 631) type IA M608 BMPR1B bone NM_001203 GAAGGCTCAGATTTTCAGTGTC

50 bp, e5-6, 48% GC morphogenetic GACACTCCCATTCCTCATCAAA

protein AG receptor (SEQ ID NO: 632) type IB M609 BMPR2 bone NM_001204 TGCTTTGGATACAGAATGTTGA

50 bp, e4-5, 44% GC morphogenetic GGAGACCGTAAACAAGGTCTTC

protein CAG receptor (SEQ ID NO: 633) type 2 M610 GDF1 growth NM_001492 TCTTCTTTGACAACAGCGACAA

49 bp, e2, 51% GC differentiation TGGTGCTGCGGCAGTATGAGGA

factor 1 AT (SEQ ID NO: 634) M611 GDF1 growth NM_004962 CATGTGAGTTCCCCATGCCTAA

48 bp, e3-4, 52% GC differentiation TCGTTCGTCCATCCAACCATGC

factor 10 (SEQ ID NO: 635) M612 GDF3 Growth NM_020634 GGAATGTACTTCGCTTTCTCCCA

50 bp, e1-2, 48% GC differentiation ACCAAGGTTTCTTTCTTTACCCA

factor 3 AG (SEQ ID NO: 636) M613 GDF7 Growth NM_000557 ACCAGCTTTATTGACAAAGGGC

50 bp, e1-2, 52% GC differentiation AGATGACCGAGGTCCCGTGGTC

factor 7 GGAA (SEQ ID NO: 637) M614 GDF8 Growth NM_005259 CAGGACCAGGAGAAGATGGGCT

50 bp, e2-3, 48% GC differentiation AATCCGTTTTTAGAGGTCAAGGT

factor 8 ACA (SEQ ID NO: 638) M615 GDF9 Growth NM_005260 AAGCAGGCTCCTGGAGACCAGG

48 bp, e1-2, 52% GC differentiation AACAGGAATCCTTCCATCAGTG

factor 9 A (SEQ ID NO: 639) M616 AQP1 aquaporin 1 NM_000385 TGTAGCCCTTGGACACCTCCTG

50 bp, e2-3, 52% GC TATTGACTACACTGGCTGTGGGA

TA (SEQ ID NO: 640) M617 AQP10 aquaporin 10 NM_080429 GGAGCCACCTATGTTCTCTACCA

50 bp, e3-4, 50% GC GATGCCCTACAGAACTATACAG

GG (SEQ ID NO: 641) M618 AQP2 aquaporin 2 NM_000486 TGTCGTCACTGGCAAATTTGAT

48 bp, e3-4, 52% GC CCACTGGGTCTTCTGGATCGGA

(SEQ ID NO:642) M619 AQP3 aquaporin 3 NM_004925 CTGGAATAGTTTTTGGGCTGTAT

50 bp, e3-4, 44% GC ATGATGCAATCTGGCACTTTGC

AC (SEQ ID NO: 643) M620 AQP4 aquaporin 4 NM_001650 CAGTTATCATGGGAAATTGGGA

50 bp, e4-5, 48% GC AACCAUGGATATATTGGGTTG

CCC (SEQ ID NO: 644) M621 AQP5 aquaporin 5 NM_001651 ACCCTGGGCCACCTTGTCGGAAT

47 bp, e4-5, 55% GC TACTTCACTGGCTGCTCCATGAA

(SEQ ID NO: 645) M622 AQP6 aquaporin 6 XM_113241 ATCCGAGAGACCCTTGGGATCA

48 bp, e1-2, 54% GC CGTGGTCCGGAACAGTGTCTCAA

T (SEQ ID NO: 646) M623 AQP7 aquaporin 7 NM_001170 AGTTCATGAGCACATATGTCAT

50 bp, e3-4, 50% GC TGGTATTCGGCCTTGGTTCCGTT

CC (SEQ ID NO: 647) M624 AQP8 aquaporin 8 NM_001169 GCCATCTGATCCTGATGTCTGGA

50 bp, e1-2, 48% GC AGATAGCCATGTGTGAGCCTGA

TT (SEQ ID NO: 648) M625 AQP9 aquaporin 9 NM_020980 CGTTCATCTTGATTGTCCTTGGA

50 bp, e1-2, 48% GC GTGGCTGTGTTGCCCAAGCTATT

TC (SEQ ID NO: 649) M626 SLC6A1 neurotransmitter NM_003042 TACCTGTACAACTCCTTCACCA

50 bp, e4-5, 52% GC transporter, ACACTGCCGTGGAAACAGTGCG

GABA CAA (SEQ ID NO: 650) M627 SLC6A11 neurotransmitter NM_014229 GGAGGAAAGTTTGCCCTTTATTT

50 bp, e2-3, 46% GC transporter, AAGGCATTGGCTATGCAACACA

GABA GTG (SEQ ID NO: 651) M628 SLC6A9 neurotransmitter TGGAGGATCAGCCCCATGTTCAA

50 bp, e3-4, 52% GC transporter 9 GGAGTGGGCTATGGTATGATGG

GGT (SEQ ID NO: 652) M629 SLC6A13 neurotransmitter NM_016615 TATCTCTGCTACAAAAATGGGG

50 bp, e1-2, 50% GC transporter, GGTGCCTTCTTCATCCCCTACCT

may detect also GABA GT SLC6A12 (SEQ ID NO: 653) M630 SLC6A14 neurotransmitter NM_007231 GTTTCTTCAAGTGCAGGGAGAA

50 bp, e1-2, 46% GC transporter GAGAAAGTGTCGGCTTCATCAG

GAAT (SEQ ID NO: 654) M631 SLC6A2 neurotransmitter NM_001043 TGGAAAATCTGCCCATTCTTCAA

50 bp, e2-3, 48% GC transporter, GGCGTTGGCTATGCTGTCATCCT

noradrenalin AT (SEQ ID NO: 655) M632 SLC6A3 neurotransmitter NM_001044 AACAAGTTCACCAACAACTGCTA

50 bp, e7-8, 50% GC transporter, AGGGACGCGATTGTCACCACCT

dotamine AT (SEQ ID NO: 656) M633 SLC6A4 neurotransmitter NM_001045 ACAACAAGTTCAACAACAACTG

50 bp, e6-7, 50% GC transporter, TACCAAGATGCCCTGGTGACCA

serotonin GTG (SEQ ID NO: 657) M634 SLC6A5 neurotransmitter NM_004211 AGACTTCAGGAAAAGTGGTGTA

50 bp, e7-8, 50% GC transporter, TTCACGGCCACGTTCCCGTATGT

glycine GTA (SEQ ID NO: 658) M635 SLC6A6 neurotransmitter NM_003043 ACAAGTACAAGTATAACTCGTA

50 bp, e3-4, 48% GC transporter, AGGGACTGTATGCTGCTGGGAT

taurine CTG (SEQ ID NO: 659) M636 SLC6A7 neurotransmitter NM_014228 CCACCACTTGTTGTCTTCCAAGG

50 bp, e6-7, 48% GC transporter, L- GTGGATTGAAGCTGCTCTTCAGA

proline CT (SEQ ID NO: 660) M637 SLC6A8 neurotransmitter NM_005629 CGCTTCAACAACAACTGCTACAA

50 bp, e6-7, 50% GC transporter, GACGCCATCATCCTGGCTCTCAT

creatine AA (SEQ ID NO: 661) M638 GABBR1 gamma- NM_001470 CAATACCCGCAGCATTTCCAACA

50 bp, e9-10, 46% GC aminobutyric a

GACATCCCAGGAATTTGTGGAG

B receptor, 1 AAC (SEQ ID NO: 662) M639 GABRA1 gamma- NM_000806 TTCTGAGCACACTGACTGGAAGA

50 bp, e2-3, 46% GC aminobutyric a

AGCTATGGACAGCCGTCATTACA

A receptor, GAT alpha 1 (SEQ ID NO: 663) M640 GABRA2 gamma- NM_000807 GATAATCGGCTTAGACCAGGAC

50 bp, e3-4, 46% GC aminobutyric a

GGGAGACAGTATTACTGAAGTC

A receptor, GAG alpha 2 (SEQ ID NO: 664) M641 GABRA3 gamma- NM_000808 CTGCGACCTGGGCTTGGAGATG

50 bp, e3-4, 52% GC aminobutyric a

GTGACTGAAGTGAAGACTGACA

A receptor, CTA alpha 3 (SEQ ID NO: 665) M642 GABRA4 gamma- NM_000809 AGGCTGCGTCCTGGATTTGGGG

50 bp, e2-3, 50% GC aminobutyric a

CCTGTTACAGAAGTGAAAACTG

A receptor, CAT alpha 4 (SEQ ID NO: 666) M643 GABRA5 gamma- NM_000810 ACTGAGAACATCAGCACCAGCA

50 bp, e1-2, 48% GC aminobutyric a

AGGCGAATACACAATCATGACA

A receptor, CTCA alpha 5 (SEQ ID NO: 667) M644 GABRA6 gamma- NM_000811 ATGGAACCATTTTATACACCAT

50 bp, e4-5, 46% GC aminobutyric a

GGCTTACCATCAATGGTGACTGT

A receptor, CC alpha 6 (SEQ ID NO: 668) M645 GABRB1 gamma- NM_000812 TGATGGAACAGTTCTCTATGGA

50 bp, e4-5, 46% GC aminobutyric a

CCGAATCACAACCACAGCTGCA

A receptor, GTA beta (SEQ ID NO: 669) M646 GABRB2 gamma- XM_011222 ACCAAGAAGGTTGTTTTTTCCA

50 bp, e1-2, 48% GC aminobutyric a

GGTTCCTATCCCAGGTTATCCCT

A receptor, AG beta (SEQ ID NO: 670) M647 GABRB3 gamma- XM_007751 GAACTGCACTCTGGAAATTGAA

50 bp, e4-5, 46% GC aminobutyric a

GCTATGGCTACACCACGGATGA

A receptor, ATTG beta (SEQ ID NO: 671) M648 GABRD gamma- NM_000815 AGCATCGACCACATCTCAGAGG

50 bp, e2-3, 52% GC aminobutyric a

CAACATGGAGTACACCATGACG

A receptor, TGTT delta (SEQ ID NO: 672) M649 GABRE gamma- NM_004961 GGATGGCAAGGTGTTGTACACA

50 bp, e4-5, 48% GC aminobutyric a

TTAGGATGACCATTGATGCCGGA

A receptor, GCT epsilon (SEQ ID NO: 673) M650 GABRG2 gamma- NM_000816 TGGTCGAGTGCTCTACTCCCTAA

50 bp, e4-5, 48% GC aminobutyric a

GTTGACAATTGATGCTGAGTGC

A receptor, AT gamma 2 (SEQ ID NO: 674) M651 GABRG3 gamma- NM_033223 AAAAGATGCTACGCCAGCAAGA

50 bp, e6-7, 50% GC aminobutyric a

CAGCATTAGGCATCACCACGGT

A receptor, TGA gamma 3 (SEQ ID NO: 675) M652 GABRP gamma- XM_003708 AATTTCTCAGGCCCAATTTTGGT

50 bp, e3-4, 48% GC aminobutyric a

GAGAACCCGTACAGATAGCGCT

A receptor, pi ACT (SEQ ID NO: 676) M653 GABRR1 gamma- NM_002042 ATGAAGATGCCCACAAGCAAGT

50 bp, e2-3, 50% GC aminobutyric a

AGCCCAATTCTGAGACGAAGTC

A receptor, rho GAC (SEQ ID NO: 677) M654 GABR2 gamma- NM_002043 CAGACCTGTTCTTTGGAGCTGGA

50 bp, e1-2, 48% GC aminobutyric a

AGCTATGCCTATACAGATGAAG

A receptor, rho CT (SEQ ID NO: 678) M655 CRH-R1 GGGCCCCATGATCCTGGTCCTG

50 bp, e10-11, 48% G

GATCAATTTCATCTTCCTTTTCAA

A (SEQ ID NO: 679) M656 CCATGATCCTGGTCCTGCTGAT

40 bp, e1-2, 42% GC ATTTCATCTTCCTTTT (SEQ ID NO: 680) M657 ATCCTGGTCCTGCTGATCAATTT

30 bp, e1-2, 42% GC ATCTTC (SEQ ID NO: 681) M658 Insulin AGCTGGAGAACTACTGCAACTA

40 bp ACGCAGCCCGCAGGCAG (SEQ ID NO: 682) M659 Insulin CACCACTTCTTCTGACATGTGGT

45 bp receptor CTTTGGCGTGGTCCTTTGGGA (SEQ ID NO: 683) M660 Insulin TGTCACAAGCACCAGCCTTGCCA

45 bp degradi

AACCTGAAGTGATTCAGAACA enzyme (SEQ ID NO: 684) M661 Proenkephalin GCCGACATCAACTTCCTGGCTT

45 bp GTAATGGAATGTGAAGGTAAA (SEQ ID NO: 685) M662 Pituitary GGATCAGGCCAGAGGAAGAGG

40 bp adenylate cycla

TACGGCGAGGACGGAAA activating (SEQ ID NO: 686) peptide M663 Pituitary GCAACCACTGCTTCATCTCCACT

45 bp Detects recepto

adenylate cycla

TGGAATGTAAGGCCGTCATGG A, B, B2, C activating (SEQ ID NO: 687) peptide recetor A M664 PC1 PC1 (NEC1 M90753 AGAAGATGGTGGATCCAGGGGA

45 bp GAGCAGCCCACACAAGAGAAC

(SEQ ID NO: 688) M665 PC2 proprotein NM_002594 AGGAAAAGGAACCCCGAGGCC

convertase TGTGGCAACCACAGATTTGTAC subtilisin/kexin (SEQ ID NO: 689) type 2 M666 polypeptide 7B Y00757 GAAGGGAGGAGAGAGACGAAA

CGGAGGAGTGTCAATCCATATC

(SEQ ID NO: 690) M667 COL14A collagen, type XM_044622 CAGTGTTTATACAAAGCTCCAG

50 bp, 42% GC XIV, alpha 1 GATTGAAGGACCTAGTGTGAGC

TAA (SEQ ID NO: 691) M668 COL1A1 collagen, type NM_000088 ATGCCATCAAAGTCTTCTGCAA

50 bp, 50% GC I alpha 1 TGGAGACTGGTGAGACCTGCGT

AC (SEQ ID NO: 692) M669 COL1A2 collagen, type NM_000089 TGAACTTGTTGCTGAGGGCAACA

50 bp, 46% GC I alpha 2 CAGGTTCACTTACACTGTTCTTG

AG (SEQ ID NO: 693) M670 COL3A1 collagen, type NM_000090 GTAGATATTGCACCCTATGACAT

50 bp, 42% GC; dete

I alpha 1 GGTGGTCCTGATCAAGAATTTG

also COL5A2 GT (SEQ ID NO: 694) M671 COL5A1 collagen, type

NM_000093 GGACATCATGTTCAATGACTTC

50 bp, 42% GC alpha 1 TGAAGCGTCACAGAAATTTGGA

TG (SEQ ID NO: 695) M672 COL7A1 collagen, type NM_000094 AGTATTCTGTGGAGGAGTACCA

50 bp, 50% GC VII, alpha 1 GACCCTGAAGCTCCTTGGGATA

GAT (SEQ ID NO: 696) M673 FN1 fibronectin 1 NM_002026 TGAGTGCTTCATGCCTTTAGATG

ACAGGCTGACAGAGAAGATTCC

GAG (SEQ ID NO: 697) M674 LAMA2 laminin, NM_000426 ATCAGATCCCTGAAGCTCACCAA

alpha 2 GGCACAGCAAGCCACTGGAGGT

(merosin) AAT (SEQ ID NO: 698) M675 LAMB2 laminin, NM_002292 GACCAGCATCTTGACTTGCTCAA

beta 2 CATTCAAACTTCCTGGGTGCCTA

GA (SEQ ID NO: 699) M676 LAMB3 laminin, NM_000228 GATTGGGTTGGAATGCTTTCCAT

beta 3 TCCAGGAGACTTTCATGCAGCCT

AA (SEQ ID NO: 700) M677 LAMC2 laminin, NM_018891 TTACAATCCAAGACACACTCAA

gamma CATTAGACGGCCTCCTGCATCT

TG (SEQ ID NO: 701) M678 LOX lysyl NM_002317 GACTATACCAACAATGTTGTGC

oxidase TGTGACATTCGCTACACAGGACA

CA (SEQ ID NO: 702) M679 MMP1 interstitial NM_002421 ATCTACAGCTCCTTTGGCTTCCC

collagenase AGAACTGTGAAGCATATCGATG

GC (SEQ ID NO: 703) M680 MMP10 stromelysin 2 NM_002425 TCAGTGGATCATCACAGTTTGA

TTGACCCCAATGCCAGGATGGT

CA (SEQ ID NO: 704) M681 MMP11 stromelysin 3 NM_005940 CCTCTACTGGAAGTTTGACCCT

GAAGGTGAAGGCTCTGGAAGG

T (SEQ ID NO: 705) M682 MMP3 stromelysin 1 NM_002422 AGGAAATCAATTCTGGGCCATC

GAGGAAATGAGGTACGAGCTG

TACC (SEQ ID NO: 706) M683 MMP9 gelatinase B NM_004994 AGTGAGTTGAACCAGGTGGACC

AGTGGGCTACGTGACCTATGAC

(SEQ ID NO: 707) M684 PLOD lysine NM_000302 AGAACGTGCCGACTATTGACAT

hydroxylase ACATGAACCAGATCGGCTTTGA

(SEQ ID NO: 708) M685 prolyl 4- X05130 AGGAGCCAGACATGGAGGAAGA

hydoxylase GATGACCAGAAAGCTGTGAAAG

beta subunit TGAA (SEQ ID NO: 709) M686 prolyl 4- U12762 GTCTTCACTGAGGCCAAGTCTA

hydroxylase ATTCTGCCCACCAAGAATGATG

alpha CT subunit (SEQ ID NO: 710) M687 TNXB tenascin XB NM_019105 ACTATGCCCATGGTTTTGGGAA

TCTCTGGAGAGTTCTGGCTGGG

AT (SEQ ID NO: 711) M688 VTN vitronectin NM_000638 CTTCTTCTTCTCTGGAGACAAGT

CTACCGAGTCAATCTTCGCACA

GC (SEQ ID NO: 712) M689 FLG filaggrin XM_048104 ATCATCCCATGAACAGGCAAGA

CAAGTGCAGGAGAGAGACATG

TCCC (SEQ ID NO: 713) M690 IVL involucrin NM_005547 AGAGCAGCAGGTAGGACAGCCA

AGCACCTGGAACAGCAGGAAA

CA (SEQ ID NO: 714) M691 KRT1 keratin 1 NM_006121 CAGTTCCAGCGTGAGGTTTGTTT

TACCACTTATTCCGGAGTAACCA

AT (SEQ ID NO: 715) M692 KRT10 keratin 10 NM_000421 CTGAAACCGAGTGCCAGAATAC

GAATACCAACAACTCACGGATA

AAG (SEQ ID NO: 716) M693 KRT14 keratin 14 NM_000526 TGACCAGTATGAGAAGATGGCA

AGAAGAACCGCAAGGATGCCGA

GAAT (SEQ ID NO: 717) M694 KRT17 keratin 17 NM_000422 GAGATGCGTGACCAGTATGAGA

GATGGCAGAGAAGAACCGCAA

ATG (SEQ ID NO: 718) M695 KRT19 keratin 19 NM_002276 TGCTCGAGGGACAGGAAGATCA

TACAACAATTTGTCTGCCTCCAA

GTC (SEQ ID NO: 719) M696 KRT5 keratin 5 NM_000424 GAAGAGCTTCAAGAGCTAAGAA

CTGCTGCAAGTCACTGCCTTCCA

GTG (SEQ ID NO: 720) M697 KRTHA5 keratin, NM_002280 TGGAGATTGAGCTGCAGGCTCA

hair, CACAGCATGAGAGATGCTTTGG

acidic, 5 AT (SEQ ID NO: 721) M698 KRTHB5 keratin, NM_002283 ATCACTGCACTGAATGGCATGT

hair, ATGGAAAATGTGTGCTTGCTTC

basic, 5 GA (SEQ ID NO: 722) M699 LOR loricrin NM_000427 TGCAAATCCTTCATGTCTTAAC

ACCTGGAAGAAGCCATTGAGCT

CC (SEQ ID NO: 723) M700 TGMI transgluta- NM_000359 ACAGTGAAACTGCACCTCTACCT

minase 1 TCAGTCACTTTCTATACTGGTGT

AG (SEQ ID NO: 724) M701 TGM2 transgluta- NM_004613 TCCTCTTTGCATCCTCTATGAGA

minase 2 ATACCGTGACTGCCTTACGGAGT

CA (SEQ ID NO: 725) M702 TGM3 transgluta- NM_003245 AAGAGGCAGAACATCCCATAAA

minase 3 ATCTCGTACGCTCAGTATGAGA

TAG (SEQ ID NO: 726) M703 THH trichohyalin NM_007113 CTTAAGTGATGTTGCCAATATCT

GACACCTGCCAAAGCTTCCAGCA

GG (SEQ ID NO: 727) M704 TRHY trichohyalin L09190 CAATACCGCCCTTAAGTGATGTT

CCAATATCTTGACACCTGCCAAA

CT (SEQ ID NO: 728) M705 agouti U12770 TATATAGGCTGCTCGAAGGTGT

GGCTGTTTCTGTAAAGGTCCCGA

AG (SEQ ID NO: 729) M706 AGRP agouti NM_001138 TTCTTCAATGCCTTCTGCTACTG

related GCAAGCTGGGTACTGCCATGAA

protein (SEQ ID NO: 730) M707 CCS copper NM_005125 CAGAATGGAGGATGAGCAGCTG

chapero

AGGTGTGGGATGTGATTGG for super- (SEQ ID NO: 731) oxide dismutase M708 GCH1 GTP NM_000161 GCTACCAGGAGACCATCTCAGA

cyclo- GTCCTAAACGATGCTATATTTGA

hydrolase GAA (SEQ ID NO: 732) M709 GGT1 gamma- NM_005265 ACAACCAGCTTCTGCCCAACGT

glutamyl- CGACAGTGGAGAGAAACATTGA

transferase 1 CA (SEQ ID NO: 733) M710 GSR glutathione NM_000637 CAGTGAAGATGGGAGCAACGAA

reductase GCAGACTTTGACAACACAGTCG

ATT (SEQ ID NO: 734) M711 LAMP1 lysosomal- NM_005561 CAAGGAATCCAGTTGAATACAA

associated CTTCCTGACGCCAGAGACCCTG

membrane TT protein 1 (SEQ ID NO: 735) M712 Pmel17 S73003 GCAGGTCTGAGTACTCTCATAT

TGCTGTGATTTTCCTGGAGTTGA

AG (SEQ ID NO: 736) M713 TXNRD1 thioredoxin NM_003330 TCAGAGGCTCTATGCAGGTTCCA

reductase 1 TGTCAAGTGTGACTATGAAAAT

TC (SEQ ID NO: 737) M714 TXNRD2 thioredoxin NM_006440 GCGAAGTTACTCAAGGATTTGCT

reductase 2 TGGGGATCAAGTGTGGGGCTTC

AT (SEQ ID NO: 738) M715 BMAL1a D89722 CAACGACCAAGGATCAAGTAGT

CCAGTAATGATGAGGCAGCAAT

GCTG (SEQ ID NO: 739) M716 CLOCK clock NM_+ AF8- ACAACAGCAACAGTCACAGACA

homolog 004898 TGTCAGTAACGCAGCAGCAGCA

CAG (SEQ ID NO: 740) M717 CRY1 cryptochrome NM_004075 CTATCAGCAGCTTTCACGATATA

1 AGGACTAGGTCTTCTGGCATCA

AC (SEQ ID NO: 741) M718 CRY2 cryptochrome XM_051030 TATGGCGAGAGTTCTTCTACAC

2 CAGCTACCAACAACCCCAGGTTT

A (SEQ ID NO: 742) M719 CYP39A1 cytochrome P4

NM_016593 TGAATATAAACAAAGAATATGA

subfamily ATCTGTTGGGCCTCACAAGGAC

XXXIX GGG (oxysterol 7 (SEQ ID NO: 743) alpha- hydroxylase), polypeptide 1 M720 CYP7A1 cholesterol NM_000780 ATCCGGACAGCTAAGGAGGATT

7alpha- CACTTTGCACCTTGAGGACGGTT

monooxygenase CTA (SEQ ID NO: 744) M721 CYP7B1 oxysterol 7 NM_004820 CCTACATGGTGACCCTGAAATCT

alpha TGAAGCTCCAGAGGAGTTTAGA

hydroxylase ATG (SEQ ID NO: 745) M722 DHCR7 7-dehydro- NM_001360 TGCAGGCCATCTACGTGATTGA

cholesterol TCTTCTGGAACGAAACCTGGTA

reductase TG (SEQ ID NO: 746) M723 PAH phenylalanine NM_000277 GCCTCTCTGGGTGCACCTGATGA

hydroxylase TACATTGAAAAGCTCGCCACAA

TA (SEQ ID NO: 747) M724 PER1 period NM_002616 CAGTCCAGCCTTACCTACAGCA

homolog AAACTGCACCAGCTAGACTCCA

CT (SEQ ID NO: 748) M725 PER2 period NM_022817 CCTTCTCTGGGACTCAGCGAAGT

homolog TCGGACACCAAAGAAGACGAAA

TGG (SEQ ID NO: 749) M726 PER3 period NM_+ AF8- CTCATGGGCAAAAGGAGGAGCT

homolog 016831 GCTAAGGTGTATAATTGGATTCA

AGC (SEQ ID NO: 750) M727 TH tyrosine NM_000360 CTACCAAGACCAGACGTACCAG

hydroxylase CAGTCTACTTCGTGTCTGAGAG

TCA (SEQ ID NO: 751) M728 GSTA1 glutathione NM_145740 ACCAGAGCCATTCTCAACTACAT

S-transferase GCCAGCAAATACAACCTCTATG

A1 GAA (SEQ ID NO: 752) M729 GSTA2 glutathione NM_000846 TGAAAACCAGAATCAGTAACCT

S-transferase CCCACAGTGAAGAAGTTTCTACA

A2 CCT (SEQ ID NO: 753) M730 GSTA3 glutathione NM_000847 CATTGCCAGCAAATACAACCTCT

S-transferase CGGGAAAGACATAAAGGAGAGA

A3 CCC (SEQ ID NO: 754) M731 GSTA4 glutathione NM_001512 CAGACCCGAAGCATTCTCCACTA

S-transferase ATAGCAGACAAGCACAATCTCT

A4 GG (SEQ ID NO: 755) M732 GSTM1 glutathione NM_000561 AGTACTTGGAGGAACTCCCTGAA

S-transferase AAGCTAAAGCTCTACTCAGAGTT

M1 CTG (SEQ ID NO: 756) M733 GSTM3 glutathione NM_000849 AGCTCTGACCACGAAAAACTGA

S-transferase GCCTCAGTACTTGGAAGAGCTA

M3 (brain) TGG (SEQ ID NO: 757) M734 GSTM4 glutathione NM_000850 GCCAGAATACTTGGAGGAACTT

S-transferase TACAATGATGCAGCACTTCTCA

M4 GT (SEQ ID NO: 758) M735 GSTM5 glutathione NM_000851 TTTCCTTGCCTATGATGTCCTTGA

S-transferase ATGAAGCGTATATTITGAGCCCAA

M5 T (SEQ ID NO: 759) M736 GSTP1 glutathione NM_000852 GCTGCTGATCCATGAGGTCCTA

S-transferase CCCTGGCTGCCTGGATGCGTT pi (SEQ ID NO: 760) M737 GSTT1 glutathione NM_000853 AAACCTCACCCTTGCACCGTCCT

S-transferase AGCAGTCCACAAAGCATTTTCAT

theta TC (SEQ ID NO: 761) M738 GSTZ1 glutathione NM_145870 CATATACTGTGTAGGAGACGAG

transferase TGACCATGGCTGATCTGTGCTT

zeta T (SEQ ID NO: 762) M739 MGST1 microsomal NM_145792 GGAGTTACTCTTTCCATGGCTTA

glutathione AGGTTGCTGAAAAGTAAATTGTA

S-transferase CT 1 (SEQ ID NO: 763) M740 MGST2 microsomal NM_002413 CCAAGAAACTGAGGCGGCAATT

glutathione TAACTTTTTCTCTTCCCTTTAAT

S-transferase TT 2 (SEQ ID NO: 764) M741 MGST3 microsomal NM_004528 AAGTACAAAGTGGAGTATCCTA

glutathione ATGTACAGCACGGACCCTGAAA

S-transferase TGG 3 (SEQ ID NO: 765) M742 AKR1A1 Ido-keto NM_153326 ATCTGCATCCCCAAAAGTATCA

reducta CCTTCTCGAATCCTTCAGAACAT

family 1, AA member A1 (SEQ ID NO: 766) M743 ALDH1A aldehyde NM_000689 TGGTGGATTCAAGATGTCTGGAA

dehydrogenase TGGAAGAGAACTGGGAGAGTA

family, GTT member A1 (SEQ ID NO: 767) M744 ALDH1A aldehyde NM_170697 AAGCTGGGACTGTTTGGATCAAT

dehydrogenase GTTACAATGCCTTAAATGCCCA

family, GC member A2 (SEQ ID NO: 768) M745 ALDH1A aldehyde NM_000693 CAACATGCGGATTGCCAAAGAG

dehydrogenase AGATTTTCGGGCCAGTGCAACCA

family, TAC member A3 (SEQ ID NO: 769) M746 ALDH1B aldehyde NM_000692 AGAGGTAAAGACGGTCACCATC

dehydrogenase AGGTTCCTCAGAAGAACTCGTAA

family, GAGC member B1 (SEQ ID NO: 770) M747 ALDH2 aldehyde NM_000690 GTCAAAGTGCCTCAGAAGAACT

dehydrogenase ATAAGAATCATGCAAGCTTCCT

family CTC (SEQ ID NO: 771) M748 ALDH3A aldehyde NM_000691 CCTCTACATGTTCTCCAGCAAC

dehydrogenase CAAGGTGATTAAGAAGATGATT

family, CAG member A1 (SEQ ID NO: 772) M749 ALDH3A aldehyde NM_000382 GAATGATCCTGTTCAACCTCCTA

dehydrogenase TGCCTCTACTGAATTATTCCTCT

family, T member A2 (SEQ ID NO. 773) M750 ALDH4A aldehyde NM_003748 ATGCTGCCGGCAACTTCTACAT

dehydrogenase ACGACAAGTCCACTGGCTCGATA

family, GTG member A1 (SEQ ID NO: 774) M751 ALDH5A aldehyde NM_170740 ATGCTGTGCACTCATGAAGAGA

dehydrogenase TTCGGGCCTCTGGCACCAGTTAT

family, AA member A1 (SEQ ID NO: 775) M752 ALDH6A aldehyde NM_005589 AGGGCATCCAATFCTACACTCA

dehydrogenase TAAAGACCATTACTTCTCAGTG

family, AA member A1 (SEQ ID NO: 776) M753 ALDH7A aldehyde NM_001182 CTTGGACCTAAAGGATCAGACT

dehydrogenase GGCATTGTAAATGTCAACATTC

family, AC member A1 (SEQ ID NO: 777) M754 ALDH8A aldehyde NM_022568 CTGGAATAGGTAGAGAGGGAG

dehydrogenase AAGGACTCTTACGACTTCTTCA

family, GAG member A1 (SEQ ID NO: 778) M755 ALDH9A aldehyde NM_000696 TAGCTGAGCTTCAGGCTGGGAC

dehydrogenase GCTTCATTAACAACTATAACGT

family, GC member A1 (SEQ ID NO: 779) M756 GPX1 glutathione NM_000581 TACGAGGGAGGAACACCTTGAT

peroxidase 1 TTACAGAAAATACCACCTCGAG

GGG (SEQ ID NO: 780) M757 GPX2 glutathione NM_002083 AATGAGGAGATCCTGAACAGTC

peroxidase 2 CAAGTATGTCCGTCCTGGGGGT

ATA (SEQ ID NO: 781) M758 GPX3 glutathione NM_002084 CAACCAATTTGGAAAACAGGAA

peroxidase 3 CAGGAGAGAACTCAGAGATCCT

CCTA (SEQ ID NO: 782) M759 GPX4 glutathione NM_002085 TGTAACCAGTTCGGGAAGCAGG

peroxidase 4 GCCAGGGAGTAACGAAGAGAT

AAGA (SEQ ID NO: 783) M760 GPX5 glutathione NM_001509 CTGAACTAAATGCACTCCAGGA

peroxidase 5 GAGCTGAAGCCCTATGGTCTAGT

GTG (SEQ ID NO: 784) M761 GPX6 glutathione NM_015696 ACCTACAGTGTCTCATTCCCCAT

peroxidase 6 TTTAGCAAGATTGCAGTCACCG

AC (SEQ ID NO: 785)

EXAMPLE 10

Analysis of Gene Expression

The molecular chip showed distinctive skin patterns of transcriptional expression of functional neuro-endocrine-immune and barrier forming pathways after ultraviolet light exposure. The full list of differentially expressed genes is presented in Table 2, classified into several major functionally-related groups: water and salt balance; prostaglandin metabolism; interleukins and growth factors; metalloproteinases; markers of keratinocyte differentiation and stress response. Genes from the same group that were similarly expressed presumably reflected a highly coordinated keratinocyte response to UV, which indicated genetic regulation. Each gene had a unique time response that was classified as early, when the maximum induction of expression had occurred by 4 h after treatment. A late response group was defined by expression maximum occurring at 24 h after irradiation.

EXAMPLE 11

Genes Involved in Water and Salt Balance

Up-regulation of gastrin, vasopressin and aquaporin genes was detected. All these genes are involved in the regulation of water and salt balance (Table 2, FIG. 2). The highest stimulation was observed at 12 to 24 h post-irradiation. Vasopressin is highly relevant to water metabolism by being involved in water resorption in the kidneys. Other genes related to water balance are those coding for aquaporin water channels (AQP). Aquaporins are a family of membrane proteins that facilitate water movement across biological membranes; they are important for osmotic water movement across cell membranes of epithelial and endothelial barriers. Aquaporins are also expressed in the skin. AQP3 knockout mice are remarkably polyuric and have dry skin (Verkman, 2002). The microarray data was verified by real-time quantitative RT-PCR, which showed 2-fold increases of aquaporin 3 mRNA (FIG. 2A, p<0.05).

The gastrin gene is related to salt balance since gastrin receptors are expressed in the kidneys on tubules and collecting ducts, where they mediate renal potassium and sodium absorption (von Schrenck et al., 2000). Gastrin has potent growth stimulatory effects on gastrointestinal tissues and human kidney cells (Stepan et al., 1999). Gastrin-releasing peptide may also accelerate wound healing in burns, injuries, chronic ulcers, and skin graft donor sites through enhancement of keratinocyte growth and spreading (Yamaguchi et al., 2002). Since the gastrin message was not previously detected in skin, this gene was amplified herein from several skin cell lines including human keratinocytes, melanocytes, fibroblasts and different melanomas (FIG. 2B). The band of correct length was detected only in normal and immortalized keratinocytes (FIG. 2B); after sequencing, the gene was showed perfectly matched with gastrin. Thus, gastrin is expressed in human keratinocytes and its expression is stimulated by UVR (Table 2). TABLE 2 Genes differentially expressed in ultraviolet irradiated human epidermal keratinocytes UP-REGULATED GENES DOWN-REGULATED GENES mean ± SD mean ± SD gene 4 h 12 h 24 h gene 4 h 12 h 24 h Water and salt balance Gastrin 1.17 ± 0.35 2.06 ± 0.32 1.46 ± 0.17 Vasopressin precursor 1.04 ± 0.49 1.56 ± 0.01 1.54 ± 0.01 Aquaporin 1 1.53 ± 0.24 1.87 ± 0.37 4.11 ± 0.42 Aquaporin 3 1.11 ± 0.10 1.49 ± 0.09 2.37 ± 0.19 Aquaporin 9 1.04 ± 0.28 1.87 ± 0.42 2.05 ± 0.07 Prostaglandin metabolism CYP4F8 (cytochrome P450, 1.57 ± 0.02 2.41 ± 0.32 3.15 ± 0.72 subfamily IVF, polypeptide 8) Prostaglandin-endoperoxide 1.87 ± 0.25 3.61 ± 0.40 1.20 ± 0.16 synlhase 2 (COX-2) Interleukins and growth factors Interferon-beta-2 0.94 ± 0.33 1.61 ± 0.12 0.98 ± 0.04 Epidermal growth 1.31 ± 0.71 0.50 ± 0.10 1.00 ± 0.3 (interleukin 6) factor receptor Interleukin 1, beta 2.14 ± 0.07 2.22 ± 0.48 0.98 ± 0.10 Keratinocyte 1.07 ± 0.10 0.49 ± 0.10 0.74 ± 0.1 growth factor Interleukin 2 1.16 ± 0.25 1.13 ± 0.07 2.02 ± 0.10 Keratinocyte 0.78 ± 0.09 0.46 ± 0.04 0.59 ± 0.0 growth factor Interleukin 8 2.44 ± 0.28 1.95 ± 0.12 1.70 ± 0.20 Activin A recept 0.58 ± 0.04 0.49 ± 0.07 0.99 ± 0.0 type I 1.76 ± 0.08 2.10 ± 0.10 1.28 ± 0.22 TNFSF10 (TRAI 0.51 ± 0.03 0.65 ± 0.03 0.73 ± 0.0 TNFSF9 Bone morphogenetic 1.16 ± 0.06 1.67 ± 0.03 1.10 ± 0.06 protein 3 Insulin-like growth 1.78 ± 0.24 0.98 ± 0.16 1.78 ± 0.42 factor binding protein 6 Endothelin 1 2.30 ± 2.70 2.78 ± 4.10 2.10 ± 2.20 Vascular endothelial growth factor 1.10 ± 0.09 2.09 ± 0.08 1.85 ± 0.49 Metalloproteinases Stromelysin 1^(a) n/d 2.02 ± 0.03 n/d Stromelysin 2^(a) n/d 2.78 ± 0.93 n/d Markers of keratinocyte differentiation Filaggrin 1.04 ± 0.21 1.57 ± 0.12 1.14 ± 0.04 Fibronectin 1 0.96 ± 0.04 0.62 ± 0.07 0.41 ± 0.0 Involucrin 1.05 ± 0.04 1.57 ± 0.08 1.46 ± 0.03 Keratin 1 1.26 ± 0.18 1.80 ± 0.17 1.57 ± 0.04 Keratin 10 1.18 ± 0.06 2.09 ± 0.43 0.98 ± 0.04 Keratin 19 0.92 ± 0.38 0.85 ± 0.23 3.17 ± 0.31 Transglutaminase 1 1.05 ± 0.15 1.18 ± 0.22 2.01 ± 0.23 Loricrin 1.29 ± 0.21 1.54 ± 0.24 0.51 ± 0.07 Stress-related genes CRF-R2 gamma 1.10 ± 0.08 1.99 ± 0.45 1.60 ± 0.07 Urotensin 2 1.10 ± 0.08 0.81 ± 0.13 0.62 ± 0.0 Aldo-keto reductase family 1, 1.10 ± 0.08 1.25 ± 0.12 1.56 ± 0.05 member C2 ^(a)effect was seen only when keratinocytes were co-cultivated with melanocytes; n/d—not done; data represents mean +/− SD (N = 4); underlined ratios (UV versus control) are significantly different from 1 (no difference), P < 0.05.

EXAMPLE 12

Prostaglandin Synthesis

Up-regulation of several genes involved in prostaglandin metabolism including prostaglandin-endoperoxide synthase 2 (Cyclooxygenase 2 or COX-2 gene) (Table 2, FIG. 2); and, of cytochrome P450, subfamily IVF, polypeptide 8 (CYP4F8) (Table 2) were detected. This was consistent with the increase in prostaglandin E2 in UVR-induced inflammation in the skin (Gresham et al., 1996). Real-time PCR also showed a 6-fold increase of COX-2 message (FIG. 2), which was in fact the highest up-regulation ever detected by quantitative PCR. Stimulation of COX-2 expression by UVR had been previously reported (Brecher, 2002) and when taken together with findings presented here, indicated de novo synthesis of prostaglandins. Therefore, the increases in prostaglandin levels in inflammation would be due to increased prostaglandin production coupled with enhanced arachidonate deacylation from the membrane (Gresham et al., 1996).

Another prostaglandin-related gene CYP4F8 was also up-regulated in UV-irradiated keratinocytes (Table 2). That gene, expressed both in human seminal vesicles and skin, catalyzes the 19-hydroxylation of prostaglandins H(1) and H(2) (Stark et al., 2003). CYP4F8 immunoreactivity and mRNA are prominently induced in psoriasis suggesting a pathophysiological role in skin (Stark et al., 2003).

Prostaglandins function has been investigated on melanocytes and keratinocytes. Prostaglandins can induce melanin synthesis in cutaneous melanocytes. Uveal melanocytes also demonstrate increased tyrosinase activity upon exposure to prostaglandin E1 (Fuller and Meyskens, 1981). Prostaglandin E2 receptor agonist has stimulating effects on growth, melanogenesis and dendrification of iridal melanocytes (Hu et al., 2001). In keratinocytes prostaglandins increase vascular endothelial growth factor (VEGF) expression (Trompezinski et al., 2001), the latter a well-recognized effect of UV radiation (Mildner et al., 1999).

EXAMPLE 13

Interleukins and Growth Factors

Ultraviolet B radiation generates cutaneous inflammation in part, by inducing oxidative stress and cytokine production in human keratinocytes. Expression of the cytokines interleukin (IL)-1, IL-6, IL-10, endothelin 1, VEGFB has already been reported to increase in epidermal keratinocytes upon UV radiation (Kirnbauer et al., 1991; Grewe et al., 1995; Kang et al., 1998; Petit-Frere et al., 1998; Mildner et al., 1999; Brink et al., 2000). An increase of message corresponding to these genes (Table 2) was detected. Additionally, the microarray showed stimulation of IL-2, IL-8, tumor necrosis factor superfamily member 9 (TNFSF9), bone morphogenetic protein 3 (BMP3) and insulin-like growth factor binding protein 6 (IGFBP6) (Table 2).

Decreased expression was noted for the following genes in UV-treated keratinocytes (Table 2): epidermal growth factor receptor (EGFR or erbB), keratinocyte growth factor (KGF or fibroblast growth factor 7), keratinocyte growth factor receptor (KGFR or fibroblast growth factor receptor 2), Activin A receptor type I and tumor necrosis factor superfamily member 10 (TNFSF10 or TRAIL).

The majority of the gene expression changes that were detected herein had been already reported in UV-irradiated skin cells. Therefore, real-time RT-PCR was used only to verify the novel TNFSF9, KGFR and KGF changes in gene expression. TNFSF9 increased 3-fold (FIG. 2A, p<0.05); KGFR gene expression was significantly inhibited in UV-irradiated keratinocytes and to even more significant degree in co-cultures of keratinocytes and melanocytes (FIG. 2A, p<0.05). KGF was also down-regulated (data not shown), but since original expression of this gene was low, it was technically difficult to amplify the amount of message to allow analysis of the data in a statistically meaningful manner.

The functional significance of the differential gene expression could be explained as follows. IL-8 is a neutrophil chemoattractant cytokine with proinflammatory and growth-promoting activities, and is involved in the pathogenesis of several inflammatory diseases. IL-8 is produced in response to ultraviolet B radiation (Countryman et al., 2000). Tumor necrosis factor superfamily member 9 (TNFSF9 or 4-1BBL) is also an important proinflammatory mediator binding CD137 receptors on activated CD4 and CD8 T cells. TNSF9 provides a costimulatory signal that induces a high level of IL-2 production by primary resting T cells (DeBenedette et al., 1999).

Within this context, it would be anticipated that IL-2 expression would increase after UVR, as was indeed found (Table 2). Investigation of infiltrating inflammatory cells and cytokine levels in UV-irradiated skin has shown that interferon-gamma and IL-2, together with the proinflammatory cytokine IL-8, become detectable at 6 h (Terui et al., 2001). In the present invention,-IL-2 was detected 24 h after radiation and most interestingly only after up-regulation of TNFSF9 (4, 12 h; Table 2). This might reflect autocrine stimulation of IL-2 by TNFSF9. The significance of this response is underlined by the effectiveness of interferons and IL-2 in the treatment of skin cancers that include metastatic melanomas (Garbe, 1995).

Stimulation of bone morphogenic protein 3 (BMP-3) and insulin-like growth factor binding protein 6 (IGFBP-6) was detected. Both these proteins inhibit proliferation and differentiation. Treatment of human bone marrow osteoprogenitors with BMP-3 causes dose- and time-dependent inhibition of DNA synthesis and cell proliferation. Simultaneously, BMP3 stimulates type I collagen synthesis (Amedee et al., 1994). IGFBP-6 is a negative effector of oligodendrocyte survival and differentiation (Kuhl et al., 2003), and is secreted by an immortalized human keratinocyte cell line (HaCaT) (Marinaro et al., 1999). Purified IGFBP-6 inhibits the growth of HaCaT and Balb/MK keratinocyte cell lines, as well as Mv1Lu cells (Kato et al., 1995).

EGFR overexpression is important for the expression of malignant behavior, since activation of the receptor stimulates tyrosine kinase activity, which initiates signal transduction cascade (including other kinases) leading to cell proliferation and protection from apoptosis (Lage et al., 2003). Conversely, anti-EGFR agents posses antitumor activity (Lage et al., 2003). Within this context, the known effect of EGF stimulating extracellular receptor-activated kinases (ERK) is prevented by UVR, in a dose-dependent manner. Therefore, the data presented herein on UVR-induced transient (12 hours) inhibition of EGFR expression, suggested that this effect on EGFR was the most likely explanation of the described ERK response inhibition.

Down-regulation of the tumor necrosis factor superfamily member 10 (TNFSF10 or TRAIL), which is a TNF-related apoptosis-inducing ligand was observed. Both up- and down-regulation of TRAIL and its receptors had been reported after exposure to UVB. Since TRAIL and TRAIL receptors function as important sensors in the human epidermis preserving skin integrity and preventing cell transformation, down-regulation of these molecules with sensor function increases the risk for less efficient elimination of aberrant cells. Supporting this concept is the low amount or absence of these molecules in precancerous states developing after long-term ultraviolet exposure (Bachmann et al., 2001).

Keratinocyte growth factor (KGF or fibroblast growth factor 7) is a potent mitogen for human keratinocytes, stimulating proliferation and migration of these cells and also affecting their differentiation process (Werner, 1998). Deletion of the KGF receptor (KGFR) gene results in severe functional defects of the anterior pituitary and also, in developmental abnormalities of the skin (De Moerlooze et al., 2000). IL-6, interferon-gamma, and ultraviolet B (UVB) treatment lead to substantial down-regulation of KGFR expression (Zhou et al., 1996). Down regulation of both KGF and KGFR (Table 2) was detected, confirmed by real-time PCR (FIG. 2A). The UV-induced down-regulation of KGF and KGFR synthesis might therefore represent an antiproliferative mechanism addressed at preventing cells from entering malignant transformation.

EXAMPLE 14

Genes Involved in Extracellular Matrix Rearrangement

Involvement of matrix metalloproteinases (MMPs), the enzymes responsible for extracellular matrix rearrangement, UVR-induced skin aging and promotion of skin cancer (Brenneisen et al., 2002), was also observed. This was represented by a significant stimulation of stromelysins 1 and 2 expression, but only when keratinocytes were co-cultivated with melanocytes (Table 2). Real-time quantitative RT-PCR did confirm this observation (FIG. 2A, p<0.05), suggesting that either keratinocytes express UV-induced metalloproteinases only when they are in contact with melanocytes or, that the matrix metalloproteinases are produced by melanocytes.

EXAMPLE 15

Stress Response Genes

CRH may be the primary mediator of autonomic, behavioral and neuroendocrine responses to stress. While CRH receptors type 1 were previously detected exclusively in human skin cells (Slominski et al., 2004), the CRH receptor type 2 gamma isoform, whose expression is increased in UVR-treated human keratinocytes were included in the present invention.

Aldo-keto reductase, another stress-response related gene, was observed to be up-regulated. Interestingly, the fungi S. cerevisiae that have aldo-keto reductases deleted show enhanced sensitivity to stress (Chang et al., 2003).

The following references were cited herein:

-   Amedee, J., et al: Differentiation 58 (1994) 157-64. -   Bachrnann, F., et al: J Invest Dermatol 117 (2001) 59-66. -   Bilban, M., et al: Curr Issues Mol Biol 4 (2002) 57-64. -   Brecher, A. R.: J Drugs Dermatol 1 (2002) 44-7. -   Brenneisen, P., et al: Ann N Y Acad Sci 973 (2002) 31-43. -   Brink, N., et al: Inflamm Res 49 (2000) 290-6. -   Chang, Q., et al: Chem Biol Interact 143-144 (2003) 325-32. -   Countryman, N. B., et al: J Invest Dermatol 115 (2000) 267-72. -   DeBenedette, M. A., et al: J Immunol 163 (1999) 4833-41. -   De Moerlooze, L., et al: Development 127 (2000) 483-92. -   Fuller, B. B. and Meyskens, F. L., Jr.: J Natl Cancer Inst 66 (1981)     799-802. -   Garbe, C.: Recent Results Cancer Res 139 (1995) 349-69. -   Gresham, A., et al: Am J Physiol 270 (1996) C1037-50. -   Grewe, M., et al: J Invest Dermatol 104 (1995) 3-6. -   Hu, D. N., et al: Exp Eye Res 73 (2001) 93-100. -   Ichihashi, M., et al: Toxicology 189 (2003) 21-39. -   Kang, K., et al: J Invest Dermatol 111 (1998) 31-8. -   Kato, M., et al: J Biol Chem 270 (1995) 12373-9. -   Kirnbauer, R, et al: J Invest Dermatol 96 (1991) 484-9. -   Kuhl, N. M., et al: Glia 44 (2003) 91-101. -   Lage, A., et al: Ann Med 35 (2003) 327-36. -   Maeda, T., et al: J Cutan Med Surg 5 (2001) 294-8. -   Marinaro, J. A., et al: Am J Physiol 276 (1999) E536-42. -   Maziere, C., et al: Free Radic Biol Med 34 (2003) 629-36. -   Mildner, M., et al: Photochem Photobiol 70 (1999) 674-9. -   Petit-Frere, C., et al: J Invest Dermatol 111 (1998) 354-9. -   Pisarchik, A. and Slominski, A. T.: Faseb J 15 (2001) 2754-6. -   Slominski, A. and Pawelek, J.: Clin Dermatol 16 (1998) 503-15. -   Slominski, A., et al: Endocrinology 145 (2004) 941-50. -   Slominski, A. and Wortsman, J.: Endocr Rev 21 (2000) 457-87. -   Stark, K., et al: Arch Biochem Biophys 409 (2003) 188-96. -   Stepan, V. M., et al: Am J Physiol 277 (1999) R572-81. -   Terui, T., et al: Acta Derm Venereol 81 (2001) 8-13. -   Trompezinski, S., et al: Inflamm Res 50 (2001) 422-7. -   Verkmnan, A. S.: Ann Med 34 (2002) 192-200. -   von Schrenck, T., et al: Kidney Int 58 (2000) 995-1003. -   Werner, S.: Cytokine Growth Factor Rev 9 (1998) 153-65. -   Yamaguchi, Y., et al: Dermatol Surg 28 (2002) 314-9. -   Zhou, Y., et al: Exp Dermatol 5 (1996) 138-44.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. Further, these patents and publications are incorporated by reference herein to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. 

1. A DNA microarray chip for measuring transcriptional responses to stress in a cell, said chip comprising oligonucleotides for genes related to production and metabolism of hormones, neurotransmitters, neuropeptides, cytokines, biological modulators, growth factors, corresponding receptors and normal skin metabolism genes.
 2. The DNA microarray chip of claim 1, wherein said chip comprising about 761 oligonucleotide sequences.
 3. The DNA microarray chip of claim 1, wherein said oligonucleotides for genes have SEQ ID Nos. shown in SEQ ID No. 25-785.
 4. A method of detecting transcriptional responses to stress in a cell, comprising the steps of: challenging said cell with stress; isolating nucleic acid samples from said cell; measuring gene expression levels; and analyzing said gene expression levels statistically as compared to those without stress, wherein a statistically significant upregulation of said gene expression indicates transcriptional responses to stress.
 5. The method of claim 4, wherein said gene expression is measured by DNA microarray.
 6. The method of claim 5, wherein said gene expression is further verified by RT-PCR.
 7. The method of claim 4, wherein said stress comprises ultraviolet radiation, thermal stress, chemical stress, and immune stress.
 8. The method of claim 4, wherein said cell comprises epidermal keratinocyte, melanocyte, fibroblast, and immune cell.
 9. The method of claim 4, wherein said statistical analysis is one-way analysis of variance or post-hoc test or student t test.
 10. The method of claim 4, wherein said statistically significant upregulation is at least a 1.5-fold increase of expression of said genes.
 11. The method of claim 4, wherein said genes comprises genes involved in water and salt balance, genes involved in prostaglandin metabolism, interleukin genes, growth factor genes, markers of keratinocyte differentiation genes, metalloproteinases genes, and stress response genes.
 12. The method of claim 4, wherein said upregulated genes are selected from the group of genes encoding for gastrin, vasopressin, aquaporin, prostaglandin-endoperoxide synthase 2, CYP4F8, IL-1, IL-2, IL-6, IL-8, tumor necrosis factor superfamily member 9, bone morphogenetic protein 3, insulin-like growth factor binding protein 6, vascular endothelial growth factor B, stromelysins 1 and 2, corticotropin releasing factor receptor type 1 and 2, and aldo-keto reductase.
 13. A method of detecting transcriptional responses to stress in a cell, comprising the steps of: challenging said cell with stress; isolating nucleic acid samples from said cell; measuring gene expression levels; and analyzing said gene expression levels statistically as compared to those without stress, wherein a statistically significant downregulation of said gene expression indicates transcriptional responses to stress.
 14. The method of claim 13, wherein said gene expression is measured by DNA microarray.
 15. The method of claim 14, wherein said gene expression is further verified by RT-PCR.
 16. The method of claim 13, wherein said stress comprises ultraviolet radiation, thermal stress, chemical stress, and immune stress.
 17. The method of claim 13, wherein said cell comprises epidermal keratinocyte, melanocyte, fibroblast, and immune cell.
 18. The method of claim 13, wherein said statistical analysis is one-way analysis of variance or post-hoc test or student t test.
 19. The method of claim 13, wherein said statistically significant downregulation is at least a 1.5-fold decrease of expression of said genes.
 20. The method of claim 13, wherein said a group of genes comprises genes involved in water and salt balance, genes involved in prostaglandin metabolism, interleukin genes, growth factor genes, markers of keratinocyte differentiation genes, metalloproteinases genes, and stress response genes.
 21. The method of claim 13, wherein said downregulated genes are selected from the group of genes encoding for epidermal growth factor receptor, keratinocyte growth factor, keratinocyte growth factor receptor, activin A receptor type I, and tumor necrosis factor superfamily member
 10. 